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ABSTRACT 
Dicatonic gemini surfactants have, within the past two decades, demonstrated 
advancing non-viral gene transfection ability in cell cultures and in animal models. 
However, knowledge of the intracellular/subcellular fate of gemini surfactants that may 
further advance gemini surfactant-based gene transfection is very limited. Therefore, my 
Ph.D. research conducted the investigation of gemini surfactants within transfected 
PAM212 keratinocytes including the development of effective bioanalytical mass 
spectrometric (MS) methods necessary for such investigations. 
For effective mass spectrometric bioanalysis of the gemini surfactants within 
cellular matrix their fingerprint fragment ions necessary for targeted identification and 
quantification were first determined through single-stage (MS), tandem (MS/MS) and 
multi-stage (MS3) analyses. The molecular composition of gemini surfactants was 
confirmed. In addition, fragmentation mechanisms of novel dipyridinium and β-
cyclodextrin-based diquaternary ammonium molecules (chosen as study compounds) 
were established in detail, allowing for their qualititive and quantitative analysis. 
Hydrophilic interaction liquid chromatography-based (HILIC)-MS/MS methods, 
alone and in conjunction with the method of standard addition, were subsequently 
developed/validated by adopting multiple reaction monitoring (MRM), ensuring 
selectivity alongside the distinctive chromatographic separation. The analytical strategy 
ensured selectivity/specificity for target gemini surfactants including two lead 
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compounds, 16(Py)-S-2-S-(Py)16 and 16-3-16. The validated HILIC-MS/MS methods 
were more sensitive, faster and have simplified isocratic elution relative to recently 
reported methods. 
In the application to nanoparticle-based gene transfection studies, the HILIC-
MS/MS and standard addition–HILIC-MS/MS methods allowed a comprehensive 
investigation of the cellular uptake, intracellular deposition and subcellular distribution of 
the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants. The results showed similar 
cellular uptake and intracellular depletion trends but different subcellular distribution 
profiles. Both gemini surfactants showed an initial spike in their concentration within 
cells upon addition of gemini surfactant-based DNA nanoparticles to the cells, as would 
be expected to achieve nanoparticle entry into cells during transfection. The intracellular 
gemini surfactant content, however, underwent a depletion upon removal of the added 
nanoparticles – a trend observed for the first time and attributable to either gemini 
surfactant biodegradation or exocytosis from host cells. 
Results of subcellular distribution showed higher distribution of 16-3-16 to the 
mitochondria and nucleus relative to its 16(Py)-S-2-S-(Py)16 counterpart (p < 0.05), with 
the two having similar distribution to the cell membrane, cytosol and the remnant 
subcellular residue. This differential subcellular distribution, determined for the first 
time, may explain a suggested higher toxicity for 16-3-16 as its increased distribution to 
the mitochondria and nucleus could impact their biological integrity and function. Herein, 
the investigations and findings will benefit further exploration of gemini surfactants 
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through the established molecular fragmentation fingerprints of novel compounds and 
comprehensive LC-MRM-MS bioanalytical strategies for studying the biological fate, 
elucidating varying toxicity and assessing possible metabolite formation. 
 v 
 
ACKNOWLEDGEMENTS 
My appreciation is first to my supervisor, Dr. Anas El-Aneed, for his professional 
and moral support, guidance and patience throughout my studies. I have benefited from 
his knowledge, solid advice and vision, particularly so when we explored new ideas. His 
confidence in my research inspired me and his careful editing contributed enormously to 
the production of this thesis. 
I also thank the members of my advisory committee, Drs. Ildiko Badea, John 
Headley and George Katselis. By the same measure, many thanks is extended to Dr. Ed 
Krol, who chaired my first three committee meetings and to Dr. Dave Blackburn who 
chaired my final committee meetings. Their solid review and advice on my proposed 
research and my yearly progress were ultimately beneficial to my overall research and 
experience. 
I thank Dr. Ronald Verrall and Dr. Jackson Chitanda for kindly providing some of 
the geimi surfactants required for my research and for availing their helpful expertise to 
me during synthesis of other required gemini surfactants. Here, I extend thanks to Ms. 
Behshad Vatanparast who undertook and completed the synthesis with me during her 
summer 2012 research. Equally, I thank Dr. Joshua Buse for thoughtfully providing one 
gemini surfactant at the time of completing his PhD research, thus helping save time and 
resources in an otherwise required synthesis. 
 vi 
 
Sincere appreciation must be extended to Ms. Deborah Michel for the basic training 
in mass spectrometry provided to me and for the professionaly cordial support throughout 
my research. Appreciation also goes to my colleagues of the Drug Discovery & 
Development Research Group (DDDRG) for fruitful friendships, technical assistance and 
other support; Ms. Mays Al-Dulaymi, Ms. Saniya Alwani, Ms. Mona Hamada, Dr. Amal 
Makhlouf, Mr. Waleed Mohammed-Saeid and Mr. Hossein Rafiei. In the same vein, I 
remember and also thank immediate-past colleagues of the DDDRG team: Ms. Hanan 
Elsayed, Ms. Catherine Hutchinson, Ms. Randeep Kaur, Dr. Isaac Asiamah, Dr. Joshua 
Buse, Dr. M. Poorghorban, Dr. Istvan Hajdu and Dr. Jagbir Singh. 
The following institutions are duly recognized: the College of Pharmacy & 
Nutrition (University of Saskatchewan, Saskatoon, SK) provided post-graduate 
scholarship, research workspace/facilities and reputable leadership/mentorship. The 
College of Graduate Studies & Research also provided funding the form of travel award, 
enabling me present my research at conferences. The research equipment and supplies 
were funded by the Natural Sciences and Engineering Research Council of Canada 
(NSERC), Canadian Foundation for Innovation and College of Pharmacy & Nutrition. 
The Saskatchewan Structural Science Centre (Saskatoon, SK) also provided the use of 
their instrumental research facility. 
Deep appreciation is owed to a large number of friends, fellows and individuals 
whose coming together creates a perfect community that fosters a sense of belonging, 
mutual support and greater impact on society. Much thanks to M. Bagonluri family, E. 
 vii 
 
Mupondwa family, M. Nketia family, N. Puobi family, A. Salifu family, E. Tuurosong 
family, Seraphine Kogo, Evelyn Songsore, among numerous others that are not listed 
simply for lack of space. In the same vein, much appreciation goes to friends and fellows 
of GCAS, ACCC, KenSask and Our Lady of Lourdes Church, Saskatoon, SK [GCAS: 
Ghanaian-Canadian Association of Saskatoon Inc., ACCC: African-Canadian Catholic 
Community, KenSask: Community of Kenyans and East-African neighbours in 
Saskatoon]. 
Finally and most importantly, I would like to give ultimate gratitude to my parents 
and siblings (Aaron, Bruce, Ernestina, Martina, Edna) and all my extended family for the 
continued love, support and prayers throughout my academic pursuits. The first and 
lasting strength I have had for this journey is that which came from all of my family. 
 
McDonald Donkuru 
June 2017, Saskatoon, SK, Canada 
 
 viii 
 
DEDICATION 
To Micah, Belicia and Beata, who are my brightest diamonds. To my parents, 
Clothilda and Moses Donkuru, who are my roots. And to Uncle Martin Abu, who has 
been a source of opportunity, goodwill and inspiration. 
 
 ix 
 
TABLE OF CONTENTS 
PERMISSION TO USE ..................................................................................................... I 
ABSTRACT ...................................................................................................................... II 
ACKNOWLEDGEMENTS ............................................................................................ V 
DEDICATION.............................................................................................................. VIII 
TABLE OF CONTENTS ............................................................................................... IX 
LIST OF FIGURES ..................................................................................................... XVI 
LIST OF TABLES ....................................................................................................... XXI 
LIST OF ABBREVIATIONS .................................................................................. XXIII 
 : LITERATURE REVIEW AND PROPOSED RESEARCH ............... 1 
1. INTRODUCTION................................................................................................. 1 
1.1 Nanomedical drug delivery: an overview ................................................................. 1 
1.2 Nanotechnology, its scope and principles ................................................................. 5 
1.3 Nanomaterial compostion and origins ....................................................................... 7 
1.3.1 Organic amphiphilic nanoparticles.................................................................. 8 
1.3.2 Lipid-based nanoparticles and drug delivery ................................................ 11 
1.3.3 Gemini surfactant-based nanomaterials ........................................................ 13 
1.4 Mass spectrometry ................................................................................................... 19 
1.4.1 Bio-analytical Mass spectrometry ................................................................. 19 
1.4.2 Qualitative and quantitative analysis in mass spectrometry.......................... 22 
 x 
 
1.4.3 Molecular structure elucidation using mass spectrometry ............................ 27 
1.4.4 Highthroughput bio-analysis using mass spectrometry ................................ 28 
1.4.5 HILIC-HPLC-tandem mass spectrometry (HILIC-LC-MS/MS).................. 30 
1.4.6 HILIC-LC-MS/MS for intracellular analysis of gemini surfactants ............. 32 
1.5 Biological fate of nanoparticles ............................................................................... 34 
1.5.1 Intracellular fate of biomedical lipid nanoparticles ....................................... 36 
1.5.2 Trafficking and distribution of lipid nanoparticles in cells ........................... 36 
1.6 Isolation of subcellular organelles and structures for LC-MS/MS bioanalysis ...... 47 
1.7 The proposed research ............................................................................................. 52 
1.7.1 Rationale of the proposed research ............................................................... 52 
1.7.2 Research Hypotheses..................................................................................... 53 
1.7.3 Research Objectives ...................................................................................... 54 
1.8 REFERENCES: ....................................................................................................... 57 
 : RESEARCH PUBLICATION 1 .......................................................... 94 
2. MULTI-STAGE TANDEM MASS SPECTROMETRIC ANALYSIS OF 
NOVEL Β-CYCLODEXTRIN-SUBSTITUTED AND NOVEL BIS-
PYRIDINIUM GEMINI SURFACTANTS DESIGNED AS 
NANOMEDICAL DRUG DELIVERY AGENTS ........................................... 95 
2.1 Abstract .................................................................................................................. 97 
2.2 Introduction ........................................................................................................... 98 
2.3 Materials and Methods ....................................................................................... 103 
 xi 
 
2.3.1 Gemini surfactants....................................................................................... 103 
2.3.2 Sample preparation ...................................................................................... 104 
2.3.3 Mass spectrometric analysis ........................................................................ 104 
2.4 Results .................................................................................................................. 107 
2.4.1 Single-stage QToF MS analysis .................................................................. 107 
2.4.2 Multi-stage MS analysis .............................................................................. 109 
2.4.3 R-7N(X-suc-β-CD)-R compounds: MS/MS fragmentation pathway ........... 114 
2.4.4 Ȓ(Py)-S-2-S-(Py)Ȓ compounds: MS/MS fragmentation pathway ............... 126 
2.5 Discussion ............................................................................................................. 130 
2.5.1 Mass accuracy and compound structural confirmation .............................. 130 
2.5.2 Multi-stage tandem MS/MS fragmentation patterns ................................... 130 
2.5.3 Fragmentation: R-7N(X-suc-β-CD)-R vs. Ȓ(Py)-S-2-S-(Py)Ȓ ..................... 134 
2.5.4 Conclusion ................................................................................................... 135 
2.6 Acknowledgements ................................................................................................ 136 
2.7 References ............................................................................................................. 137 
 : RESEARCH PUBLICATION 2 ........................................................ 140 
3. NOVEL HILIC-LC-MS/MS QUANTITATIVE METHOD FOR THE 
CELLULAR ANALYSIS OF VARYING STRUCTURES OF GEMINI 
SURFACTANTS DESIGNED AS NANOMATERIAL DRUG CARRIERS.
............................................................................................................................. 142 
3.1 Abstract ................................................................................................................ 143 
 xii 
 
3.2 Introduction ........................................................................................................... 144 
3.3 Materials and Methods .......................................................................................... 147 
3.3.1 Materials ...................................................................................................... 147 
3.3.2 LC-MS/MS instrumentation ........................................................................ 148 
3.3.3 Preparation of standard solutions ................................................................ 150 
3.3.4 Preparation of nanoparticle formulations .................................................... 150 
3.3.5 PAM 212 cell treatment and sample collection .......................................... 150 
3.3.6 Sample Preparation for LC-MS/MS analysis .............................................. 152 
3.3.7 LC-MS/MS method validation ................................................................... 153 
3.4 Results .................................................................................................................. 154 
3.4.1 HILIC-LC-MS/MS specificity for gemini surfactant bio-analysis ............. 154 
3.4.2 Method validation for bio-analysis of 16(Py)-S-2-S-(Py)16 and 16-3-16 .. 157 
3.4.3 Selectivity and matrix effects ...................................................................... 157 
3.4.4 Calibration curve linearity and sensitivity .................................................. 160 
3.4.5 Recovery...................................................................................................... 163 
3.4.6 Accuracy and precision ............................................................................... 165 
3.4.7 Stability ....................................................................................................... 166 
3.4.8 Bio-analysis of P/G/L-nanoparticle-treated cells ....................................... 168 
3.5 Discussions ............................................................................................................ 171 
3.6 Conclusion ............................................................................................................. 173 
3.7 Acknowledgements ............................................................................................... 174 
 xiii 
 
3.8 References ............................................................................................................. 175 
3.9 Supplementary Information ................................................................................... 181 
 : RESEARCH MANUSCRIPT (PUBLICATION 3 - PENDING) .... 194 
4. EVALUATION OF THE SUBCELLULAR DISTRIBUTION OF GEMINI 
SURFACTANT GENE DELIVERY NANOPARTICLES USING LIQUID 
CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY. ................ 196 
4.1 Abstract ................................................................................................................ 197 
4.2 Introduction ........................................................................................................... 198 
4.3 Materials and Methods .......................................................................................... 201 
4.3.1 Materials ...................................................................................................... 201 
4.3.2 LC-MS/MS instrumentation ....................................................................... 202 
4.3.3 Preparation of standard solutions ................................................................ 203 
4.3.4 Preparation of nanoparticle formulations .................................................... 204 
4.3.5 PAM 212 cell treatment and sample collection .......................................... 204 
4.3.6 Subcellular fractionation and subcellular sample collection ....................... 205 
4.3.7 Protein recovery, 1-Dimensional SDS-PAGE and western blotting ........... 208 
4.3.8 Sample preparation for LC-MS/MS analysis .............................................. 208 
4.3.9 Assessment of the suitability of the Standard addition–LC-MS/MS method
 210 
4.3.10 Statistical analysis ....................................................................................... 211 
4.4 Results .................................................................................................................. 211 
 xiv 
 
4.4.1 Purity and Western blot characterization of subcellular fractions .............. 211 
4.4.2 Standard addition–HILIC-LC-MS/MS for subcellular bio-analysis of gemini 
surfactants ................................................................................................................ 212 
4.4.3 Matrix effects, accuracy and precision in standard addition–LC-MS/MS . 214 
4.4.4 Standard addition–HILIC-LC-MS/MS analysis of cellular and subcellular 
samples .................................................................................................................... 215 
4.5 Discussions ............................................................................................................ 218 
4.6 Conclusion ............................................................................................................. 222 
4.7 Acknowledgements ............................................................................................... 223 
4.8 References ............................................................................................................ 224 
4.9 Supplementary Information ................................................................................... 232 
4.9.1 Supplementary Methods .............................................................................. 232 
4.9.2 Supplementary Results ................................................................................ 234 
4.9.3 Supplementary Figure S1 ............................................................................ 236 
4.9.4 Supplementary Table S4.1 .......................................................................... 237 
4.9.5 Supplementary References ......................................................................... 238 
 :  DISCUSSIONS, CONCLUSION AND FUTURE WORK ............. 239 
5.1 General Discussion ................................................................................................ 239 
5.1.1 Mass spectrometric characterization of dipyridinium and β-cyclodextrin-
based diammonium gemini surfactants ................................................................... 240 
 xv 
 
5.1.2 Quantitative, hydrophilic interaction liquid chromatography tandem mass 
spectrometric method for of gemini surfactants ...................................................... 242 
5.1.3 Bio-quantfication of 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants: 
intracellular and subcellular fate in PAM 212 cells ................................................ 244 
5.2 Summary and conclusions ..................................................................................... 245 
5.3 Future directions .................................................................................................... 247 
5.3.1 Evaluation of the tandem mass spectrometric fragmentation across structural 
varieties of gemini surfactants ................................................................................. 247 
5.3.2 Quantitative assessment of in vivo and in vitro profiles of gemini surfactants
 248 
5.3.3 Investigation of gemini surfactant biodegradation and metabolite formation
 249 
5.4 References ............................................................................................................. 251 
 
 xvi 
 
LIST OF FIGURES 
Figure 1.1: A logarithmic scale depiction of matter at the nanometer scale (see blue 
outline). ........................................................................................................................ 3 
Figure 1.2: Lipid-based nanoparticles. .............................................................................. 9 
Figure 1.3: The interactions between a target cell and a nanoparticle. ............................ 12 
Figure 1.4: General structural scheme of m-s-m gemini surfactants. .............................. 14 
Figure 1.5: Structure scheme of the three series of gemini surfactants. .......................... 16 
Figure 1.6: Illustration of MS experimentation process using a triple quadrupole–linear 
ion trap (QqQ-LIT-MS) instrument. .......................................................................... 29 
Figure 1.7: Multi-functional HILIC stationary phases. ................................................... 33 
Figure 1.8: Cellular uptake mechanism and intracellular distribution of lipid/DNA 
nanoparticle complexes. ............................................................................................ 38 
Figure 1.9: Subcellular fractionation scheme based on differential centrifugation. 
Adopted with some modifications from refs.(251, 313, 314) ........................................... 49 
Figure 2.1: Gemini surfactant structural schemes. ........................................................ 100 
Figure 2.2: MS/MS spectrum of 12-7N(O-suc-β-CD)-12 as a representative example of 
the β-CD-substituted gemini surfactants. This compound may also be designated by: 
12-+N(Me)2-7N(O-suc-β-CD)- +N(Me)2-12. ........................................................... 115 
Figure 2.3: MS3 spectrum of product ion m/z [764.72]2+ which originates from MS/MS 
fragmentation of the compound 12-7N(O-suc-β-CD)-12, with precursor ion [M]2+ 
 xvii 
 
m/z 870.99. Insert: MS3 spectrum of product ion m/z [990.42]2+ which was also 
observed in the MS3 fragmentation of the product ion m/z [764.72]2+. ................... 123 
Figure 2.4: MS/MS spectrum of 12(Py)- S-2-S-(Py)12 as a representative example of the 
bis-pyridinium gemini surfactants. Inset: full MS scan of the precursor ions [M]2+ of 
four bis-pyridinium gemini surfactants: m/z 293.28, 321.27, 349.29, 377.32. 
Analysis: positive mode........................................................................................... 127 
Figure 2.5: MS3 spectrum of product ion m/z [253.19]2+ which originates from MS/MS 
fragmentation of the compound 12(Py)-S-2-S-(Py)12, with precursor ion [M]2+ m/z 
293.28. Insert: MS3 spectrum of product ion m/z [450.26]+ originating from MS3 
fragmentation of the product ion m/z [253.19]2+. .................................................... 133 
Figure 0.1: A) Schematic representation of gemini surfactant general structure; B) The 
exact molecular structures of intact compounds and monitored product ions during 
HILIC-MS/MS of 16-3-16: N,N-bis(dimethylhexadecyl)-1,3-propanediammonium; 
C) 16(Py)-S-2-S-(Py)16: 1,1'-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-
diyl)]dipyridinium. .................................................................................................. 145 
Figure 1.2: Chromatograms of the 16(Py)-S-2-S-(Py)16 and 16(Py)-S-2-S-(Py)16-d10 
gemini surfactants, i.e., the analyte and IS, respectively. Panel A indicates the 
absence of any interference against the selective determination of both 16(Py)-S-2-S-
(Py)16 and 16(Py)-S-2-S-(Py)16-d10 by showing the detection of no signals around 
the established HILIC-LC-MS/MS elution times of these compounds within "double 
blank" cell samples. B) chromatogram from an injection of only 16(Py)-S-2-S-
 xviii 
 
(Py)16-d10 and C) Chromatogram from an injection of only 16(Py)-S-2-S-(Py)16 at 
lower limit of quantitation, LLOQ. No cross-interference occurred between 16(Py)-
S-2-S-(Py)16 and 16(Py)-S-2-S-(Py)16-d10............................................................. 160 
Figure 1.3: Chromatograms of the 16(Py)-S-2-S-(Py)16 gemini surfactant at LLOQ, 
ULOQ and LLOD. The relative response signal is shown for the analyte at: A) 
LLOQ – insert is a zoomed in spectrum of the analyte and B) ULOQ in relation to 
the internal standard, 16(Py)-S-2-S-(Py)16-d10, which was present at a constant 
concentration. C) Extracted ion chromatogram for 16(Py)-S-2-S-(Py)16 at LLOD.
 ................................................................................................................................. 162 
Figure 1.4: Analyte recovery efficiencies for Bligh/Dyer lipid extraction vs octanol 
extraction. Bligh/Dyer lipid extraction gave a better recovery (typically 98%) of the 
analyte and was the chosen liquid-liquid extraction method, departing from a recent 
report in which octanol extraction (70% efficiency) was used. Unsurprisingly, the 
new HILIC-LC-MS/MS methods reported herein show better sensitivity (60-fold 
increase). .................................................................................................................. 164 
Figure 1.5: Representative experiments showing the intracellular concentration vs. time 
profile of the gemini surfactants, 16(Py)-S-2-S-(Py)16 (top panel) and 16-3-16 
(bottom panel). The intracellular concentration increased progressively throughout 
the duration of nanoparticle administration to cells, followed by a gradual decrease 
after removal of the nanoparticle-dosed supernatant culture media. The dashed 
horizontal line “y-axis = 200 ng/mL” shows that the results is reported only for data 
 xix 
 
with concentration above 200 ng/mL as noted under Section 3.8. Each plotted data 
point represents mean ± SD, n = 3. .......................................................................... 170 
Figure S1.6: Product ions monitored for the internal standards 16(Py)-S-2-S-(Py)16-d10 
and 16-3-16-d66 during HILIC-LC-MS/MS analysis. ............................................. 181 
Figure S1.7: Chromatograms of the gemini surfactants, 16(Py)-S-2-S-(Py)16, 16-3-16, 
16(Py)-S-2-S-(Py)16-d10, 16-3-16-d66. [Panel A indicates the absence of any 
interference against the selective determination of all four compounds by showing 
the detection of no signals around the established HILIC-LC-MS/MS elution times 
of these compounds within "double blank" cell samples. B) chromatogram from an 
injection of only 16(Py)-S-2-S-(Py)16-d10 and C) Chromatogram from an injection 
of only 16(Py)-S-2-S-(Py)16 at lower limit of quantitation, LLOQ. No cross-
interference occurred between 16(Py)-S-2-S-(Py)16 and 16(Py)-S-2-S-(Py)16-d10]. 
D) Chromatogram from an injection of only 16-3-16; and, E) Chromatogram from 
an injection of only 16-3-16-d66. No cross-interference occurred between 16-3-16 
and 16-3-16-d66 since the injections produced signal for only the respective but not 
both compounds. In general, the chromatograms showed symmetry and smoothness 
for quantitative analysis as shown. .......................................................................... 183 
Figure S1.8: Calibration curves for the 16-3-16 and 16(Py)-S-2-S-(Py)16 gemini 
surfactants. In both cases, the linear range was 50 – 5000 ng/[1 × 106 cells], r2 ≥ 
0.99. ......................................................................................................................... 185 
 xx 
 
Figure S1.9: Chromatograms of the 16-3-16 gemini surfactant at LLOQ, ULOQ and 
LLOD. The relative response signal is shown for the analyte at: A) LLOQ and B) 
ULOQ in relation to the internal standard, 16-3-16-d66, which was present at a 
constant concentration. C) Extracted chromatogram for 16-3-16 at LLOD. .......... 187 
Figure S1.10: Contrasting analyte recovery efficiencies for Bligh/Dyer lipid extraction 
vs octanol extraction. Bligh/Dyer lipid extraction gave a better recovery (typically 
98%) of the analyte and was the chosen liquid-liquid extraction method, departing 
from a recent report in which octanol extraction (70% efficiency) was used. ........ 188 
Figure 4.1: Gemini surfactant structures. ....................................................................... 199 
Figure 4.2: Subcellular fractionation scheme based on differential centrifugation. ...... 206 
Figure 4.3: Subcellular and whole-cell sample processing steps prior to LC-MS/MS 
analysis. ................................................................................................................... 209 
Figure 4.4: Four-point ꞌstandard additionꞌ calibration curve. ......................................... 213 
Figure 4.5: Subcellular distribution of the gemini surfactants, 16(Py)-S-2-S-(Py)16 and 
16-3-16..................................................................................................................... 216 
Figure S0.1: Immunoblot verification and assessment of the subcellular fractions from 
differential centrifugation. ....................................................................................... 234 
Figure S0.2: Product ions monitored for the internal standards 16(Py)-S-2-S-(Py)16-d10 
and 16-3-16-d66 during HILIC-LC-MS/MS analysis. ............................................. 236 
 xxi 
 
LIST OF TABLES 
Table 2.1. Detected doubly charged precursor ion species [M]2+ for β-CD-based and bis-
pyridinium gemini surfactants in the positive ion mode. Mass accuracy analysis was 
conducted on a QSTAR® QqToF-MS/MS system. ................................................. 108 
Table 2.2. Major product ions of the R-7N(X-suc-β-CD)-R gemini surfactants and their 
theoretical m/z values from CID-MS/MS analysis of the precursor ions [M]2+. The 
distinctive product ions include those numbered 1–7. Several minor product ions are 
also observed (not listed); they include those corresponding to neutral loss of H2O, 
CO or CO2 from the listed ions. .............................................................................. 110 
Table 2.3. Major product ions of the Ȓ(Py)-S-2-S-(Py)Ȓ gemini surfactants and their 
theoretical m/z values from CID-MS/MS analysis of the precursor ions [M]2+. The 
m/z values differ for all product ions except for product ion number 5. Other, but 
minor, product ions were also observed, resulting from various neutral losses in the 
form CᵪH2ᵪ‒y, y = 0 or 2. .......................................................................................... 112 
Table 2.4. The structure of various fragment ions series illustrated in Schemes 1 and 2. 
A) Fragment ion series for the 12-7N(O-suc-β-CD)-12 gemini surfactant; B) 
fragment ion series for the 12(Py)-S-2-S-(Py)12 gemini surfactant. ....................... 116 
Table 1.1. Conditions for MRM transitions of the analytes on AB Sciex 4000 QTRAP® 
System. .................................................................................................................... 149 
 xxii 
 
Table 1.2. HILIC-LC-MS/MS bio-analysis of 17 gemini surfactants with varying 
molecular structures. ................................................................................................ 155 
Table 1.3. Recovery of 16(Py)-S-2-S-(Py)16 from the aqueous cellular matrix. .......... 163 
Table 1.4. Intra- and inter-day accuracy and precision in the analysis of 16(Py)-S-2-S-
(Py)16. ..................................................................................................................... 165 
Table 1.5. Stability of 16(Py)-S-2-S-(Py)16 analyte within the sample matrix. ............ 167 
Table S1.6. Gemini surfactant mass concentrations equivalent to 3 mM molarity. ...... 189 
Table S1.7. Overview of the HILIC-LC-MS/MS method validation parameters. ........ 190 
Table S1.8. Recovery of 16-3-16 (analyte) from the aqueous cellular matrix. .............. 191 
Table S1.9. Intra- and inter-day accuracy and precision in the analysis of 16-3-16. ..... 192 
Table S1.10. Stability of the 16-3-16 gemini surfactant within the sample matrix. ...... 193 
Table 4.1. Accuracy and precision of quality control samples in the standard addition–
HILIC-ESI-MS/MS analysis gemini surfactants. .................................................... 215 
 
 
 xxiii 
 
LIST OF ABBREVIATIONS 
16-3-16 N,N-bis(dimethylhexadecyl)-1,3-propane-diammonium dibromide 
16-3-16-d66 N,N-bis(dimethylhexadecyl-d16)-1,3-propane-diammonium dibromide 
12(Py)-S-2-S-(Py)12: 1,1'-[ethane-1,2-diylbis(sulfanediyldodecane-1,2-diyl)]dipyrid-
inium 
16(Py)-S-2-S-(Py)16: 1,1'-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-diyl)]dipyrid-
inium 
14(Py)-S-2-S-(Py)14: 1,1'-[ethane-1,2-diylbis(sulfanediyltetradecane-1,2-diyl)]dipyrid-
inium 
18(Py)-S-2-S-(Py)18: 1,1'-[ethane-1,2-diylbis(sulfanediyloctadecane-1,2-diyl)]dipyrid-
inium 
16(Py)-S-2-S-(Py)16-d10: 1,1'-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-diyl)]di-
pyridinium-d10 
CE  Collision energy 
CID  Collision-induced dissociation 
CMC  Critical micelle concentration 
DART  Direct analysis in real time 
DESI  Desorption electrospray ionization 
DNA  Deoxyribonucleic acid 
DOPE  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
 xxiv 
 
ESI  Electrospray ionization 
FC  Fast liquid chromatography 
FIA  Flow injection analysis 
m-s-m  Composition of diquaternary ammonium gemini surfactants with the 
structure sequence hydrocarbon tail–carbon spacer chain–hydrocarbon 
tail 
HILIC  Hydrophilic interaction lliquid chromatography 
HPLC  High performance liquid chromatography 
HQC  High quality control 
HR-MS High resolution mass spectrometry 
IFN-γ  Interferon-gamma (interferon-γ) 
LC  Liquid chromatography 
LLOQ  Lowest limit of quantification 
LLOD  Lower limit of detection 
LQC  Low quality control 
MALDI Matrix assisted laser desorption ionization 
MEM   Minimal essential media 
MQC   Middle quality control 
MRM   Multiple reaction monitoring 
MS   Mass spectrometry 
MS/MS  Tandem mass spectrometry 
 xxv 
 
MSn   Multi-stage mass spectrometry 
m/z  Mass-to-charge ratio 
PAM212  Murine epidermal keratinocyte cells 
PEG  Polyethylene glycol 
P/G/L  Plasmid/gemini surfactant/DOPE nanoparticle formulation 
ppm  Parts per million 
QqQ-LIT-MS Triple quadrupole-linear ion trap mass spectrometer 
Q-ToF-MS Quadrupole time of flight mass spectrometer 
RNA  Ribonucleic acid 
RSD  Relative standard deviation 
ToF  Time of Flight 
USFDA United States of America Food and Drug Administration 
UV  Ultraviolet 
 
 1 
 
: 
Literature Review and Proposed Research 
1. Introduction 
As the development and biomedical application of novel lipid-based nanoparticles 
intensifies, there is a need to evaluate the intracellular deposition and biological fate of such 
nanoparticles. Mass spectrometry (MS) is capable of investigating the intracellular fate/profiles 
of lipid-based nanoparticles with highthroughput capabilities. MS, as an analytical technique, 
allows for screening, detection and quantification of targeted molecular species. 
Used in the form of supramolecular aggregates, biomedical nanoparticles inevitably enter 
or accumulate in cells wherein the exact intracellular fate of the foreign chemical material is 
largely unknown.(1) Mass spectrometric analysis can be conducted on lipid-based nanoparticles 
extracted from simple, highly purified samples or within highly complex, multi-component 
biological extracts(2). Unlike other methods, MS offers high sensitivity and specificity to its 
qualitative and quantitative analysis even for unrefined, complex biological samples.(3, 4) Thus, 
various mass spectrometric-based analytical methods are proposed for studying the intracellular 
fate of gemini surfactant-based nanoparticles as outlined in this report. 
1.1 Nanomedical drug delivery: an overview 
Safe and efficient delivery of therapeutic agents, such as cytotoxic anti-cancer drugs and 
therapeutic DNA, into diseased cells remains a critical objective of an increasingly intense drug 
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delivery research within both academia and the pharmaceutical industry.(5-7) However, when 
introducing any foreign chemical substances into cells, there is an accompanying imperative to 
determine their intracellular profiles and safety. In this regard, MS provides a suitable and 
sensitive means of investigating the biotransformation and safety profiles of foreign substances 
found within cells. 
Developments in nanotechnology is enabling the design of new molecules (biological, 
biomimetic), and their novel complex aggregates, at the nanometer (nm) scale (Figure 1.1), to 
achieve desired structures, functions and applications. Such new molecules include new 
amphiphilic lipids,(8-12) surfactants (conventional(13) and the so-called “gemini” types(14-17)), 
peptides(18-23), polymers(24-28) and dendrimers(29-32). On the other hand, the complex aggregates 
include micelles, liposomes (or vesicles), cubosomes and similar supramolecular aggregates(33-35) 
(covered under Section 1.3.2). These supramolecular structures fulfill functions including drug 
solubilization, encapsulation, transmembrane transport and delivery into target cells.(33-35) 
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Figure 1.1: A logarithmic scale depiction of matter at the nanometer scale (see blue outline). 
Much smaller unit H2O molecule and larger-sized entities are included for 
comparisons. Adopted from International Iberian Nanotechnology Laboratory (official 
website: “http://inl.int/what-is-nanotechnology-2”). 
 
 
The novelty with these supramolecular nanomaterials is the ability to precisely control 
their functions by fine-tuning specific parameters such as particle size, shape (morphology), 
structure (internal, external), surface properties (coating, zeta potential, binding specificity), 
chemical composition and concentrations.(36-44) Although liposomes and similar nanoparticles, 
with these fine-tunable parameters, can encapsulate and deliver active ingredients to cells to 
elicit therapeutic effect, the nanoparticles are also known to cause cytotoxicity following in vitro 
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and in vivo treatments. In addition, the fate of the delivery agent (i.e., nanoparticle carrier) is still 
not fully studied or understood.(45-50) 
While this research focuses on nanoparticle drug carriers that serve biomedical purpose, it 
is worth noting that the lack of clarity on biological fate also surrounds environmentally released 
nanoparticles which become passively incorporated within organisms.(1, 51-53) Biological uptake 
of nanoparticles from nanoparticle-polluted environments represents an unintended consequence, 
but it nonetheless happens from the continuous interaction between organisms (skin, lungs, gut) 
and the environment. 
Given the above knowledge gap, my research will implement a range of analytical mass 
spectrometric methods to study the intracellular persistence/retention and bio-localization 
properties of novel gemini surfactant molecules recently reported to possess effective drug-
delivery capabilities. The broader research on biological fate of xenobiotics also involves 
investigating their biodegradation profiles. But for the chosen novel gemini surfactants, their 
intracellular persistence and subcellular distribution must first be determined so as to guide 
future studies on the gemini surfactant biotransformation. 
Specifically, my research focus is to screen, identify and quantify nanoparticles’ constituent 
amphiphiles (discussed in Section 2.2.2) after introduction into the cells via transfection. This will 
be achieved by developing and validating MS-based methods, which will then be used to analyze 
the nanoparticle-treated cells. Ultimately, an understanding of the gemini surfactant biological 
fate will be useful for the development of safer, less toxic and more efficient gemini surfactants; 
and, for establishing safety guidelines regarding nanoparticle composition and application. 
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1.2 Nanotechnology, its scope and principles 
A unique craftsmanship of nature is that, matter has the ability to be organized at various 
scales of structural build-up (Figure 1.1). Nanotechnology, in a classical sense, involves the 
“understanding and control of matter at dimensions of roughly 1-100 nm, where unique 
phenomena enable novel applications” (NNI, USA)(54). In a wider context, nanotechnology, 
covers matter having dimensions measuring up to 100–500 nm.(55) A reason for this is that, the 
nano-scale properties can remain undiminished for dimensions ranging up to 500 nm (or more) 
when focusing nanotechnology on drug delivery. 
It should be recognized that the nanometer-scale (1 nm: 10-9 m) is next to the angstrom-
scale (1 Å: 10-10 m) for bond lengths or interatomic distances. Thus naturally, when dimensions 
decreases to the nanometer range, the building blocks of the nano-materials are arranged at just 
few layers of atoms or molecules.(56-60) Intense fabrication of nanomaterials, nanoparticles and 
nanodevices has evolved based on the concept of atom-by-atom or molecule-by-molecule 
organization of matter.(56, 57, 59) Nanotechnology itself is traced back to the late 1950s when 
scientists began to conceptualize the nano-scale realm of matter and the immense synthetic 
approach in being able to “re-create” matter by directly assembling or organizing atoms.(61) 
Nanomaterials, nanoparticles or nanodevices may be described, summarily, as: 1) 
originating by natural, incidental or engineered phenomena;(62) 2) existing as or containing 
particulate entities (or films) that are discrete or aggregated/agglomerated, but not covalently 
bonded;(62, 63) 3) having one or more dimensions (of the particles, films) breaking into the classic 
threshold of 1-100 nm;(62, 63) 4) having parameters that can constitute productive functionalities to 
 6 
 
fulfill novel applications. In undesired cases, however, nanoparticles can pose toxicological 
properties that could threaten health and safety.(62-65) 
The practical (experimental) development of engineered nanoscale structures broadly 
follows two alternative approaches, namely, bottom-up and top-down manufacturing. The 
bottom-up approach covers fabrication schemes that drive nanoparticle formation solely from the 
constituent building blocks, such as atoms and molecules, which aggregate into particles. 
Bottom-up approach may encompass self-assembly, positional assembly and chemical synthesis 
as all these bring constituent units together to fulfill nanostructure formation.(61, 66-69) The top-
down approach refers to the downsizing of bulk matter into nanostructures which can be 
achieved by such processes as milling, etching and pulverization.(70) In both approaches, control 
of size and other parameters is critical toward achieving desired functionality.(55, 71-73) 
The crucial aspect of nanotechnology lies in the small size and the associated large surface 
area-to-volume ratio of matter organized at the nano-scale. With extreme small sizes, a change 
occurs in the relative strength of acting forces; influence of gravity diminishes, whereas major 
influence arises for forces such as surface tension and non-covalent forces such as Van der 
Waals interaction.(74-76) In addition, the extreme reduction of solid particle sizes consequently 
results in the quantum size effect: 1) characterized by the presence of confined electrons and their 
quantized energy that exerts strong influence on nanoparticles; and, 2) noticed by dramatic 
changes in optical, electrical, magnetic and mechanical properties, as well as, physical, chemical, 
thermal and biological behaviour.(77) To illustrate, copper in bulk is opaque and it becomes 
transparent at the nanoscale. Similarly, bulk properties yield to nano-properties in other 
materials: solid gold becomes liquid at room temperature; stable aluminum becomes 
 7 
 
combustible; inert platinum becomes a catalyst; and, the insulator silicon becomes a 
conductor.(77-80) 
Although nanotechnology has been mostly driven by the applications enabled by unique 
nanoparticle properties, an increasing recognition has arisen regarding the uncertainties or 
potential hazards in the context of some applications or exposure to humans.(64, 81) Nanoparticles 
have a high propensity to penetrate and accumulate in large loads within organisms, where 
toxicity could be observed. However, as noted above, the exact fate of nanoparticles (within 
cells, body or environment) is still unknown.(64, 65, 82, 83) As a result, nanotoxicology has emerged; 
it aims to measure the magnitude, characterize the correlations and mechanisms of toxicity 
associated with nanomaterials and, trace the end-fate of nanomaterials.(84, 85) 
1.3 Nanomaterial compostion and origins 
Nanomaterials exist in the atmosphere, waters (underground, surface, sea, ocean), soils, 
organisms and laboratories. In particular, engineered nanomaterials are being increasingly 
researched and their fabrication has been demonstrated using matter ranging from living virus 
particles to lifeless colloidal particles.(62) They exhibit varied functional attributes and so can be 
categorized by many different criteria. Based on chemical composition, that is, nature of 
constituent ingredients, the following categories arise: 1) soft, organic nanoparticles which are 
developed from synthetic or naturally-derived organic amphiphiles (and other molecules), and 
engineered microbiological components; 2) allotropic carbon nanoparticles such as 
nanodiamonds, carbon nanotubes, and fullerenes; and, 3) inorganic nanoparticles made of rigid 
core cluster of metal atoms, metal oxides or semiconductor core material such as silicon.(62, 86)  
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Added to the above categories, newer platform nanoparticles are evolving that incorporate 
aspects of all three conventional categories to yield unique nanoparticles. These “hybrid” 
nanoparticles fall somewhat under an integrated nanoparticle category.(14, 86) The focus of this 
research is on lipid-based nanoparticles which are widely used for drug delivery. Lipid-based 
nanoparticles fall under the category of organic amphiphilic nanoparticles (CATEGORY 1). 
1.3.1 Organic amphiphilic nanoparticles 
The organic nanoparticle category covers such supramolecular systems as micelles, 
liposomes (or vesicles), cubosomes and other amphiphile aggregates (Figure 1.2). They typically 
arise through self-assembly and self-organization (in aqueous media) of tailored amphiphile 
molecules such as gemini surfactants.(87) The particular aggregate type depends on governing 
factors such as concentration, molecular structure of the amphiphile, temperature, and 
characteristics of solvent media including pH, ionic strength, composition and nature of the 
solvent components.(87, 88) The formed amphiphile aggregates may then be loaded with a 
measured proportion of, for instance, active drugs. The self-assembly-formation and 
maintenance of these organic nanoparticles is driven by a combination of non-covalent forces 
and hydrocarbon–water unfavourable interactions, which both induce aggregate formation and 
allow unfavourable interactions to be minimized, resulting in thermodynamic stability.(87, 89, 90) 
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Figure 1.2: Lipid-based nanoparticles. 
A complex array of nanoparticle structures can be obtained depending on a number of 
factors. The nanoparticles shown here have varying structural phases as function the 
packing parameter of different lipid molecules. Packing parameter is a characteristic 
related to architecture and structure of the amphiphile compounds; it is mathematically 
defined by v al ; where v = volume of alkyl tail, a = headgroup area, l = alky tail length. 
Adopted from ref.(91) 
 
Self-assembly is both dynamic and reversible, that is, the starting primary building blocks 
(molecules, ingredients) aggregate into complex secondary structures, which the system can 
integrates into its next level of organization. This organizational scheme then continues (Figure 
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1.2), and can produce one of two effects.(90) First, it allows for the incorporation of any added 
ingredients, and helps attain an equilibrium characterized by greater stability and lower Gibbs 
free energy.(88, 89) Second, it can also allow the aggregates to disintegrate back into the 
constituent building blocks due to a perturbation of thermodynamic variables arising from 
external forces such as excessive dilution.(92-94) Extending such combined character, organic 
amphiphilic nanoparticle systems are able to interact with biological components such as cell 
membrane, organelles as well as the physiological environment within cells, and respond to 
stimuli such as change in pH, temperature and ionic strength. Such behaviour accounts for the 
function and use of organic nanoparticles as cellular drug delivery systems.(87, 89, 90) 
As noted earlier, the molecular building-blocks for organic nanoparticles range from lipids 
to gemini surfactants, peptides, polymers, dendrimers and anti-oxidants such as vitamin E. The 
drug transporter portion, which mainly comprises the amphiphiles, generally constitutes the bulk 
of these nanoparticles, accounting for about 90 mol% of the dry weight of drug-loaded 
nanoparticles.(14, 39, 95, 96) The active ingredients, namely, therapeutic DNA or small molecule 
anti-cancer drugs, make up the other portion. The molecular structure of the amphiphiles is 
known to strongly correlate with the nanoparticle properties, starting from the formulation stages 
to downstream in vitro/in vivo drug delivery and toxicity.(16, 17, 97, 98) In terms of compound 
structural effects, the wide range of lipids that exists, including natural and synthetic or semi-
synthetic lipid compounds, can be organized in groups for MS investigations of both the similar 
and different intracellular profiles among the different compound structures. 
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1.3.2 Lipid-based nanoparticles and drug delivery 
The field of lipid-based nanoparticle drug delivery now has several established strategies 
through which the drug delivery function and safety of the nanoparticles can be improved.(6, 18, 32, 
39, 95, 99, 100) These strategies include the design of novel lipids capable of efficient nanoparticle 
formation and drug packaging (Figure 1.3, top panel);(98) the optimization of nanoparticle 
behaviour via improved preparation and processing;(12, 101) and uncovering the intracellular 
behaviour of nanoparticles to circumvent challenges such as toxicity.(102) 
Lipid-based nanoparticle development is ultimately aimed to give safe and effective drug 
delivery systems. To this end, the gap in ongoing research is to determine the best compound 
structures needed for both efficient lipid-based drug delivery and non-toxic effects. An 
increasing variety of lipids are being investigated in this regard, including, several phospholipids 
with long hydrocarbon chains,(103, 104) the unique steroid-based lipid cholesterol,(105, 106) and 
several synthetic compounds such as gemini surfactants.(14, 16) 
As the analytical capability of MS-based techniques has improved, their application has 
also widened to allow analysis of an increasing variety of lipids and lipid-based drug delivery 
nanoparticles.(107, 108) Lipid molecules that are naturally produced within cells help form/maintain 
biological membranes and films, among other roles.(109) These natural cellular lipids, with their 
unique molecular structure and chemistry, lend themselves to routine use and metabolic 
processing within cells. In general, natural cellular lipid compounds are being progressively 
studied using MS,(110) and the information gained has given a better understanding of the 
function, deposit locations and distribution of some natural lipids. 
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Figure 1.3: The interactions between a target cell and a nanoparticle.  
Three mechanisms of interaction, which represent different means of entry of the whole 
nanoparticle or only its contents into the cell, are endocytosis, lipid-mediated poration 
and lipid fusion. Entry into cells triggers further events including intracellular trafficking 
and/or unpacking of the internalized material, entry of DNA into the nucleus and 
DRUG DELIVERY VIA 
NANOPARTICLE
FATE OF NANOPARTICLE   
(POST-DRUG RELEASE).
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subsequent protein expression. NOTE: Here, the DNA–lipid complex nanoparticle (also 
termed lipoplex) is made of cationic liposomes and a load of DNA that is neutralized, 
condensed and encapsulated within interior cavity of liposomes. Adopted from ref.(111) 
 
There is a broad similarity in the nature of analyte between lipid components of 
nanoparticles and natural cellular lipids. Therefore, MS is expected to be effective in analyzing 
lipid-based nanoparticles found within cells. In this context, data for intact and authentic lipids 
standards can be examined in parallel with data for lipid components of nanoparticles (such as 
gemini surfactants) that have been incorporated into cells. Gemini surfactant (a class of 
amphiphiles) present unlimited versatility in compound structures and this could be exploited 
using mass spectrometry(112-114) for the assessment of their intracellular deposition and fate, and 
the effects of different compound structures. 
1.3.3 Gemini surfactant-based nanomaterials 
Gemini surfactants, or simply bis-surfactants, are compounds in which two conventional 
surfactants (each bearing one polar head and one hydrocarbon chain) are covalently incorporated 
into one molecule or chemical compound. A gemini surfactant therefore has structural 
components that include two polar, hydrophilic head-groups and two hydrophobic, hydrocarbon 
tails, whereby the two head-tail segments are connected by a chosen linker chain.(16, 17, 115) An 
illustration is given by the N,N-bis(dimethylalkyl)-α,ω-alkanediammonium surfactants (denoted 
as m-s-m; where m = alkyl tail length, s = alkyl spacer length; Figure 1.4). 
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One characteristic effect of the “gemini” structural scheme is that it allows a pairing of 
different head, tail and linker groups, leading to unlimited number of possible gemini surfactants. 
A second effect is that gemini surfactants have greatly reduced critical micelle concentration 
(CMC) values. Therefore, their nanoparticle formation ability is far greater than that of the 
corresponding conventional surfactants bearing one polar head and one hydrocarbon chain.(16, 17, 
115) Also, low CMC means that lower gemini surfactant concentrations are adequate for efficient 
drug delivery and minimized concentration dependent-toxicity. 
 
 
 
 
H2m +1Cm N (CH2)s N
CH3
CH3CH3
CH3
CmH2m +1
 
 
Figure 1.4: General structural scheme of m-s-m gemini surfactants.  
A) General structure, showing how any two monomer surfactants can be connected using 
a spacer group. B) Structure of the m-s-m gemini surfactants. Two traditional monomeric 
surfactants with Cm alkyl tails (where m = chain length) are connected at their quaternary 
 
B 
A 
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ammonium heads via a polymethylene Cs chain containing s methylene units. Adopted 
from ref.(15) 
 
Among a wide variety of customized gemini surfactants that have evolved for use as drug 
delivery nanomaterials, many are reported to possess suitable structural attributes. The gemini 
surfactants being investigated in this research exhibit different molecular structures – Figure 1.5. 
These include: i) m-s-m gemini surfactants (currently the most studied types);(14, 96) ii) bis-
pyridinium-containing dialkyl compounds;(116-119) and, iii) cyclodextrin-substituted gemini 
surfactants.(120) The three compound series are reported to have drug delivery efficiency.(14, 96, 119-
121) Other reported gemini surfactants with efficient activity are those with amino acid/peptide-
moieties,(95, 122-124) sugar-/saccharide-based substituents,(125-127) and amine-groups.(14, 128, 129) 
The above range of compounds display chemical groups that include amines, amides, 
esters and ethers, carboxylates, phosphates, disulphide-bond-bearing units and quaternary 
ammoniums. These functional groups give gemini surfactants useful traits such as being cationic, 
anionic, nonionic, zwitterionic, pH-sensitive and interactive with other molecules.(16, 17) For 
example, a recently reported series of gemini surfactants (abbreviated as m-7NH-m) bearing two 
cationic ammonium headgroups and a pH-sensitive amino group have demonstrated effective 
DNA encapsulation and its delivery into cells.(14) Selected gemini surfactants with compound 
structures containing select chemical groups and characteristics, as listed above, will be good 
candidates for investigations aimed at probing the intracellular profiles/fate of gemini surfactant-
based nanoparticles. 
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Gemini surfactant series General structure 
 
R-7N(X-suc-β-CD)-R 
(β-cyclodextrin-substituted series) 
 
R, x  = n-C12H25, O. 
        = n-C12H25, NH. 
        = n-C16H33, O. 
        = n-C18H35, O. 
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R(Py)-S-2-S-(Py)R 
(Bis-pyridinium series) 
R (total) = n-C12H24. 
              = n-C14H28. 
              = n-C16H32. 
              = n-C18H36. 
N+
S
R
S
N+
R  
 
m-s-m series 
R      = n-C16H33 and s = 3 N
+
R
N+
R
s
 
 
Figure 1.5: Structure scheme of the three series of gemini surfactants.  
The specific compounds from each series being investigated in this research are as 
follows. R-7N(X-suc-β-CD)-R series, four compounds: R, x = n-C12H25, O; n-C12H25, 
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NH; n-C16H33, O; n-C18H35, O. R(Py)-S-2-S-(Py)R series, four compounds: R = -C10H22, 
-C12H24, -C14H28, -C16H32. m-s-m series, one compound: R = n-C16H33 with s = 3. The 
structural variations when correlated with the various characteristics to be determined 
from the studies will present vital information on the biological fate of these 
nanomaterials. Abbreviations: Py, pyridinium ring. 
 
 
Studies and understanding of the intracellular (or biological) fate of gemini surfactants 
used in the form of lipid-based drug delivery nanoparticles can allow for structural modification 
to improve function. For instance, insights into their intracellular biodegradation profiles will 
enable safer, less toxic and more efficient gemini surfactants to be developed. Currently, most 
efforts at improving gemini surfactant nanoparticles for efficient and safe drug delivery rely on 
data relating to drug packaging efficiency, biological/cell membrane penetration effectiveness 
(Figure 1.3, top panel), and cell death (toxicity).(15) For instance, groups of gemini surfactants are 
frequently screened in nanoparticle drug delivery experiments to identify those factors resulting 
in the highest efficacy and lowest toxicity.(14, 95, 122, 128) Such investigations mainly arrive at 
findings that emphasize the importance of compound structure and nanoparticle formulation 
methods, among other factors. However, little or no attention is paid to how the nanoparticles 
and the constituent amphiphiles are distributed or metabolized in cells (Figure 1.3, bottom panel) 
despite the potential correlation to both efficacy and toxicity. 
To better understand cell death induced by gemini surfactant nanoparticles and to control 
it, an understanding of the gemini surfactant intracellular fate or metabolism is needed (Figure 
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1.3, bottom panel). The application of MS has recently been shown to allow for the 
determination of fragmentation mechanisms of gemini surfactants where the collision-induced 
dissociation yielded product ions that included unique product ion species (fingerprints) for 
specific compound structures.(112-114) With known (pre-established) mass spectrometric 
fingerprints and fragmentation mechanisms, a highthroughput investigation of the subcellular 
deposition and intracellular fate of gemini surfactants can be conducted.
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1.4 Mass spectrometry 
1.4.1 Bio-analytical Mass spectrometry 
Mass spectrometry attracts much application as a bio-analytical tool and is ideal for the 
identification and quantification of target molecular species – xenobiotics or endogenous cellular 
compounds.(113, 130-133) In drug delivery, soft amphiphilic organic nanoparticles are commonly 
assumed to unpack and/or disassemble after incorporation (entry) into cells so as to release their 
cargo (drug). Therefore, the constituent amphiphiles (herein, gemini surfactants, Figure 1.5) can 
be reasonably expected to localize or be distributed to various sites within cells. In reality, 
quantitative experimental data supporting disassembly of nanoparticles and/or distribution to 
subcellular sites is yet to be reported.(46, 47) 
As proposed, studies to help address the above issue include: investigation of the 
intracellular persistence/retention and the subcellular localization of the 16(Py)-S-2-S-(Py)16 
gemini surfactant in comparison with its structurally contrasting and counterpart, 16-3-16. This 
will allow for future work to screen, detect and quantify possible metabolites of these gemini 
surfactants. The possible metabolites will include species whose m/z values, compared with that 
of the intact compounds, reflect certain conjugation or cleavage products from metabolism. For 
the chosen gemini surfactants, 16-3-16 and 16(Py)-S-2-S-(Py)16 (Figure 1.5), the former was 
recently found to be less toxic.(119) This observation is neither understood nor expected.(134-138) 
My work will focus mainly on the cytotoxicity, intracellular persistence, subcellular deposition 
in relation to the molecular structure of tested compounds. 
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Data on the subcellular localization for gemini surfactants is essential: (1) it provides 
insights into the intracellular trafficking, elimination, recycling or other processes that the gemini 
surfactants may undergo; (2) it will enable a comparison of the measured cytotoxicity levels with 
the observed intracellular distribution of the lipids to give insights into how different molecular 
structures influence toxicity or other in vitro parameters. To determine the subcellular 
localization, treated PAM 212 cell sample will be fractionated and analyzed to quantify the 
proportion of 16(Py)-S-2-S-(Py)16 and 16-3-16 present within various intracellular 
compartments. 
1.5 Mass spectrometric studies of in vitro profile of nanoparticles 
In this research, MS is being implemented for investigating the intracellular fate of gemini 
surfactant nanoparticles previously found to give good drug delivery efficiency and varying 
cytotoxic profile depending on the molecular structure.(119, 120) MS as an analytical technique that 
has evolved and improved since the late 1880s, allows for the detection, identification and 
quantification of samples containing chemical analytes.(130) MS operates by a fundamental design 
that consists of three modular parts which are laid out in the order: 1) ionization source, 2) mass 
analyzer and 3) detector.(139) It works by generating vapourized ions of the analyte, followed by 
measuring their mass-to-charge ratio, m/z, and providing data in the form of mass spectra.(112, 113, 
140) 
In addition to MS, several alternative techniques exist that may be applied to study and 
characterize nanoparticles. These include fluorescent and electron microscopies, atomic force 
microscopy (AFM), dynamic light scattering (DLS), fluorescent and UV-vis spectroscopy (UV 
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spec), nuclear magnetic resonance (NMR) and synchrotron techniques.(141, 142) But each of these 
techniques alone does not appear suitable for the specific purpose of studying the biodegradative 
transformation and intracellular fate of gemini surfactant-based nanoparticles. This is due to their 
inability to track nanoparticles up to a stage of disassembly; lack of UV-active or fluorescent 
moieties or probes in gemini surfactants typically used in drug delivery applications; and, 
complexity or unrefined state of actual biological samples containing the gemini surfactants. 
Aims of my research include the screening, detection and measurement of gemini surfactants, 
contained within unrefined, complex cellular extracts. 
Given the considerations above, MS emerges as a means of investigating gemini surfactant 
nanoparticle bio-fate, but with challenges. First: in metabolic studies, the anticipated degradation 
of the nanoparticles can be speculated to differ from simple metabolic breakdown or 
transformations of dispersed, non-aggregated molecules introduced into cells. A wide variety of 
xenobiotics (foreign compounds in cells) including drugs and delivery agents, are subject to 
phase I or phase II biotransformation and consequent detoxification and/or elimination.(143, 144) In 
some cases the metabolic derivatives, the parent xenobiotic compounds or both result in 
toxicity.(144, 145) 
In the case of molecules aggregated or bound together as nanoparticles, their metabolism 
may not be feasible until there is disintegration of the nanoparticle into the individual 
molecules.(144, 146) Thus, a limiting step in nanoparticle metabolism could, speculatively, be 
identified as the disassembly of nanoparticles into the corresponding dispersed, non-aggregated 
molecules which may then readily undergo metabolic breakdown. For investigations using MS, 
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the common assumption is that organic nanoparticles disassemble into the constituent molecules 
(dispersed) during or after uptake into cells.(17, 147, 148) 
The second challenge is related to the complexity of the biological matrix with the 
possibility of interfering with MS analysis. Even for cellular samples which have experienced 
some refinement such as solid phase and/or liquid phase extraction, co-extracted natural cellular 
compounds can still interfere with the analysis.(149-151) Given the above potential challenges, 
several analytical modes and methods in MS, detailed ahead, will be utilized in this research. 
The MS techniques that will be used in my research are hybrid quadrupole–time-of-flight 
MS and triple quadrupole-linear ion trap MS which are suitable for studies of the intracellular 
profile of gemini surfactants. These two techniques offer high resolution and highthroughput that 
are immensely beneficial to the proposed analysis. They also allow for both qualitative and 
quantitative analysis either alone or in conjunction with HPLC. 
1.5.1 Qualitative and quantitative analysis in mass spectrometry 
Over the past few decades, qualitative and quantitative MS has improved due to new and 
versatile ionization sources, mass analyzers and detectors.(130, 163) Tandem or hybrid MS systems 
allow for tandem MS (MS/MS) analysis; this can be combined with other analytical techniques 
such liquid chromatography to add analytical separation of compounds. Qualitative MS-based 
analysis covers identification and differentiation of known and unknow analytes, and the 
determination of molecular formulae and structures including metabolic changes to compound 
structures. 
Quantitative MS-based analysis detrermines and monitors analyte concentrations and/or 
changes in concentrations to study analytes in biological tissues where the analyte may 
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quantitatively show a bio-distribution, depletion and metabolic profile. The analyteꞌs bio-
distribution, depletion and metabolic profile may then reveal its biological role, fate or impact. A 
number of assorted instrumental platforms in analytical MS, considered for this research, are 
briefly reviewed below. This includes a discussion of the selected modular parts, that is, 
ionization sources and mass analyzers. 
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Electrospray Ionization (ESI): 
ESI technique primarily achieves ionization of polar analytes (dissolved in organic 
solvents: mostly methanol, with or without acetic acid) via generation of fine aerosol of very 
small, charged droplets, using high voltage, temperature and a nebulizing gas. The charged 
droplets become smaller by solvent evaporation from their surfaces, making the droplet gain 
increasing charge density and instability, ultimately leading to the threshold Rayleigh limit at 
which point the droplet explodes (Coulumbic explosion) into even smaller droplets. Repeated 
cycles of the solvent evaporation, droplet contraction and Coulombic explosions lead to the final 
droplet from which the molecular adducts or charged ions are released in gaseous form. 
Ionization in positive ion mode generates positive ions including [M+nH]n+, [M+Na]+ or [M]n+; 
while a negative mode ionization generates negative ions including [M–nH]n- or [M]n-. The 
[M]n+ and [M]n- ions (n = 1, 2, etc) are for analytes which bear permanent charge (n+, n-) and 
gain no additional charge from the ionization process. Positive ionization uses positive voltage 
and negative uses negative voltage.(142) 
ESI is a soft ionization technique, allowing for the formation of intact protonated or 
deprotonated ions, which are singly or multiply charged. ESI is suitable for analyzing large 
molecules such as peptides/proteins and non-covalent complexes.(143) ESI operates at ambient 
conditions and offers an ease of interfacing with HPLC. 
 
Time-of-flight (ToF) mass analyzers: 
In ToF mass analyzers, ions are freely accelerated through a flight tube toward the detector 
using uniform electric field. The time-of-flight through the tube (of fixed distance) is measured 
for the ions. A ToF analyzer allow all ions (entering it from the ionization source) to be detected 
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as opposed to other mass analyzers (e.g., quadrupole and linear ion trap analyzers) that act as ion 
filter. Use of a uniform electric field imparts the same kinetic energy to ions, but the observed 
velocity of ions through the flight tube is dependent on the m/z values: ions with smaller m/z 
reach detector before “heavier” ions. (144, 145) 
To give superior resolution, ToF analyzers often have delayed ion extraction capability 
and/or a reflectron for eliminating undesired kinetic energy variations for ions with identical m/z 
values.(132, 144, 145) Delayed ion extraction implies that ions are briefly delayed to correct (or 
minimize) the variations in initial kinetic energies before entering the mass analyzer where ion 
separation occurs.(132, 144, 145) Reflectron also serves to correct kinetic energy variation but for 
ions already extracted into the flight tube: ions having identical m/z values but different energies 
travel into a “reflectron” region at varying depths so that they emerge with equal energy and 
reach the detector at the same time. Commonly encountered systems with an interfaced ToF 
analyzer include ESI-ToF-MS, MALDI-ToF-MS. Also in existence are tandem ToF-ToF-MS 
and hybrid system such as Qq-ToF-MS (Q = quadrupole analyzer, discussed ahead). Tandem and 
hybrid systems generally allow precursor ions to be isolated in the first analyzer, then 
fragmented in a collision cell, followed by analysis of the product ions in the second 
analyzer.(144, 145) 
 
Quadrupole mass analyzers 
Quadrupole mass analyzers  consist of four circular, parallel metal rods which are arranged 
at the corners of a square. The rods carry oscillating electric fields between them and filter 
(analyze) ions based on their m/z values. The oscillating electric field is created by connecting a 
positive electrical charge to one pair of opposite rods, while remaining pair is connected a 
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negative electrical charge. A radio-frequency (rf) voltage and a direct current voltage that will 
superimpose on the rf voltage are then applied to the rods. The result of this setting is that ions 
are permitted through the four rods to a detector based on thier trajectories within the analyzer. 
Only ions with the right trajectory will reach the dectector while all other ions  will collide with 
the rods and be removed. Quadrupole mass analyzers can operate either in the scanning mode 
scanning all ionized species or as ion filiter with particular m/z values selected for .(146) 
 
Linear ion trap (LIT) mass analyzers: 
A linear quadrupole ion trap (LIT) analyzer  is similar to quadrupole analyzer being made 
of four parallel rod electrodes supplied with oscillating electric fields and thus is geometrically 
similar to a quadrupole analyzer. However, an LIT analyzer can scan ions too. By design, LIT 
analyzers provide a potential well bound by the four quadrupole rod electrodes, such that, ions 
that enter the LIT are confined in two ways: radially and axially. Radial confinement is provided 
by an appropriate rf voltage while axial confinement is provided by DC voltage at both ends of 
the rod electrodes. Ion ejection to the detector is permitted by manipulations of the two voltages. 
Ideally, ions entering LIT analyzers are: 1) stably trapped in the right amounts; 2) undergo 
collisional cooling due to the presence of He damping gas; 3) confined into a packet of ions (as 
opposed to a diffuse cloud) and focused at the center of the trap; and, 4) ejected (mass selective 
ejection: in order of increasing m/z) to a detector to yield mass spectra data.(112, 139, 140) 
The ion detection can also be done in situ using Fourier Transform techniques. Ion 
trapping, mass selective ejection and detection underpin the capability of ion trap MS for MSn 
experiments in structural elucidation studies.(112, 139, 140) LIT analyzers have advantages, such as 
high ion storage capacity (related to dimensions of internal volume space), ideal scan times, wide 
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dynamic range and simplicity of construction. In addition, they can be used as stand-alone 
analyzers or interfaced with other analyzers to give hybrid MS instruments as demonstrated by 
hybrid triple quadrupole–linear ion trap Q-LIT-MS systems(112, 138) described below. 
1.5.2 Molecular structure elucidation using mass spectrometry 
Quadrupole–time-of-flight MS (Qq-ToF-MS) equipped with an electrospray ionization 
source (ESI-Qq-ToF-MS) has the unique capability of recording mass spectra with high mass 
accuracy, particularly if compared with triple quadrupole instruments.(164, 165) ESI is commonly 
chosen as it is easily interfaced with HPLC and because it is a soft ionization technique that 
allows the conversion of analytes into intact precursor ions (singly or multiply charged).(166, 167) 
Other ionization techniques such as matrix-assisted laser desorption ionization (MALDI) may 
also be used depending on the analysis.(168, 169) 
The arrangement of the Qq-ToF hybrid mass analyzer allows the first quadrupole Q to 
receive and isolate target ions (e.g., precursor ion) generated from the ionization source, 
followed by CID-fragmentation of ions within a linear hexapole or octapole collision cell 
(regarded as the second “quadrupole”, q).(170, 171) The product ions are then analyzed in a 
reflectron ToF analyzer with orthogonal acceleration, bringing about superior ion separation and 
detection of high resolution signal.(172) 
The ion separation provided by reflectron ToF analyzer accounts for a relatively high 
resolution and mass accuracy. Mass accuracy of the newest ToF systems is routinely better than 
1 ppm after both external and internal calibration, while resolution is routinely over 60,000 
(m/Δm; Δm = the full peak width at half-maximum, FWHM).(173, 174) Qq-ToF-MS offers high 
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resolution and accuracy and is widely used for analysis of known and unknown analytes within 
complex biological matrices.(164, 165, 171) 
1.5.3 Highthroughput bio-analysis using mass spectrometry 
Triple quadrupole–linear ion trap MS (QqQ-LIT-MS, Figure 1.6) is based on the format of 
three-linearly-connected (in-tandem) quadrupole analyzers, termed triple quadrupole (Q1q2Q3). 
However, in this case the standard triple quadrupole system is modified such that the third 
quadrupole Q3 has both quadrupole (mass filtering) and linear ion trap operational functions. As 
a result the QqQ-LIT-MS platform combines the sensitivity of conventional QqQ-MS with the 
capability of ion trap MSn. Therefore, qualitative and quantitative analysis can be performed 
simultaneously.(175) An electrospray ionization source is frequently used (i.e., an ESI-QqQ-LIT-
MS), but other ionization methods such as atmospheric pressure chemical ionization (APCI) can 
also be employed. 
Using the QqQ-LIT-MS system (Figure 1.6), the first quadrupole can isolate a precursor 
ion, with the ion entering into and undergoing CID-fragmentation in the second quadruople 
(collision cell) which is supplied with Ar, He, or N2 collision gas. This is followed by analysis of 
product ions in the third quadruople-linear ion trap analyzer, which then releases the ions for 
detection by mass selective ejection.(130, 176, 177) The process also allows further trapping and 
fragmentation of initial product ions into smaller ions (multiple-stage MS) before detection. 
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Figure 1.6: Illustration of MS experimentation process using a triple quadrupole–linear ion trap 
(QqQ-LIT-MS) instrument.  
The stepwise process allows selection of precursor (or target) ion, its fragmentation into 
product ions and detection of the product ions. Also, the process allows further 
fragmentation (multiple-stage) of initial product ions into smaller fragment ions before 
detection. Adopted from ref.(147) 
 
The mechanism, as described above, allows QqQ-LIT-MS systems to give highthroughput 
analysis. QqQ-LIT-MS systems also perform neutral loss scans and selected reaction monitoring 
to strengthen its use for obtaining information on compound structure, fragmentation mechanism 
and molecular fingerprints. Triple quadruople systems typically have a mass range in the limit of 
≤ 4 kDa, and are characterized by low mass resolution. QqQ-LIT-MS systems are easily 
interfaced with HPLC and GC.(178) An alternative type of ion trap analyzer is the 3D (i.e., 
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spherical) quadrupole ion trap analyzer. However, it has an inferior ion storage capacity relative 
to LIT analyzers.(130) 
In bio-analysis, liquid chromatography (LC: conventional HPLC) is commonly coupled to 
tandem MS instruments, giving the hyphenated LC-MS/MS system. LC-MS/MS systems have 
the combined capabilities of multiplexed analyte separation and high-speed, sensitive mass-
selective determination of analytes.(179, 180) LC-MS/MS is widely used in the analysis of complex 
mixtures to separate, identify and quantify the constituent analytes (known, unknown) including 
compounds in their intact form, their derivatized or breakdown products as in the pharmaceutical 
industry.(2, 149, 181-183) One class of separation technologies to be used in this research is 
hydrophilic liquid chromatography (HILIC) and is discussed below. 
1.5.4 HILIC-HPLC-tandem mass spectrometry (HILIC-LC-MS/MS) 
In LC-MS/MS, the ability of the liquid chromatographic step to effectively separate target 
analytes within complex mixtures is critical and requires suitable HPLC separation columns (i.e., 
stationary phase), mobile phases, and optimized analytical conditions.(184-186) Among liquid 
chromatographic separation modes, HILIC (utilizes a uniquely different separation mechanism) 
has given the highest sensitivity for analysis of polar compounds.(184-186) In other words, HILIC-
HPLC is a more sensitive variant of traditional reversed-phase (RP-HPLC) and normal-phase 
liquid chromatography (NP-HPLC) in terms of application to polar analytes.(187-189) Consistent 
with the above, the hyphenated HILIC-LC-MS/MS method is expected to be superior to its RP-
LC-MS/MS and NP-LC-MS/MS counterparts.(187, 190) As a result, HILIC-based LC methods are 
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generally established as the separation mode of choice for polar/ionic analytes and also as 
complimentary option for other analytes.(191) 
HILIC-HPLC draws similarities from RP-HPLC and NP-HPLC as well as ion-exchange 
chromatography.(189, 192-195) It uses polar stationary phases to retain polar analytes similar to 
typical NP-HPLC systems; but for the elution, organic mobile phases (mostly acetonitrile, 
containing at least 3% water) are used.(192, 196, 197) In RP-HPLC systems, nonpolar stationary 
phases (e.g., octadecyl silane) are used to retain nonpolar analytes, with the elution driven by 
mobile phases that are mixtures of aqueous and organic solvents.(192) Thus HILIC-HPLC is 
similar to NP-HPLC based on column polarity and to RP-HPLC based on the use of water in the 
mobile phase.(189) HILIC-HPLC is also similar to ion-exchange chromatography as it is 
compatible with charged analytes.(189, 193) The inclusion of water in the HILIC mobile phases 
permits the use of ionic additives. Organic acids and salts (acetic, formic; and ammonium acetate 
and formate) allow, for instance, the control of mobile phase pH, ionic strength, and charge of 
analytes.(198) 
A major modification in HILIC-HPLC is its separation mechanism, although the exact 
interactions between its two phases (stationary, mobile) and analytes are under debate. Typically, 
RP-HPLC mode separation involves partitioning of analytes between the two chromatographic 
phases, while NP-HPLC mode separation involves adsorption of analytes onto the stationary 
phase. For HILIC, various combined interactions account for the separation, including 
adsorption, partitioning, hydrogen bonding, and electrostatic interactions.(189, 192-195) The exact 
interactions depend on the polarity of the HILIC stationary phase while the order of retention and 
elution depends directly on the polarity of analytes and inversely on the polarity of mobile 
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phases.(189) Partitioning is believed to be a major HILIC interaction particularly for simple 
nonionic, neutral stationary phases. The aqueous mobile phase forms a semi-immobilized, water-
enriched layer on the hydrophilic stationary phase, allowing analytes to partition into the water-
enriched layer.(189) 
1.5.5 HILIC-LC-MS/MS for intracellular analysis of gemini surfactants 
The suitability of HILIC-LC-MS/MS for the analysis of gemini surfactants depends on the 
polar chemistry of the gemini surfactants in question. The gemini surfactants in this research 
(Figure 1.5) contain alkyl tails along with either quaternary ammonium or pyridinium head-
groups, which both have a cationic nitrogen atom, N+. Recently, the suitability of HILIC-LC-
MS/MS for the analysis of representative quaternary amine compound(s) has been remarkably 
demonstrated. In the study, HILIC-LC-MS/MS gave higher sensitivity over RP-LC-MS/MS by 
75 times.(187, 190) Based on broader scale, HILIC-LC-MS/MS is generally projected to be at least 
10× more sensitive than RP-LC-MS/MS when working at optimal analytical conditions.(188, 189, 
199) 
Currently, multi-functional HILIC stationary phases such as those with sulfoalkylbetaine 
(zwitterionic) functional groups are gaining increasing use in HILIC-LC-MS/MS applications. 
Multi-functional HILIC columns employ mixed-mode interactions (adsorption, partitioning, 
hydrogen bonding, electrostatic interaction), allowing for the analysis of different polar 
analytes.(200-203) Compared with simple/single-mode HILIC columns, mixed-mode HILIC 
stationary phases (branded commercial example: ZIC®-HILIC column, Figure 1.7) gives very 
efficient separations through differential retention of polar, ionic, neutral and zwitterionic 
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analytes.(200-203) For the ZIC®-HILIC column (evaluated and chosen for this research), its 
obvious compatibility with the gemini surfactants involves electrostatic interaction, +N∙∙∙SO3–. 
 
 
 
Figure 1.7: Multi-functional HILIC stationary phases.  
A) Zwitterionic sulfoalkylbetaine-based HILIC stationary phase ‒ created by covalent 
attachment of a sulfoalkylbetaine group onto silica particles. B) Interaction modes of a 
zwitterionic HILIC stationary phase ‒ interactions are shown for different functional 
polarities that are representative of acidic, basic, hydrophobic and zwitterionic analyties. 
HILIC: hydrophilic interaction liquid chromatography. Adopted with modifications from 
ref.(203) 
 
The improved sensitivity of HILIC-LC-MS/MS methods is partly due to their highly 
organic mobile phases (typically, ≥ 60% acetonitrile) since highly organic solvents promote 
desolvation and ensure efficient ionization. In addition, the low viscosities of relatively organic 
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mobile phases affords a low pressure drop across a working HILIC column and allows the use of 
high flow rates for maximizing throughput.(187, 189, 190) HILIC mobile phases do not require ion-
pairing reagents (e.g., triethylamine, TEA) and this eliminates the associated ion suppression and 
ion source contamination.(204) In contrast, the less volatile, highly aqueous RP-HPLC mobile 
phases and their frequent use of ion-pairing reagents significantly compromises sensitivity.(189) 
Despite the many advantages described, the HILIC mode has a disadvantageous trade-off 
in one aspect − a specificity to retain only polar/ionic analytes but not hydrophobic compounds. 
As a result, HILIC separation typically resolves only the hydrophilic components of a mixture. 
For equilibration, HILIC stationary phases may require short or lengthy equilibrations depending 
on the case. When switching mobile phase or sample types, a lengthy equilibration (e.g., 200(205) 
and 400(206) column volumes) can be required. The long equilibration process however did not 
deteriorate subsequent retention ability. Overall, the HILIC mode offers strong compatibility and 
better sensitivity for studying the bio-fate (intracellular persistence, distribution) of the chosen 
gemini surfactants when considering the advantages(189, 192-195) and the demonstrated sensitivity 
in the analysis of representative quaternary ammonium compounds.(187) 
1.6 Biological fate of nanoparticles 
The biological fate of nanoparticles begins from the port of entry into the host organism. It 
is influenced by events including biodistribution, interaction with endogenous components and 
biotransformation or biopersistence before or after translocation into specific cell types or to 
subcellular structures. The nature and effects of these events vary depending mainly on the 
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nanoparticle characteristics, the biological environment/host and the port of entry. The nature 
and effects of these events can studied using mass spectrometry. 
In biomedicine, lipid-based nanoparticles for drug delivery or diagnostic nanoparticles with 
inner metal/metal-oxide core and outer organic coating are introduced into organisms through 
injections, topical application or inhalation. But with small size and superior diffusion, 
nanoparticles can also enter organisms via the skin,(64) lungs(64) and gastrointestinal (GI)(64) tract 
through exposure to nanoparticles released into the environment during production, storage and 
disposal. Exposure to nanoparticle-polluted environment including food and water, exposes 
organisms to complex mixtures of nanoparticles, including those used biomedically. 
Once in host organisms, nanoparticles can migrate by active or passive diffusion from the 
entry port into or away from blood circulation. They can theoretically be destroyed by enzymes, 
cleared by macrophage and/or excreted in feces or in urine, as noted for particles in very small 
size range (≤ 20 nm).(207-211) It has been established that nanoparticles mainly with evasive 
stealth surface can reach the circulatory system from the lungs (respiratory tract) as an entry port. 
(64) In the blood, they can circulate freely, reaching the liver, heart, spleen, bone marrow, 
tumours, and other sensitive sites.(64, 212-214) 
For the GI tract and skin as entry ports, systemic distribution is curtailed or eliminated 
depending on the skin integrity and the penetration capability of the nanoparticles. The skin 
barrier limits entry of nanoparticles and has dermal macrophages for phagocytotic clearance of 
transgressive nanoparticles.(62, 64) Similarly, the GI tract either destroys nanoparticles or carries 
them along for clearance in feces.(64) However, nanoparticle translocation from the outer skin 
into circulation may be possible particularly if transdermal penetration is strong or if skin is 
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unhealthy (e.g., cancer, lesions); and from GI tract into circulation if the particle size is 
sufficiently small.(64) 
1.6.1 Intracellular fate of biomedical lipid nanoparticles 
Both the properties of nanoparticles and cell type (i.e., biological environment), strongly 
influences the intracellular fate of nanoparticles. The PAM 212 epidermal keratinocytes 
(predominant cell type in epidermis) chosen for my work are found in the basal layer of the skin 
which is estimated at ~0.07 mm(215-219) beneath the outer skin surface. In vivo targeting of 
keratinocytes using topical nanoparticles relies on good transdermal diffusion from outer skin to 
keratinocytes in the basal layer. Nanoparticles may, in some cases, penetrate beneath the basal 
layer (made of keratinocytes) into the deeper skin and distribute its native cells.(64) 
For in vitro studies, the applied nanoparticles readily interact or bind to cells resulting in 
cellular uptake. Uptake into cells, leads to intracellular trafficking and distribution to various 
subcellular compartments, with or without eventual metabolism, recycling or exocytosis from 
cells. Within cells, drug-loaded lipid-based nanoparticles should ideally release their drug 
contents and undergo biodegradation. In reality, these nanoparticles impose toxic or benign 
effects; the toxicity is often higher when nanoparticles are tested as drug-free excipients relative 
to when drugs are incorporated.(122) 
1.6.2 Trafficking and distribution of lipid nanoparticles in cells 
The most accepted mechanism of cellular uptake, intracellular trafficking and drug release 
for drug-encapsulated lipid nanoparticles focuses on major steps as given in bulleted summary 
below and illustrated in Figure 1.8. 
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_______ 
1) Binding to outer cell membrane.(6, 98) Binding is driven by the biomembrane-binding ability of 
nanoparticles – an ability explained by large surface area-to-volume ratio along with cationic 
surface charge and/or surface-attached ligands for targeting cell-membrane receptors.(6, 98) 
2) Endocytosis leading to enveloping within endosomes (early, late).(6, 98) Other entry modes 
(minor ones) include cell–particle fusion and lipid-mediated membrane poration.(6, 98) 
3) Release from late endosome into cytoplasm (completed delivery if drug is small-molecule).(6, 
98) The release stage competes with non-release and/or imminent fusion with lysosomes.(6, 98) 
4) Movement from cytoplasm to the nucleus– drug either free or still in nanoparticle.(6, 98) In 
case of nucleic acid drugs, further migration into nucleus is needed, except for RNAs.(6, 98) 
5) Entry across nuclear membrane into nucleus (final destination if drug is DNA).(6, 98) It should 
be noted that the integrity of freed nucleic acid is susceptible to degradation by 
endonucleases.(6, 98) 
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Figure 1.8: Cellular uptake mechanism and intracellular distribution of lipid/DNA nanoparticle 
complexes.  
The multi-step interaction process begins with binding of nanoparticle to cell, leading to 
internalization. Endocytosis (step 2A) accounts for internalization of majority of 
nanoparticles into the cells. However, other important but minor internalization routes are 
lipid-mediated poration and cell–nanoparticle fusion. After entry into cells, unpacking of 
the nanoparticle and intracellular trafficking occurs are required to propel the DNA drug 
into the nucleus for subsequent protein expression. Adopted with minor modifications 
from ref(220)  
 
Most likely, steps 1−5 only indicate part of nanoparticle distribution and fate in cells. The 
subcellular distributions implied by these steps are discussed below, with an added discussion on 
DRUG DELIVERY VIA 
NANOPARTICLE
 39 
 
other plausible distributions which may not be inferable from the above steps. The nanoparticle 
distribution around subcellular compartments most likely changes with time.(64, 221-223) The 
distributions can be revealed by quantitative changes of the nanoparticles or the constituent lipids 
around subcellular compartments. Using differential centrifugation(224) for isolation of 
subcellular compartments from homogenized, treated cells and LC-MS/MS for quantitative and 
qualitative analysis,(225, 226) knowledge of intracellular distribution of nanoparticles can be 
advanced. 
1.6.2.1 Whole cells 
An important aim in drug delivery is efficient uptake of drug-loaded lipid-based 
nanoparticles by target cells.(6, 98) As recently reported,(227) studies of intracellular fate can begin 
with LC-MS/MS analysis of nanoparticle uptake by quantitative detection of the constituent 
lipids in whole cell lysates. The report observed a plateaued-persistence of gemini surfactants in 
cells 55-hours after treatment with gemini surfactant-based nanoparticles.(227) Also, uptake often 
requires optimization based on several factors (e.g., lipid molecular structure, applied dose, 
particle size, surface charge, and targeting ligands).(6, 98) Quantitative uptake data from LC-
MS/MS methods could contribute to understanding the correlations and to defining optimal 
conditions. 
1.6.2.2 Subcompartment of the plasma membrane 
Interaction of lipid nanoparticles with target cells begins from the binding of the two 
entities, followed by internalization mainly via endocytosis and marginally via cell–particle 
fusion and lipid-mediated poration (opening of connecting pores)(98, 111, 228, 229) Consequently, the 
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cell–nanoparticle binding and the three internalization modes can create a distribution of 
nanoparticles around the plasma membrane.(230) The quantitative changes of the nanoparticles or 
the constituent lipids at the plasma membrane that show the distribution can be determined by 
LC-MS/MS analysis of the outer cell membranes isolated by differential centrifugation(224) 
(Figure 1.9). 
1.6.2.3 Microsomal subcompartment 
The possible microsomal localization of nanoparticles, which is currently unknown, merits 
investigation for two reasons. Microsomes (vesicles, 20−200 nm) represent valuable tool for 
studying the metabolism of xenobiotics including nanoparticles.(231, 232) Microsomes are formed 
from the reorganization of fragmented pieces of endoplasmic reticulum (ER) after cell 
homogenization/disruption. In the re-aggregation process, the broken pieces of ER envelope 
cytochrome P450 enzymes along with their bound xenobiotic substrate reassemble, resulting in 
microsomal viscles.(231, 233, 234) The metabolism of lipid nanoparticles will require the assembly 
of their constituent lipids from various intracellular sites to the CYP450 enzymes, known to 
metabolize over 90% of drugs and other xenobiotics in humans.(235-237) 
Nanoparticles made from natural biological lipids or other molecules may easily undergo 
biotransformation (metabolism) upon disassembly of the nanoparticles into separated molecules. 
For synthetic lipid nanoparticles, the constituent synthetic lipids similarly undergo 
metabolism.(235-237) LC-MS/MS analysis can allow a quantitative determination of nanoparticle 
sequestration into microsomal vesicles.(238-240) Microsomes of nanoparticle-treated cells are be 
obtained by homogenization and differential centrifugation (Figure 1.9).(224) 
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1.6.2.4 Endosomes, transport/endocytotic vesicles 
Endosomes which arise from endocytotic uptake of nanoparticles represent the first 
intracellular nanoparticle accumulation site; they partly determine the subsequent distribution of 
the nanoparticles to other organelles.(202, 241) In general, various exogenous materials internalized 
by cells go through different intracellular processes. For lipid nanoparticles, they may be 
confined within endosomes for subsequent low-pH hydrolytic destruction involving the fusion of 
endosomes with lysosomes.(242) Alternatively, the nanoparticles may also be released into the 
cytosol(6, 98) or removed from cells by endosomal exocytosis.(243) 
Ideally, endocytosed drug-loaded nanoparticles should interface with the endosomal 
environments in order to escape from endosomes or allow only the drug molecule to escape. One 
example of interfacing is the ability of pH-sensitive nanoparticles to expand in response to 
endosomal acidification, with resultant endosomal rupture and release of the nanoparticles in the 
cytosol.(6, 98) Therefore, nanoparticles from endosomes may lead into the cytosol, lysosomes or 
may be exocytosed from cells.(244, 245) 
The accumulation of nanoparticles from extracellular environments into endosomes can be 
studied using LC-MS/MS quantitative analysis. The endosomal accumulation data can be 
compared with the ones obtained for nanoparticle deposition in the cytosol in order to help refine 
nanoparticle characteristics that allows optimal release into cytosol.(246, 247) Comparisons can also 
be conducted between the endosomal accumulation and efficiency of drug release/deposition 
from nanoparticles into the cytosol. 
Intact endosomes from nanoparticle-treated cells can be isolated for LC-MS/MS analysis 
using cell disruption and differential centrifugation(224) in conjunction density with shift 
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techniques.(248-250) As noted (Section 3.3, ahead) density shift techniques will help to effectively 
separate endosomes from organelles whose sedimentation coefficients often overlap with that of 
endosomes.(243, 248, 250, 251) 
1.6.2.5 Lysosomal subcompartment 
Lysosomes are major host organelles within which biomedical nanoparticles are detected 
via fluorescence microscopy after their uptake into cells.(6, 252, 253) As noted, nanoparticles found 
in lysosomes are normally transited from the endosomes, with this transfer channel representing 
an intracellular clearance pathway in which foreign materials are targeted for destruction.(6, 242, 
243, 245, 254, 255) Nanoparticles that are channeled into lysosomes may undergo degradation through 
the activity of lysosomal hydrolases at low pH; they may be exocytosed (or recycled(256)) as 
degraded products or as undegraded materials if they are not degradable.(242, 257) 
Nanoparticle entry into lysosomes can impact nanoparticle-mediated drug delivery in two 
ways: i) entry into lysosomes before the release of the drug from the nanoparticles will result in 
the destruction of the drugs if they are nucleic acids or hydrolytically-susceptible molecules; ii) 
entry into lysosomes after the release of the drug from the nanoparticles will have no effect on 
the drug.(6, 242, 258) The later scenario represents a desired end in nanoparticle-mediate drug 
delivery since it allows for successful drug delivery as well as for the degradation and/or 
exocytosis of the nanoparticles.(6, 242) 
Since lysosomal exocytosis occurs routinely in some cells, an inhibition of this process 
may be necessary in order to determine the total nanoparticle distribution to the lysosomes.(259-
261) In the absence of this inhibition, the determinations can reveal time-dependent quantitative 
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decreases of lysosome-entrapped nanoparticles or constituent lipids that may or may not be 
linked to lysosomal degradation and/or exocytosis.(242, 257) Similar to endosomes, lysosomes to 
be used for LC-MS/MS analysis can be isolated from nanoparticle-treated cells using differential 
centrifugation in conjunction density shift techniques.(224, 253, 262-264) 
1.6.2.6 Ribosomal structures 
To date, no reported study has sought to investigate ribosomal structures within cells as a 
potential site of nanoparticle localization. Ribosomes are compact, non-membrane bound 
structures (25-30 nm diameter, eukaryotic 80S);(265, 266) they represent molecular machines that 
provide the site, structural support and catalysis for the assembly of amino acids into 
polypeptides during protein synthesis.(265, 266) This role requires that the surfaces and space 
around ribosomes should be free to allow the ribosomes to interact with mRNA and tRNA to 
bring about the assembly of amino acids into proteins, which perform several intracellular 
functions.(265, 266) 
With ribosomes' roles as 'protein factory' of cells, a possible nanoparticle migration and 
localization at the surface of ribosomes could obstruct their function and therefore inhibit protein 
synthesis with or without consequent toxicity.(267, 268) In nanoparticle-mediated delivery of 
siRNA (strategy for cancer gene therapy via targeted gene suppression), the widely established 
concept is that the nanoparticles mediate the intracellular delivery of siRNA which disrupts 
expression of targeted mRNA before or after it reaches the ribosomes.(268-273) However, the 
propensity of nanoparticles to freely migrate within cells and localize at various subcellular sites 
could generate steric blocking effects around ribosomes, leading to gene supression.(98, 267, 268) 
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The suggested/possible dual effect of nanoparticles (steric obstruction of ribosomalprotein 
synthesis along with intracellular delivery of siRNA) is desirable in cancer cells. But there is a 
crucial need to investigate the nature and impact of possible nanoparticle distribution to 
ribosomes especially for applications in non-cancer cells where interference in ribosomal 
function is undesirable. To investigate the nature of possible nanoparticle distribution to 
ribosomes, these subcellular structures can isolated by differential centrifugation(224) from 
nanoparticle-treated cells and subjected to quantitative LC-MS/MS analysis. 
1.6.2.7 Cytosolic fluid fraction 
Upon cellular uptake, nanoparticles emerge into a cell's cytoplasm, where they may be 
bagged within organelles or suspended within the cytosolic fluid.(252, 274) If the uptake occurs 
through endocytosis (main uptake mode), the nanoparticles appear in the cytoplasm being 
initially enveloped in endosomes, from which their release into the cytosol follows. On the other 
hand, if uptake occurs through non-endocytotic internalization (i.e., nanoparticle–cell fusion(8) or 
lipid-mediated poration(275, 276)) the nanoparticles are deposited directly into the cytosol.(6, 98, 277) 
Cytosolic deposition of freely suspended lipid nanoparticles following cellular uptake 
(endocytotic, non-endocytotic(252, 277, 278)) and endosomal release enables the imported 
nanoparticles to migrate and localize within cytoplasmic organelles. These organelles such as 
mitochondria and nucleus (discussed below) play critical functions which can be affected by the 
presence of nanoparticles. The nature of cytosolic deposition of nanoparticles and its impact on 
nanoparticle distribution to organelles can be studied using LC-MS/MS analysis. Prior to 
analysis, the cytosolic fluid from homogenized, nanoparticle-treated cells can be isolated by 
differential centrifugation.(224) 
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1.6.2.8 Nuclear subcompartment 
In nanoparticle-mediated in vitro gene transfection, migration of nanoparticles into the 
nucleus is typically not expected. Instead, the nanoparticles should ideally transport the 
entrapped DNA cargo into cells and facilitate nuclear entry of the DNA, without the nanoparticle 
itself entering the nucleus.(98) This is because the successful protein expression has been 
demonstrated from microinjection of naked DNA(279) into the nucleus, rather than DNA 
entrapped in nanoparticles.(280, 281) In addition, DNA-encapsulated nanoparticles are not 
sufficiently small to enter through the tiny nuclear pores.(98, 147, 282-284) 
While nuclear entry of only the DNA cargo is widely supported by published data,(98, 147, 
282-284) a few reports suggest that nuclear entry can involve both the DNA/lipid nanoparticles 
complex.(285-287) Consequently, an apparent debate arises regarding the nature of nuclear entry: 
DNA alone vs. nanoparticle/DNA complexes. This debate can be clarified using LC-MS/MS 
analysis of intact nucleus from nanoparticle-treated cellsmin.(224) 
1.6.2.9 Mitochondrial subcompartment 
Currently, only qualitative, fluorescence microscopic data indicate that nanoparticles 
which are internalized by cells translocate into mitochondria. Initially, non-targeted distribution 
of micellar nanoparticles to mitochondria was reported in studies (in vitro),(252) supporting 
previously held hypothesis.(288, 289) Subsequently, strategies emerged for targeted mitochondrial 
entry and accumulation of mitochondriotropic nanoparticles.(290-293) Mitochondriotropic 
nanoparticles (first reported in 2003(294, 295)) are designed with surface-tethered residues for 
recognition and binding to mitochondria.(290-293) Mitochondria have, consequently, become a 
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recognized intracellular distribution site of nanoparticles which are designed with or without 
mitochondrial targeted ligands.(64, 285) 
Mitochondria which is the main site of lipid oxidation and generation of reactive oxygen 
species (ROS) play host to crucial events of cell death.(296, 297) Mitochondrial generation of ROS 
can be induced (but not always(298, 299)) by oxidation of lipids (by mitochondrial CYP450 
enzymes),(300) which can include the lipids used as nanoparticle building blocks. Although lipid 
nanoparticle-induced toxicity is still to be fully understood by molecular mechanism, the toxicity 
and intracellular production of ROS in the presence of nanoparticles are well-correlated.(301-305) 
 LC-MS/MS analysis of intact mitochondria from treated cells (isolated by differential 
centrifugation(224)) will reveal the quantitative nanoparticle distribution to mitochondria and the 
distribution kinetics, among others. Such quantitative data can contribute to understanding 
nanoparticle-associated toxicity. 
1.6.2.10 Extracellular space/supernatant 
After nanoparticle incorporation into cells, the total intracellular nanoparticle content can 
decrease progressively.(306) Two main processes may account for a gradual disappearance of 
engineered nanoparticles from the cell interior: i) biotransformation;(307) ii) exocytosis of the 
nanoparticles or their constituent amphiphiles.(306) Exocytosis of nanoparticles can be significant 
in two ways: first, exocytosis of drug-loaded nanoparticles before drug release within cells is not 
beneficial. Second, exocytosis of nanoparticles after drug release within cells can provide 
strategic platform for development and use 'exocytose-able' nanoparticles. 
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In the in vitro treatment of cells with nanoparticles, the administration of nanoparticles to 
cells is usually followed by changing of the supernatant cell culture media to fresh, nanoparticle-
free media.(14) To investigate the occurrence or non-occurrence of exocytosis, the 'freshly added' 
supernatant  media can be collected after selected incubation periods and probed by LC-MS/MS 
analysis, which can reveal any exocytosed nanoparticles.(308) 
1.7 Isolation of subcellular organelles and structures for LC-MS/MS bioanalysis 
The LC-MS/MS determination of gemini surfactants in subcellular organelles and 
compartments of nanoparticle-treated cells (Section 3.2.1–3.2.10) requires isolation of the target 
organelles and sub-structures. Similar to native intracellular molecules, xenobiotics such as 
gemini surfactants may occur in subcellular organelles and compartments at different abundance. 
For organelles/compartments with a low abundance of the gemini surfactants, their separation 
will particularly be beneficial for LC-MS/MS detections and quantifications. In addition, absence 
of the bulk of cellular matrix improves LC-MS/MS sensitivity and helps give reproducible 
quantitative and qualitative analysis in target organelles.(309, 310) 
Experimentally, the isolation of subcellular organelles and structures is achieved mainly 
through differential centrifugation (Figure 1.9). Differential centrifugation involves subjecting of 
cells (homogenized gently and effectively) to different centrifugal forces in different steps that 
exert differential pull on subcellular structures due to their distinct densities, sizes and shapes.(311, 
312) As a result, the cell substructures selectively pellet (or sediment) and are collected as separate 
subcellular fractions in sequence with the centrifugation steps. The collected subcellular fractions 
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may contain enriched contents of a particular organelle or may represent mixtures of a few 
organelles which can further be separated.(313, 314) 
The centrifugation steps adopted for fractionation of homogenized nanoparticle-treated 
cells herein is summarized below (Figure 1.9), taking PBS buffer as suspension medium. Step 1: 
the centrifugation will be performed at 6,300 × g for 5 min to give crude nuclei & debris (pellet 
1) and supernatant 1 containing membranes, organelles & cytoplasm. Step 2: pellet 1 will be 
rehomogenized, resuspended in media, then centrifugated at 4,000 × g for 5 min to give nuclear 
fraction (pellet 2). The supernatant from this step is typically a buffer/cellular remnant, 
containing mainly the used suspension buffer with or without cellular remnants.(313, 315) Residual 
materials as well as target subcellular fractions will be saved (-80 oC) for subsequent analysis. 
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Figure 1.9: Subcellular fractionation scheme based on differential centrifugation. Adopted with 
some modifications from refs.(251, 313, 314) 
Cultured cells
(treated, controls)
• Suspension in hypotonic medium, 5 min
• Cell disruption (50 strokes, Dounce homogenizer)
• Isotonic restoration
Homogenate
From: Tissue sample, ref(251)
This route is not used
in this work.
Step 1: 6,300 × g,  10 min
Pellet 1
(Nuclei & debris)
Supernatant 1
(Membranes, organelles, cytoplasm)
Step 2: 4,000 × g,  5 min Step 3: 107,000 × g,  30 min
Pellet 2
(Nuclei)
Pellet 3
(Membranes & organelles)
Supernatant 2
(Cytoplasm)
Pellet 4 
(Plasma membranes)
Step 4: 1,500 × g,  10 min
Pellet 5 
(Mitochondrial pellet)
Step 5: 10,000 × g,  15 min
Pellet 6 
(Microsomal pellet)
Step 6: 100,000 × g,  60 min
Step 7: 150,000 × g,  180 min
Pellet 7 
(Ribosomal pellet)
Cellular residue (supernatant)
To be explored later
Supernatant 3
buffer/cellular
remnants
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In Step 3, supernatant 1 from step 1 will be subjected to further centrifugation at 107,000 × 
g for 30 min to give cytosolic fluid (supernatant 2) and pellet 3 containing membranes & 
organelles. A well-mixed suspension of pellet 3 will be centrifugated in sequential steps to pellet 
the following subcellular fractions: 4) 1,500 × g for 10 min, plasma membranes; 5) 10,000 × g 
for 15 min, mitochondrial fraction; 6) 100,000 × g for 60 min, microsomal fraction; 7) 150,000 × 
g for 3 hr, ribosomal fraction.(224, 314) The supernatant from step 7 typically represents cellular 
residue with little chance of further recovery of intact organelles as their innate integrity 
deteriorates with continuous manipulation.(313-315) 
Differential centrifugation will be used in conjunction with density shift techniques to 
separate organelles with overlapping sedimentation coefficients if signs of overlap exist, such as 
cross-contamination between organelle fractions.(316) Overlaps can be caused by certain 
similarities among few organelles, some cell media types or in vitro cell treatments.(314, 317) 
Organelles (as a group) often affected include endosomes, lysosomes, peroxisomes and 
mitochondria.(248-250) Density shift involves altering the buoyant density of an organelle away 
from that of others to allow effective centrifugal separation. Buoyant densities will be altered by 
attaching dense metal nanoparticles (or other tailored probes) to target organelles via organelle-
selective ligands.(243, 248, 250, 251) 
The composition and purity of subcellular fractions will be assessed using immunoblot 
assays with antibodies for detecting the presence and/or absence of organelle-specific marker 
proteins.(313, 316) A drawback of differential centrifugation for subcellular fractionation relates to 
purity: that is, isolated subcellular fractions can contain other cellular components in minor or 
appreciable amounts. In addition, cell homogenization and step-to-step manipulations increase 
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chances of ruptured organelles, making it difficult to recover every organelle in intact form from 
the same batch of homogenized cells.(264, 309, 314, 318, 319) 
To circumvent the above-stated drawback, desired collections of different organelles can 
be obtained by pooling together subcellular fractions from replicate batch of cells ‒ a useful 
strategy to be employed in this research. Toward downstream analysis, the obtained subcellular 
fractions will be homogenized by probe-tip ultrasonication. The homogenized organelles will be 
subjected to liquid–liquid extraction (LLE) to recover target analytes, gemini surfactants, which 
will then be determined using LC-MS/MS analysis. 
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1.8 The proposed research 
1.8.1 Rationale of the proposed research 
Numerous research has been conducted to investigate nanoparticle function and 
efficiency.(9) However, there is a lack of in vitro, in vivo and ex vivo data on the biological fate of 
medical nanoparticles.(54, 56, 69) In drug delivery applications of nanoparticles, the nanoparticles 
transport and release drugs into cells via the unpacking of the nanoparticles into the individual 
molecules (i.e., dispersed).(14, 115, 116) However, investigations to trace the amphiphile constituents 
and give an indication of the nanoparticle biological fate are generally not pursued.(54, 56, 69) Such 
studies could give a better understanding of nanoparticle-associated cytotoxicity and present an 
opportunity of averting it. 
My research is focused on developing and implementing tandem mass spectrometric 
methods to study the intracellular/subcellular fate of gemini surfactant-based nanoparticles 
known to yield efficient in vitro drug delivery.(119, 120) As research to address the unknown fate of 
nanoparticles at the intracellular/subcellular level is still lacking,(45-50) my research findings will 
help solve the unknown nanoparticle bio-fate and help model possible correlations between 
nanoparticle intracellular distribution and nanoparticle-associated toxicity. 
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1.8.2 Research Hypotheses 
1.8.2.1 CID-MS/MS fragmentation behaviour and structural confirmation of dipyridinium 
and β-cyclodextrin-based diquaternary ammonium gemini surfactants 
HYPOTHESIS 1 of 3: β-cyclodextrin-substituted- and bis-pyridinium-based gemini surfactant 
compounds with broad structural similarities will show similarity in their CID-MS/MS 
fragmentation, and thus, will reveal a universal fragmentation pattern with similarities in 
the sequence and the structure of the product ions. 
1.8.2.2 Development and evaluation of liquid chromatograph-tandem mass spectrometry 
methods for bioanalysis of dipyridinium and diquaternary ammonium gemini 
surfactants 
HYPOTHESIS 2 of 3: LC-MS/MS methods employing a combination of sulfoalkylbetaine 
HILIC stationary phase and methanol/chloroform-based analyte recovery will show 
compatibility with gemini surfactants through significantly enhanced analytical 
sensitivity of the resultant methods relative to comparable methods without a 
demonstrated amphiphile-compatibility. 
1.8.2.3 Determination of the intracellular deposition and subcellular distribution profiles of 
representative dipyridinium and diquaternary ammonium gemini surfactants 
HYPOTHESIS 3 of 3: The two structurally contrasting gemini surfactant counterparts, 
16(Py)-S-2-S-(Py)16 and 16-3-16 (dipyridinium versus diquaternary ammonium, 
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respectively) will exhibit different (i.e., non-identical) intracellular deposition and/or 
subcellular distribution profiles. 
1.8.3 Research Objectives 
1.8.3.1 Specific Objective 1 – Based on Hypothesis 1 
Under Specific Objective 1, the molecular structure and composition of the chosen gemini 
surfactants (Figure 1.5) will be analyzed using QqQ-LIT-MS and Qq-ToF-MS plaftforms. The 
QqQ-LIT-MS system has a capability of MS3 analysis, while the capability of the Qq-ToF-MS 
system includes high resolution full scan MS and MS/MS analysis. Their combined use will 
generate data for validating the molecular composition of the compounds and for the 
determination of CID-MS/MS distinct fragmentation products (i.e., fingerprints). Similar 
structural elucidation studies were recently conducted by our group for other gemini surfactants 
having quaternary ammonium headgroups, that is, alkanediyl-α,ω-bis(dimethyl alkylammonium 
halide) gemini surfactants.(95-97) In addition, data from Objective 1 will indicate suitable 
fragment ions for multiple reaction monitoring (MRM) MS/MS quantitative analysis. 
Two specific goals under Objective 1 will be achieved: 
• Confirmation of gemini surfactant molecular structures and determination of their 
diagnostic fragment ions through single-stage MS, tandem MS/MS, and multi-stage MS3 
analysis. 
• Establishment of both universal and distinct MS/MS fingerprints. 
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1.8.3.2 Specific Objective 2 – Based on Hypothesis 2 
Quantitative LC-ESI-MS/MS methods will be developed and evaluated toward the analysis 
of representative gemini surfactants contained in PAM 212 cell cultures after treatment with 
nanoparticles of these amphiphiles. The gemini surfactants are 16(Py)-S-2-S-(Py)16 and 16-3-16 
(compound structures: Figure 1.5). Recently, MS-based methods for quantification were 
developed by our group for a group of alkanediyl-α,ω-bis(dimethyl alkylammonium halide) 
gemini surfactants,(147) but no methods are yet available for the bis-pyridinium-based-gemini 
surfactants. LC-ESI-MS/MS offers prior purification/separation for analytes within biological 
samples and this improves the detection of the analyte due to its relative purity. The methods will 
be applied for screening, detection and quantification of 16(Py)-S-2-S-(Py)16 and 16-3-16 
present within PAM 212 cells. To do this, the two gemini surfactants will first be recovered from 
PAM 212 cell cultures in the form of cell lysates after cell treatments (i.e., transfection for varied 
durations) using separate nanoparticle formulations of the two gemini surfactants. The cell 
lysates will then be analyzed to quantify the amount of intact 16(Py)-S-2-S-(Py)16 and 16-3-16 
at pre- and post-treatment times. Here, the information gained will give insights into any 
intracellular metabolism or elimination of gemini surfactants and this will, in turn, help define 
the biological fate of these representative lipids. 
There are two specific goals under Specific Objective 2: 
• Development and evaluation of HILIC-EIS-MS/MS platform for the bioanalysis of gemini 
surfactants with varying molecular structures. 
• Development and full validation of HILIC-EIS-MS/MS quantitative methods for the 
bioanalysis of two lead gemini surfactants, 16(Py)-S-2-S-(Py)16 and 16-3-16. 
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1.8.3.3 Specific Objective 3 – Based on Hypothesis 3 
In drug delivery, soft amphiphile organic nanoparticles are commonly assumed to unpack 
and/or disassemble after incorporation (entry) into cells so as to release their cargo (drug). 
Therefore, the constituent amphiphiles, which in this case are gemini surfactants, can be 
reasonably expected to localize or be distributed to various sites within cells. In this regard, 
Specific Objective 3 seeks to investigate subcellular localization of 16(Py)-S-2-S-(Py)16 in 
comparison with structurally contrasting counterpart, 16-3-16. Data on both the subcellular 
localization for structurally contrasting gemini surfactants is essential: (1) it provides insights 
into the intracellular trafficking, elimination, recycling or other processes that the gemini 
surfactants may undergo; (2) it will enable a comparison of the measured cytotoxicity levels with 
the observed intracellular distribution of the lipids to give insights into how different molecular 
structures influence toxicity or other in vitro parameters. To determine the subcellular 
localization, treated PAM 212 cell sample will be fractionated and analyzed to quantify the 
proportion of 16(Py)-S-2-S-(Py)16 and 16-3-16 present within various fractions. 
Two specific goals under Specific Objective 3 include: 
• Quantitative determination of 16(Py)-S-2-S-(Py)16 and 16-3-16 as lead gemini surfactants 
within transfected PAM 212 cells using developed/validated HILIC-ESI-MS/MS methods. 
• Quantitative determination of 16(Py)-S-2-S-(Py)16 and 16-3-16 within treated PAM212 
subcellular fractions using developed/validated HILIC-ESI-MS/MS methods in 
conjunction with standard addition approach. 
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2.1 Abstract 
RATIONALE: This study aimed at evaluating the CID-MS/MS fragmentation patterns of novel β-
cyclodextrin-substituted- and bis-pyridinium gemini surfactants currently being explored as 
nanomaterial drug delivery agents. In the β-cyclodextrin-substituted gemini surfactants, a β-
cyclodextrin ring is grafted on to a N,N-bis(dimethylalkyl)-α,ω-aminoalkane-diammonium 
moiety using variable succinyl linkers. Contrastively, the bis-pyridinium gemini surfactants are 
based on a 1,1'-(1,1'-(ethane-1,2-diylbis(sulfanediyl))bis(alkane-2,1-diyl))dipyridinium template, 
defined by two symmetrical N-alkylpyridinium parts connected through a fixed ethane dithiol 
spacer. 
METHODS: Detection of the precursor ion [M]2+ species of the synthesized compounds and the 
determination of measurement accuracies were conducted using a QqToF-MS instrument. A 
multi-stage tandem analysis of the detected [M]2+ species was conducted using a QqQ-LIT-MS 
instrument. Both instruments were equipped with an electrospray ionization source (ESI). 
RESULTS: Abundant precursor ion [M]2+ species were detected for all compounds at sub-1ppm 
mass accuracies. The β-cyclodextrin-substituted compounds, fragmented via two main pathways: 
Pathway 1: the loss of one head-tail region produces a [M – (N(Me)2-R)]2+ ion, from which 
sugar moieties (Glc) are sequentially cleaved; Pathway 2: both head-tail regions are lost to give 
[M – 2(N(Me)2-R)]+, followed by consecutive loss of Glc units. Alternatively, the cleavage of 
the Glc units could also have occurred simultaneously. Nevertheless, the fragmentation evolved 
around the quaternary ammonium cations, with characteristic cleavage of Glc moieties. For the 
bis-pyridinium gemini compounds, they either lost neutral pyridine(s) to give doubly-charged 
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ions (Pathway A) or formed complementary pyridinium and alongside other singly-charged ions 
(Pathway B). Similar to β-cyclodextrin-substituted compounds, the fragmentation was centered 
on the quaternary amine functional groups.  
CONCLUSIONS: The MSn analyses of these novel gemini surfactants, reported here for the first 
time, revealed diagnostic ions for each compound, with a universal fragmentation pattern for 
each compound series. The diagnostic ions will be employed within LC-MS/MS methods for 
screening, identification, and quantification of these compounds within biological samples. 
2.2 Introduction 
Amphiphilic compounds such as ‘gemini’ surfactants have been extensively developed and 
tested for applications in gene therapy,[1] drug delivery,[2] drug targeting[3] and antimicrobial 
treatments.[4-6] Gemini surfactants contain two conventional monomer surfactant molecules 
which are incorporated into a single molecule via a  spacer chain.[7] The drug delivery function 
of gemini surfactants is increasingly attracting intense research including design and formulation 
of supramolecular nanoparticles,[8-10] and encapsulation of therapeutic agents such as DNA and 
cytotoxic anti-cancer molecules.[2, 11, 12] As the biomedical application of gemini surfactants 
evolve toward the stage of clinical trials,[9, 13] there is a critical need for methods of identifying, 
quantifying and characterizing these compounds and their metabolites within biological tissues 
and organs. It should be noted that gemini surfactants are also known to cause toxicity;[14, 15] as 
such, analytical methods are needed for the investigation of their pharmacokinetic and other 
properties that may influence their in vivo application. 
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Mass spectrometry (MS) is ideally suited for the identification and quantification of small 
pharmaceuticals.[16, 17] It offers the capability of sensitive, selective and high throughput analyses 
of chemical analytes.[18] Recently, our group reported the collision-induced dissociation-(CID) 
tandem mass spectrometric (MS/MS) fragmentation mechanisms and fingerprints of traditional 
m-s-m type gemini surfactants and their amino acid-/dipeptide-substituted analogues.[19-21] The 
m-s-m abbreviation defines compounds in which two N,N-dimethylalkylammonium moieties of 
alkyl chain length m are joined by a poly(methylene) spacer of carbon chain length s, resulting in 
N,N-bis(dimethylalkyl)-α,ω-alkanediammonium structures (Figure 2.1A). Subsequent to these 
previous studies,[19-21] diagnostic ions were identified for the development of a LC-MS/MS 
quantification method  to analyze diquaternary ammonium gemini surfactants in treated cells.[22] 
 
 
H2m +1Cm N (CH2)s N
CH3
CH3CH3
CH3
CmH2m +1
 
 
B: R-7N(X-suc-β-CD)-R compounds 
A: Structure of m-s-m compounds 
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R = C12H25,  X = O 
= C12H25,  X = NH 
= C16H33,  X = O 
= C18H35,  X = O 
= C12D25,  X = O 
 
 
 
   
n = 9   (C12H24), R1 = H 
= 11 (C14H28), R1 = H 
= 13 (C16H32), R1 = H 
= 15 (C18H36), R1 = H 
= 11 (C16H32), R1 = D 
 
Figure 2.1: Gemini surfactant structural schemes. 
A) Structure of the m-s-m gemini surfactants. Two traditional monomeric 
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surfactants with Cm alkyl tails (where m = chain length) are connected at their 
quaternary ammonium heads via a polymethylene Cs chain containing s 
methylene units. B) Structure of the R-7N(X-suc-β-CD)-R gemini surfactants. 
The attached R groups represent alkyl tails. C) Ȓ(Py)-S-2-S-(Py)Ȓ gemini 
surfactants. Here, the Ȓ groups (shaded) comprise the hydrocarbon chains 
attached to S atoms at one end, bonded to Py head groups (on C-2 from S-atom) 
and having a terminal methyl on the other end. Thus, the full length alkyl tails Ȓ 
are: C12H24, for n = 9; C14H28, n = 11; C16H32, n = 13; C18H36, n = 15. 
 
The m-s-m gemini surfactants have traditionally been used in non-viral DNA 
transfection,[1, 23] but newer compounds are needed for optimal cellular uptake, target cell 
binding specificity, enhanced transfection efficiency and low toxicity. Our laboratory has 
recently designed/synthesized novel β-cyclodextrin-substituted-gemini surfactants in which a β-
cyclodextrin ring (β-CD) is attached to a N,N-bis(dimethylalkyl)-α,ω-aminoalkane-diammonium 
base structure via a succinyl linker (Figure 2.1B).[2] Also, Bhadani and Singh have recently 
designed bis-pyridinium gemini surfactants which contain two identical N-alkylpyridinium 
moieties and an ethane dithiol spacer (Figure 2.1C), whereby the pyridinium head groups present 
a contrast to ammonium head groups of m-s-m compounds.[24, 25] The β-cyclodextrin-substituted-
gemini surfactants have demonstrated efficient drug delivery,[2] while their bis-pyridinium 
counterparts gave efficient DNA transfection,[25, 26] with both families showing low toxicity.[2, 25] 
The β-cyclodextrin moiety of the β-cyclodextrin-substituted-compounds and the 
pyridinium head groups of the bis-pyridinium compounds introduce unique structural 
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characteristics which is instrumental to their efficient drug delivery ability.[2, 25] The MS/MS 
fragmentation pattern of the two compound types has not been reported. MS/MS analysis allows 
for the confirmation of their molecular structure and the identification of diagnostic ion pair 
(precursor → diagnostic fragments) needed for the development of quantitative MRM (multiple 
reaction monitoring) methods. The quantitative methods will be applied for high throughput sub-
cellular identification and quantification of tested compounds as well as aid in metabolite 
identification. 
As noted in the literature, gemini surfactants (and other amphipiles) have shown varying 
degrees of cytotoxicity within their biomedical applications.[14, 15] Therefore, understanding their 
intracellular metabolic profile and subcellular distribution could offer explanations into observed 
toxicities. Evaluation of the gemini surfactant fragmentation behaviour as a prior step has the 
advantage of revealing distinctive gemini surfactant fingerprint fragments that can allow for 
compound identification and the development of quantification methods. 
The aim of this study is to investigate the CID-MS/MS fragmentation behaviour of the β-
cyclodextrin-substituted and bis-pyridinium gemini surfactants. We have previously employed 
CID-MS/MS analyses to establish the fragmentation profile of the m-s-m gemini surfactants and 
their amino acid-/dipeptide-substituted analogues.[19-21] However, the β-cyclodextrin-substituted 
and bis-pyridinium gemini surfactant series introduce structural and chemical modifications from 
these earlier investigated compounds and we have observed, as anticipated, a different CID-
MS/MS behaviour for the two new series. 
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2.3 Materials and Methods 
2.3.1 Gemini surfactants 
Four β-cyclodextrin-substituted compounds (R-7N(X-suc-β-CD)-R, Figure 2.1B) were 
synthesized using previously reported synthetic methods.[2) As well, four bis-pyridinium-based 
compounds were synthesized as previously described,[25] and are denoted Ȓ(Py)-S-2-S-(Py)Ȓ 
(Figure 2.1C), where the special symbol Ȓ denotes the uniquely bonded alkyl tails. Also, 
deuterated gemini surfactants analogues, to serve as internal standards, were synthesized 
according to the respective methods above[2, 25]. These include a deuterated-pyridine(-d5)-bearing 
compound for the Ȓ(Py)-S-2-S-(Py)Ȓ series and a deuterated-dodecyl(-d25)-bearing compound 
for the R-7N(X-suc-β-CD)-R series.  
In the Ȓ(Py)-S-2-S-(Py)Ȓ and R-7N(X-suc-β-CD)-R series (Figure 2.1), there is a variation 
of both the alkyl groups R and the head group/spacer region. In the R-7N(X-suc-β-CD)-R 
compounds, the alkyl tails, R, are attached to quaternary ammonium head groups that are joined 
by a di(propyl)amine spacer, onto which a β-CD substituent is grafted via a succinyl linker. In 
the Ȓ(Py)-S-2-S-(Py)Ȓ series, pyridinium units (Py) are incorporated as head groups, an ethane-
dithiol chain is the spacer, and the alkyl tails, Ȓ, are bonded differently. They are attached at one 
end to an S atom; and on C-2 position from this end, the pyridinium head groups are bonded as 
substituents. On the other end of the Ȓ chains are terminal methyl groups (Figure 2.1). Thus for 
the “Ȓ(Py)-S-2-S-(Py)Ȓ” designation (Figure 2.1C), the full length Ȓ chains are: C12H24, for n = 
9; C14H28, n = 11; C16H32, n = 13; C18H36, n = 15. 
Methanol (Fisher Scientific) and formic acid (EMD Chemicals) were used as solvents. The 
water used was organic-free and prepared form a Milli-Q purification system (Millipore Corp).  
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2.3.2 Sample preparation 
Stock solutions of each surfactant, 3 mM, in 50:50 methanol/water (v/v) and containing 0.1% 
formic acid were prepared and stored at –20 oC prior to analysis. For MS (single-stage), MS/MS, 
and MS3 analysis, each sample was further diluted by 1000–5000× prior to sample injection and 
MS analysis. 
2.3.3 Mass spectrometric analysis 
2.3.3.1 Single-stage MS analysis 
Positive ion mode, single stage MS analysis of gemini surfactants was conducted using an 
Applied Biosystems API QSTAR® XL MS/MS quadrupole time-of-flight hybrid tandem mass 
spectrometer (QqToF-MS/MS). The declustering potential was varied between 40.0 and 50.0 V, 
while the focusing potential was fixed at 290.0 V. Using an integrated Harvard Syringe pump 
(Havard Apparatus, MA, USA), sample aliquots were infused into the mass spectrometer at a 
rate of 10 µL/min through a Turbo Ionspray Source, having a needle voltage of 5500 V and a 
temperature of 80–100 oC. Nitrogen was used both as the drying gas and ESI nebulizing gas.  
Similar to previous work,[19, 20] a two-point internal calibration was performed for all 
gemini surfactants using two doubly charged calibration standards, given that the tested gemini 
surfactants are doubly-charged species. The two calibrants were [Glu1]-Fibrinopeptide B Human 
(amino acid sequence EGVNDNEEGFFSAR, [M + 2H]2+ m/z 785.8421, C66H95N19O26; Sigma-
Aldrich, Oakville, ON, Canada) and N,N-bis(dimethyldodecyl)-1,3-propanediammonium 
dibromide (12-3-12, [M]2+ m/z 234.2685), an in-house pure-grade standard.[27] Unlike our 
previous calibration methods, each single analyte was infused simultaneously with the two 
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calibrants under optimized conditions such that the three detected species (two calibrants, one 
analyte) are within 5% variation in their recorded ion counts. This was to ensure high mass 
accuracy and minimal error. 
In addition, we employed our previous calibration method[19, 20] which involved infusion of 
the two calibrants along with multiple analytes (≥4) and the mass accuracy results were 
compared with the method of single-analyte and two-calibrant infusion, described above. With 
the single analyte infusion approach, the peak intensities of the analyte and two calibrants could 
be optimized to reduce the variation in their ion count to about 5% of each other. In contrast, 
optimization of peak intensities to such a narrow margin for multiple analytes, infused 
simultaneously, was not attainable, using the same calibrants and solvents. 
2.3.3.2 CID-MS/MS analysis 
The collision-induced dissociation (CID) tandem MS/MS analysis of each compound was 
conducted using a QTRAP® 4000 LC/MS/MS system (Applied Biosystems, Foster City, CA, 
USA). This hybrid triple quadrupole–linear ion trap mass spectrometer (QqQ-LIT) was equipped 
with a “Turbo V Ion Spray” ESI source and used nitrogen as collision gas. A freshly diluted 
sample of each compound (1000–5000× dilution of 3 mM stock) was infused directly into the 
ionization source at a flow rate of 10 µL/min using a model 11 Plus syringe pump (Harvard 
Apparatus, MA, USA). The declustering potential was varied in the range 30–100 V, while the 
collision energy was optimized for each compound in the range 16–55 eV to induce 
fragmentation while the precursor ion remained abundant. It should be note that MS/MS 
experiments using the API QSTAR® XL did not yield informative spectra regardless of the 
experimental conditions.   
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2.3.3.3 Multi-stage MS3 analysis 
MS3 experiments were conducted on the QTRAP® 4000 LC/MS/MS system using the optimized 
conditions/settings stated above. The QqQ-LIT system is suitable for obtaining vital structural 
information due to its ability to trap ions in the LIT analyzer and, subsequently, to perform MS3 
experiments.[28, 29] In the MS3 mode, the excitation energy (AF2) used to fragment of selected 
second generation ions was fixed at 100 mV. The QqQ-LIT system has up to MS3 capability. To 
further probe the sequential fragmentation patterns, multiple MS3 experiments were performed. 
 107 
 
2.4 Results 
2.4.1 Single-stage QToF MS analysis 
Abundant doubly-charged species [M]2+ were detected for all tested gemini surfactants by full 
scan MS analysis in the positive ion mode. The observation signifies the presence of‘ionized’ 
compounds with two positive charges, as expected for the β-cyclodextrin-substituted- and bis-
pyridinium gemini surfactants which contain either two diquaternary ammonium or two 
pyridinium headgroups (Figure 2.1), respectively. The exact masses of the [M]2+ species were 
detected with mass accuracies of less than 1 ppm mass error (Table 2.1) using a two-point 
internal calibration method and analyzing the compounds individually. Such level of mass 
accuracy exceeds previous mass accuracies reported for similar compound analysis.[19, 20] In 
contrast, when the mass accuracy analysis with two-point calibration was done for multiple 
compounds (infused all at once), the observed mass accuracies were less strong as previously 
shown (Table 2.1).[19, 20] 
The level of high mass accuracy for single-analyte infusion was achieved through peak 
intensity optimization for the analyte and two calibrants such that a minimized variation (≤5%) 
in their absolute ion count is attained in each calibration step. The highest measure of mass 
accuracy is normally achieved when the detected ions of the calibrants and the analyte(s) are 
approximately of the same abundance.[30] In contrast, fluctuations in ion abundance and peak 
shape can both significantly compromise the measured mass accuracy when using internal 
calibrants.[30, 31] These results clearly illustrate that very robust data can be achieved using the 
QSTAR® QqToF-MS/MS system. 
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Table 2.1. Detected doubly charged precursor ion species [M]2+ for β-CD-based and bis-pyridinium gemini surfactants in the positive 
ion mode. Mass accuracy analysis was conducted on a QSTAR® QqToF-MS/MS system. 
    Method A: single analyte infusion Method B: multi-analyte infusion 
Gemini surfactant Molecular 
formula 
Mono-
isotopic 
mass 
[M]2+ m/z, 
calculated 
 [M]2+ m/z, 
exp’talA 
Mass 
accuracy 
(ppm)A 
[M]2+ m/z, 
exp’talB 
Mass 
accuracy 
(ppm)B 
        
12-7N(O-suc-β-CD)-12 C80H147N3O372+ 1741.9702 870.98512 870.98517 0.05741 870.98940 4.91398 
12-7N(NH-suc-β-CD)-12 C80H148N4O362+ 1740.9862 870.49311 870.49313 0.02298 870.49110 -2.30904 
16-7N(O-suc-β-CD)-16 C88H163N3O372+ 1854.0954 927.04772 927.04776 0.04315 927.04830 0.62564 
18:1-7N(O-suc-β-CD)-18:1* C92H167N3O372+ 1906.1267 953.06337 953.06349 0.12591 953.06001 -3.52547 
        
12(Py)-S-2-S-(Py)12 C36H62N2S22+ 586.4343 293.21717 293.21719 0.06821 293.21701 -0.54567 
14(Py)-S-2-S-(Py)14 C40H70N2S22+ 642.4969 321.24847 321.24849 0.06226 321.24893 1.43191 
16(Py)-S-2-S-(Py)16 C44H78N2S22+ 698.5595 349.27977 349.27974 -0.08589 349.27821 -4.46633 
18(Py)-S-2-S-(Py)18 C48H86N2S22+ 754.6221 377.31107 377.31111 0.10601 377.30812 -7.81848 
AFrom the method of single analyte infusion with two internal calibrants. BFrom the method of multiple analyte infusion with two 
internal calibrants. *18:1 denotes mono-unsaturated C18 tails (oleyl − C18H35).    
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2.4.2 Multi-stage MS analysis 
Using positive ion mode ESI-QqQ-LIT-MSn analysis, distinct multi-stage CID-MSn 
fragmentation patterns were observed for the β-cyclodextrin-subsituted and the bis-pyridinium 
gemini surfactant series. The different spacer types as well as the incorporated substituent, β-CD, 
in one of the series would be expected to give rise to different fragmentation patterns and 
specific product ions that can serve as diagnostic fragments. However, the compounds from the 
same series showed a similar fragmentation pattern.[19] 
For the β-cyclodextrin-subsituted gemini surfactants, the compound-specific product ions 
originate from the neutral loss of only one quaternary ammonium head group along with the 
attached alkyl tail region, N(CH3)2-R. Additional neutral losses from the β-CD substituent of the 
remaining fragment leads to further compound-specific product ions. But the loss of the 
remaining head group–tail unit results in a fragment ion which is identical for these surfactants 
except where the structural variable X  alternates between O (16 Da) and NH (15 Da) (Figure 
2.1B). Surprisingly, the ester linkage connecting the β-CD ring to the rest of the compound 
structure remained intact during fragmentation. 
For the bis-pyridinium compounds Ȓ(Py)-S-2-S-(Py)Ȓ, the observed diagnostic product 
ions originated from the loss of either one or both pyridinium head group(s). Pyridinum was 
either eliminated as chared or neutral species. In addition, the loss of one N-alkylpyridinium (a 
combined head group–tail unit) or the cleavage of portions of the alkyl tail resulted in 
compound-specific product ions. Overall, the observed diagnostic product ions authenticated the 
molecular structures of tested compounds, confirming the presence of pyridinium head groups 
and other unique structural features.  
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Table 2.2. Major product ions of the R-7N(X-suc-β-CD)-R gemini surfactants and their theoretical m/z values from CID-MS/MS 
analysis of the precursor ions [M]2+. The distinctive product ions include those numbered 1–7. Several minor product ions are 
also observed (not listed); they include those corresponding to neutral loss of H2O, CO or CO2 from the listed ions. 
Product 
ion 
Designation of fragment 
structure 
12-7N(O-suc- 
β-CD)-12 
m/z, (CE: 50 V) 
12D25-7N(O-
suc-β-CD)-
12D25 
m/z, (CE: 50 V) 
12-7N(NH-suc- 
β-CD)-12 
m/z, (CE: 50 V) 
16-7N(O-suc- 
β-CD)-16 
m/z, (CE: 53 V) 
18:1-7N(O-suc- 
β-CD)-18:1 
m/z, (CE: 55 V) 
 [M]2+ 870.99 896.14 870.49 927.05 953.06 
1 [M−(R−H)]2+ 786.89 789.44 786.37 814.89 827.90 
2 [M−(R−H)−NH(Me)2]2+ 764.36 766.94 763.87 792.39 805.40 
3i1 [M−(R−H)−NH(Me)2−Glc]+ 1365.66 1421.73 1364.68 1421.73 1447.74 
3i2 [M−(R−H)−NH(Me)2−2Glc]+ 1203.62 1259.67 1202.63 1259.67 1285.69 
⁞       
3i6 [M−(R−H)−NH(Me)2−6Glc]+  717.45 773.52 716.47 773.52 799.53 
4i1 [M−2(R−H)−2(NH(Me2))−Glc]+ 555.39 611.46 554.42 611.46 637.48 
4i2 [M−2(R−H)−2(NH(Me2))−2Glc]+ 1152.56 1152.56 1151.43 1152.56 1152.56 
⁞       
4i6 [M−2(R−H)−2(NH(Me2))−6Glc]+ 504.21 504.21 503.21 504.21 504.21 
5i1 [M−2(R−H)−NH(Me2)−Glc]+ 342.15 342.15 341.15 342.15 342.15 
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5i2 [M−2(R−H)−NH(Me2)−2Glc]+ 314.16 314.16 313.17 314.16 314.16 
⁞       
5i6 [M−2(R−H)−NH(Me2)−6Glc]+ 522.22 522.22 521.22 522.22 522.22 
7i1 [M−2(R−H)−2(NH(Me2))−(Glc–H2O )]+ 198.11 198.11 197.11 198.11 198.11 
7i2 [M−2(R−H)−2(NH(Me2))−2(Glc–H2O )]+ 170.12 170.12 169.11 170.12 170.12 
⁞       
7i6 [M−2(R−H)−2(NH(Me2))−6(Glc–H2O )]+ 648.25 648.25 647.26 648.25 648.25 
8 [M−2(R−H)−2(NH(Me2))−6(Glc–H2O)–CO]+ 306.16 306.16 359.16 306.16 306.16 
9i1 [M−2(R−H)−2(NH(Me2))−H2O−Glc]+ 486.20 486.20 485.20 486.20 486.20 
9i2 [M−2(R−H)−2(NH(Me2))–H2O−2Glc]+ 324.14 324.14 323.14 324.14 324.14 
⁞       
9i6 [M−2(R−H)−2(NH(Me2))–H2O−6Glc]+ 324.14 324.14 324.14 324.14 324.14 
10 [M−2(R−H)−2(NH(Me2))–H2O−6Glc–CO]+ 296.15 296.15 296.15 296.15 296.15 
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Table 2.3. Major product ions of the Ȓ(Py)-S-2-S-(Py)Ȓ gemini surfactants and their theoretical m/z values from CID-MS/MS 
analysis of the precursor ions [M]2+. The m/z values differ for all product ions except for product ion number 5. Other, but 
minor, product ions were also observed, resulting from various neutral losses in the form CᵪH2ᵪ‒y, y = 0 or 2. 
Product 
ion 
Designation of fragment 
structure 
12(Py)-S-2-S- 
(Py)12 
m/z, (CE: 16 V) 
14(Py)-S-2-S- 
(Py)14 
m/z, (CE: 17 V) 
16(Py)-S-2-S- 
(Py)16 
m/z, (CE: 19 V) 
16(PyD5)-S-2-S- 
(PyD5)16 
m/z, (CE: 24 V) 
18(Py)-S-2-S- 
(Py)18 
m/z, (CE: 25 V) 
 [M]2+ 293.28 321.25 349.28 354.65 377.31 
1f1 [M−*Py]2+ 253.83 281.80 309.77 302.24 337.74 
1f2 [M−Py−C3H6]2+  232.77 260.74 290.71 293.34 318.64 
1f3 [M−Py−C3H6−CH2]2+ 225.69 253.66 283.61 291.27 311.67 
2f1 [M−2Py]2+ 214.17 269.14 299.11 299.32 327.12 
2f2 [M−2Py−C3H6]2+ 193.15 221.12 251.12 251.49 279.94 
2f3 [M−2Py−C3H6−CH2]2+ 186.14 214.11 244.09 244.26 272.06 
3f1 [M−Py]+ 506.28 562.34 618.44 623.84 674.55 
3f2 [M−Py−C3H6]+ 464.28 520.36 576.46 581.56 632.57 
3f3 [M−Py−C3H6−CH2]+ 450.24 506.41 562.63 567.73 618.74 
4f1 [M−2Py]+ 427.81 483.87 539.97 539.77 596.08 
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4f2 [M−2Py−C3H6]+ 385.73 441.79 497.89 497.99 554.05 
4f3 [M−2Py−C3H6−CH2]+ 371.28 427.44 483.54 483.64 539.65 
5 [Py+H]+ 80.10 80.17 80.11 85.21 80.31 
6f1 [M−2Py−2(CH2)]+ 399.76 455.82 511.92 502.02 568.03 
6f2 [M−2Py−C3H6−2(CH2)]+ 357.24 413.31 469.41 470.05 525.52 
6f3 [M−2Py−C3H6−3(CH2)]+ 343.26 399.37 455.43 455.75 511.54 
7f1 [3i1−(Ȓ−H2)]+ or [M−Py−(Ȓ−H2)]+ 340.65 396.69 452.79 457.89 508.90 
7f2 [M−2Py−(Ȓ−H2)]+ 261.27 317.33 373.43 373.59 429.54 
7f3 [M−2Py−(Ȓ−H2)−C2H2S2]+ 203.19 259.25 315.35 315.54 371.46 
7f4 [M−2Py−(Ȓ−H2)−C2H2S2−H2]+ 201.27 257.33 313.43 313.55 369.54 
7f5 [M−2Py−Ȓ−C2H2S2−CH2]+ 189.18 245.23 301.33 301.48 357.44 
7f6 [M−2Py−Ȓ−C2H2S2−2(CH2)]+ 175.17 231.25 287.35 287.63 343.64 
7f7 [M−2Py−Ȓ−C2H2S2−3(CH2)]+ 161.10 217.16 273.26 273.66 329.36 
* Py: indicates pyridine, i.e., either hydrogenated pyridine Py, or deuterated pyridine, PyD5.  
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The gemini surfactant fragmentation patterns are detailed below using two representative 
examples, namely 12-7N(O-suc-β-CD)-12 and 12(Py)-S-2-S-(Py)12 from the β-cyclodextrin-
substituted and bis-pyridinium compound series, respectively. The major product ions are 
tabulated for the β-cyclodextrin-subsituted (Table 2.2) and bis-pyridinium gemini surfactants 
(Table 2.3). In addition, data is given for deuterated gemini surfactant analogues that confirm the 
proposed fragmentation patterns by revealing increased m/z values for deuterated fragments in 
comparison with the corresponding non-deuterated fragments of test compounds. 
2.4.3 R-7N(X-suc-β-CD)-R compounds: MS/MS fragmentation pathway 
The five R-7N(X-suc-β-CD)-R compounds include 12-7N(O-suc-β-CD)-12, 12-7N(NH-
suc-β-CD)-12, 16-7N(O-suc-β-CD)-16, 18:1-7N(O-suc-β-CD)-18:1 and 12D25-7N(O-suc-β-CD)-
12D25, the latter being an isotope-labeled analogue of 12-7N(O-suc-β-CD)-12 (Figure 2.1B). 
Because of the identical pattern of fragmentation within this series, the compound 12-7N(O-suc-
β-CD)-12 is chosen as a representative example of the series. Figure 2.2 shows the ESI-QqQ-
LIT-MS/MS analysis of the compound, while Scheme 2.1 shows its proposed fragmentation 
pathway. Ions were designated based on the fragmentation type and Table 2.4A provides the 
definition of relationships between fragments ions which were produced by the 12-7N(O-suc-β-
CD)-12 compound in a serial pattern. 
The 12-7N(O-suc-β-CD)-12 compound (precursor ion [M]2+: m/z 870.99) fragmented 
readily, generating a first product ion observed at m/z [786.89]2+, designated as [M–(R–H)]2+ (1). 
It represents the loss of one full alkyl tail in the form of a neutral dodecene molecule (R–H = 
C12H24). The observed peak for the product ion m/z [786.89]2+ has relatively weak intensity 
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(Figure 2.2). The substantially low abundance for this fragment ion suggests that it is unstable 
and instantly fragments (further explanation in the Discussion section). 
 
 
 
Figure 2.2: MS/MS spectrum of 12-7N(O-suc-β-CD)-12 as a representative example of the β-
CD-substituted gemini surfactants. This compound may also be designated by: 12-
+N(Me)2-7N(O-suc-β-CD)- +N(Me)2-12. 
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Table 2.4. The structure of various fragment ions series illustrated in Schemes 1 and 2. A) 
Fragment ion series for the 12-7N(O-suc-β-CD)-12 gemini surfactant; B) fragment ion 
series for the 12(Py)-S-2-S-(Py)12 gemini surfactant. 
Part A:    
Gemini surfactant 
Fragment ion 
series 
General structure of 
fragment ion series 
Variation among 
serial fragment ions 
12-7N(O-suc-β-CD)-
12 
3i1 – 3i6 
 
Ion 3i1, n = 6 
Ion 3i2, n = 5 
Ion 3i3, n = 4 
Ion 3i4, n = 3 
Ion 3i5, n = 2 
Ion 3i6, n = 1 
 4i1 – 4i6 
 
Ion 4i1, n = 6 
Ion 4i2, n = 5 
Ion 4i3, n = 4 
Ion 4i4, n = 3 
Ion 4i5, n = 2 
Ion 4i6, n = 1 
 5i1 – 5i6 
 
Ion 5i1, n = 6 
Ion 5i2, n = 5 
Ion 5i3, n = 4 
Ion 5i4, n = 3 
Ion 5i5, n = 2 
N+
N
O
O
O
O
OH
OH
OH
O
O
OH
OH
O
H
n
n
NH +
N
O
O
O
O
OH
OH
OH
O
O
OH
OH
O
H
N
O
O
O
O
OH
OH
OH
O
O
OH
OH
O
H
H+
n
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Ion 5i6, n = 1 
 7i1 – 7i6 
 
Ion 7i1, n = 6 
Ion 7i2, n = 5 
Ion 7i3, n = 4 
Ion 7i4, n = 3 
Ion 7i5, n = 2 
Ion 7i6, n = 1 
 9i1 – 9i6 
 
Ion 9i1, n = 6 
Ion 9i2, n = 5 
Ion 9i3, n = 4 
Ion 9i4, n = 3 
Ion 9i5, n = 2 
Ion 9i6, n = 1 
 
Table continued on next page… 
N
O
O
O
O
OH
OH
OH
O
O
OH
OH
O
H
OH
H+
n
N
O
O
O
O
OH
OH
OH
O
O
OH
O
H
H+
n
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Part B:    
Gemini surfactant 
Fragment ion 
series 
General structure of 
fragment ion series 
Variation among 
serial fragment ions 
12(Py)-S-2-S-(Py)12 1f1 – 1f3 
 
Ion 1f1, R’ = C12 
Ion 1f2, R’ = C9 
Ion 1f3, R’ = C8 
 2f1 – 2f3 
   
Ion 2f1, R’ = C12 
Ion 2f2, R’ = C9 
Ion 2f3, R’ = C8 
 3f1 – 3f3 
 
Ion 3f1, R’ = C12 
Ion 3f2, R’ = C9 
Ion 3f3, R’ = C8 
 4f1 – 4f3 
   
Ion 4f1, R’ = C12 
Ion 4f 2, R’ = C9 
Ion 4f3, R’ = C8 
 6f1 – 6f3 
   
Ion 6f1, R’ = C10 
Ion 6f2, R’ = C7 
Ion 6f3, R’ = C6 
 7f1 
   
N/A 
N+
S S CH+
CH +
S S CH+
N+
S S
CH +
S S
CH +
S S
N+
S SH
R’ = encircled 
       part 
       remaining 
R’ = encircled 
       part 
       remaining 
 
R’ = encircled 
       part 
       remaining 
R’ = encircled 
       part 
 
R’ = encircled 
       part 
       remaining 
A full alkyl tail Ȓ 
eliminated 
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 7f2 
        
N/A 
 7f3 
        
N/A 
 8f1 – 8f3 
 
Ion 8f1, R’ = C7 
Ion 8f2, R’ = C6 
Ion 8f3, R = C5 
Ion 8f4, R’ = C4 
 
 
CH +
S SH
CH2
SH2
+
N+
S S
 
A full alkyl tail 
  
 
R’ = encircled 
       part 
        
 120 
 
 
Scheme 2.1: Multi-stage fragmentation pattern of 12-7N(O-suc-β-CD)-12 as a representative 
example of the β-CD-substituted gemini surfactant. 
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            Legend: 
            3i1–3i6: Product ions retaining one headgroup–tail region; 
            4i1–4i6: Product ions retaining no headgroup–tail region; 
            5i1–5i6: Product ions retaining one dimethylammonium headgroup but no tail region; 
            7i1–7i6: Product ions related to 4i1–4i6 by neutral loss of 144 Da glycosyl residue (Glc– H2O); 
            9i1–9i6: Product ions related to 4i1–4i6 by neutral loss of H2O molecule. 
For Pathway 2, ion 3i1 loses the remaining he 
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Figure 2.3: MS3 spectrum of product ion m/z [764.72]2+ which originates from MS/MS 
fragmentation of the compound 12-7N(O-suc-β-CD)-12, with precursor ion [M]2+ m/z 
870.99. Insert: MS3 spectrum of product ion m/z [990.42]2+ which was also observed in 
the MS3 fragmentation of the product ion m/z [764.72]2+. 
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Scheme 2.1: Major multi-stage fragmentation pathways of 12(Py)-S-2-S-(Py)12 as 
representative example of the bis-pyridinium gemini surfactants. Fragment ions 
observed are mainly of two kinds: 1) singly-charged product ions [M–Py]+, [M–Py–(R–
H)]+, [M– Py–(R–H)–(CᵪH2ᵪ‒y)]+; and 2) doubly-charged products ions [M–Py]2+, [M–
Py–(R–H)]2+, [M– Py–(R–H)–(CᵪH2ᵪ‒y)]2+. 
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2.4.4 Ȓ(Py)-S-2-S-(Py)Ȓ compounds: MS/MS fragmentation pathway 
The Ȓ(Py)-S-2-S-(Py)Ȓ family fragmentation behaviour was studied by using multi-stage 
tandem ESI-QqQ-LIT-MS analysis. Five member compounds of the series (including an isotopic 
analogue), were investigated: 12(Py)-S-2-S-(Py)12, 14(Py)-S-2-S-(Py)14, 16(Py)-S-2-S-(Py)16, 
16(PyD5)-S-2-S-(PyD5)16 and 18(Py)-S-2-S-(Py)18. The fragmentation pattern was similar for all 
of these compounds and 12(Py)-S-2-S-(Py)12 is used as an  example for illustration. The MS/MS 
analysis of the precursor ion [M]2+ m/z 293.28 for this compound is given in Figure 2.4. Ions 
were designated based on the fragmentation type and Table 2.4B provides the definition of 
relationships between fragment ions which were produced by the 12(Py)-S-2-S-(Py)12 
compound in a serial pattern. 
The 12(Py)-S-2-S-(Py)12 compound readily fragmented (Scheme 2.2); however, its 
fragmentation is markedly different and begins with two alternate fragmentation routes, 
designated Pathways A and B. Pathway A shows the fragmentation of the precursor ion [M]2+ m/z 
293.22, leading to a series of doubly-charged product ions, initiated by the elimination of a 
neutral pyridine moiety. Pathway B, on the other hand, leads to a series of singly-charged 
product ions including the initial generation of two complementary ions (Scheme 2.1). 
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Figure 2.4: MS/MS spectrum of 12(Py)- S-2-S-(Py)12 as a representative example of the bis-pyridinium 
gemini surfactants. Inset: full MS scan of the precursor ions [M]2+ of four bis-pyridinium gemini 
surfactants: m/z 293.28, 321.27, 349.29, 377.32. Analysis: positive mode. 
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For Pathway A, the first stage is the neutral loss of a pyridinium head group, leading to the 
doubly-charged diagnostic ion m/z [253.83]2+ (1f1: [M–Py]2+). Although a pyridinium head group 
is cleaved, fragment ion 1f1 remains doubly-charged because of one positive charge from the 
remaining cationic pyridinium headgroup and another positive charge created on the carbon atom 
originally bonded to the cleaved pyridinium head group. 
Ion 1f1 then fragments via successive cleavage of portions of the alkyl tail or via the neutral 
elimination of the remaining pyridinium head group, followed by successive cleavage of 
segments from the alkyl tails. The series of ions observed through stepwise breakage of alkyl 
tails with the retention of one pyridinium head group is designated as the [M–Py–(CᵪH2ᵪ‒y)]
2+ 
(1f-series). The other series observed through stepwise breakage of alkyl tails with no remaining 
pyridinium head group conforms to the designation [M–2(Py)–(CᵪH2ᵪ‒y)]
2+ (2f-series); CᵪH2ᵪ‒y 
represents the cleaved portions of the alkyl tail such as propene, ethene or methylene (Table 
2.4B). It should be noted that ions formed via Pathway A were doubly-charged and of relatively 
low abundance. 
Unlike Pathway A which produced relatively low abundant doubly-charged ions (via 
elimination of neutral pyridine and neutral hydrocarbon species), Pathway B gives rise to 
abundant singly-charged product ions. The precursor ion [M]2+ m/z 293.28 first produces two 
positively, singly-charged complementary ions, namely m/z [506.28]+ (3f1: [M–Py–H]+) and m/z 
[80.10]+ (5: [Py+H]+ ≈ C5H6N+). This complementary loss was confirmed with the analysis of 
the deuterated pyridinium-bearing compound which revealed the formation of the ion m/z 
[85.09]+ (C5HD5N+, data not shown), confirming the formation of fragment ion 5. 
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Subsequently, ion 3f1 fragments to yield multiple product ions which either i) bear two 
partial or complete tail regions (Series 3f, 4f, or 8f), or ii) bear one partial or complete tail region  
(i.e. 7f-series ions). Most fragment ions generally arise from similar sequential breakage of 
portions of the alkyl tail regions. Despite this, the observed ions still had different fragment 
structures due to differences in the exact nature of structural parts that are cleaved and/or 
retained. 
For product ions of the 4f-series, designated as [M–2Py–H with/without –(CᵪH2ᵪ‒y)]
+, ion 
4f1 (m/z [427.81]+) is first formed through the loss of a neutral pyridine molecule (C5H6N, 79 Da) 
from the preceding ion 3f1. The other 4f-series ions, including 4f2 and 4f3, similarly evolved 
through the loss of a neutral pyridine moiety from corresponding 3f-series ions (Scheme 2.1, 
Table 2.4B). The 7-series ions (dominant ions), [M–nPy–R–H–(CᵪH2ᵪ‒y)]
+, originate from the 
loss of a full alkyl tail as a neutral dodecyne molecule (CᵪH2ᵪ‒y = C12H22, x = 12, y = 2) from ion 
3f1 to first yield the major product ion 7f1 m/z [340.26]+. Ion 7f1 then leads to a succession of 
ions: 7f2 m/z [261.27]+, 7f3 m/z [203.19]+, 7f4 m/z [189.18]+, 7f5 m/z [175.17]+ and 7f6 m/z 
[161.10]+ via neutral losses as illustrated in Scheme 2.1. 
Finally, the 8-series ions [M–2(Py)–(R–H)–(CᵪH2ᵪ‒y)]
+, Table 2.4B) resulted from neutral 
loss of ethene from the partially fragmented hydrocarbon tail of ion 3f2 to give ion 8f1. Fragment 
ion 8f1 then subsequently produces smaller ions 8f2 - 8f4 via a stepwise cleavage of neutral 
ethene, methylene or other small units from the partially fragmented hydrocarbon tail. 
Regardless of the tail length, the overall CID-MSn results for the Ȓ(Py)-S-2-S-(Py)Ȓ compounds 
showed a universal fragmentation (Table 2.3).  
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2.5 Discussion 
2.5.1 Mass accuracy and compound structural confirmation 
The achievement of high mass accuracies in this work using the QSTAR® system (up to 
less than 1 ppm error, Table 2.1) is particularly important as high mass accuracies  can strongly 
confirm/establish a  compound’s identity.[30, 31] The level of mass accuracy given by the single 
analyte infusion method exceeded that given by multiple analyte infusion obviously due to the 
minimization of peak intensity variations. 
2.5.2 Multi-stage tandem MS/MS fragmentation patterns 
The bioanalysis (identification, quantification and intracellular fate investigation) of 
gemini surfactants within cells/tissues requires an understanding of their MS fragmentation 
behaviour. The fragmentation patterns for both the Ȓ(Py)-S-2-S-(Py)Ȓ and the R-7N(X-suc-β-
CD)-R gemini surfactant series (Schemes 2.1, 2.2) established by using multi-stage tandem CID-
MSn analysis has revealed unique behaviour and diagnostic fragment ions. This has led to 
confirmation of the molecular structure of tested compounds For instance, the structures of the 
R-7N(X-suc-β-CD)-R compounds were adequately confirmed with the detection of eight 
diagnostic fragment ions including 1, 2, and 3i1–3i6 series (Scheme 2.1, Table 2.2) for each 
compound. These ions reflect the distinct alkyl tails R, β-CD substituent and the presence of 
either the O- or N-succinyl linker (Figure 2.1, Table 2.2). 
In addition, identical fragment ions were also observed (e.g., ions in Pathway 2, Scheme 
2.1) following complete collision-induced cleavage of the distinct structural parts. This further 
confirms the molecular structures since the stepwise cleavage of specific structural parts matched 
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the observed changes in m/z values. For instance, the fragment ion 4i1, which was a prominent 
recurring ion among the R-7N(X-suc-β-CD)-R compounds with X = O, was obtained via the loss 
of neutral alkene molecules that depended on the carbon length of the alkyl tail region. The 
identified alkene molecules (denoted R–H, in the [M]2+→[1] and [3i1]→[5i1] transitions, Scheme 
2.1) included dodecene (168.19 Da), dodecene-d24 (192.34 Da), hexadecene (224.25 Da) and 
octadecadiene (250.27 Da). Each specific alkene molecule (i.e., the neutral loss) occurred only 
for a specific compound, and thus helped confirm the molecular identity of the compound(s). 
For the Ȓ(Py)-S-2-S-(Py)Ȓ compounds, the occurrence of several diagnostic product ions 
including 1f1, 1f2, 1f3, 3f1, 3f2 and 3f3 (Scheme 2.2, Figures 2.4, 2.5) marks a distinct identity for 
each of these compounds. The cleavage of pyridinium head groups both as a neutral pyridine 
moiety and as a pyridinium ion gives confirmation of the bis-pyridinium content of the Ȓ(Py)-S-
2-S-(Py)Ȓ compounds. Similarly, the loss of neutral aliphatic alkyne molecules (e.g., dodecyne) 
also confirms the presence of two alkyl tails. The loss of neutral alkyne molecules from the 
Ȓ(Py)-S-2-S-(Py)Ȓ compounds, when compared with the loss of neutral alkenes from the 
corresponding R-7N(X-suc-β-CD)-R compounds,  is consistent with the difference in bonding of 
the alkyl tail within the two series. 
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Figure 2.5: MS3 spectrum of product ion m/z [253.19]2+ which originates from MS/MS 
fragmentation of the compound 12(Py)-S-2-S-(Py)12, with precursor ion [M]2+ m/z 
293.28. Insert: MS3 spectrum of product ion m/z [450.26]+ originating from MS3 
fragmentation of the product ion m/z [253.19]2+. 
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2.5.3 Fragmentation: R-7N(X-suc-β-CD)-R vs. Ȓ(Py)-S-2-S-(Py)Ȓ 
The difference in molecular structure between the R-7N(X-suc-β-CD)-R and Ȓ(Py)-S-2-S-
(Py)Ȓ compounds was evident from their different tandem CID-MS/MS fragmentation  
behaviour. The quaternary ammonium head groups in the R-7N(X-suc-β-CD)-R compounds were 
lost as neutral N-methylmethanamine molecules (Me-N(H)-Me, 45 Da; Scheme 1). On the other 
hand, the pyridinium head groups in the Ȓ(Py)-S-2-S-(Py)Ȓ compounds were cleaved either as  a 
neutral pyridine moiety (C5H5N, 79 Da) or as a pyridinium ion (ion 5, C5H6N+, m/z 80 Da; 
Figure 2.4, Scheme 2.2). Also, the neutral loss of full alkyl tail moieties gave different forms of 
neutral aliphatic molecules for the R-7N(X-suc-β-CD)-R vs. Ȓ(Py)-S-2-S-(Py)Ȓ compounds. To 
illustrate this, the R-7N(X-suc-β-CD)-R compounds showed the loss of full alkyl tail groups R as 
alkene molecules (CnH2n, e.g., dodecene, 168 Da, Scheme 2.1). The corresponding neutral loss 
for the Ȓ(Py)-S-2-S-(Py)Ȓ compounds, gave alkyne molecules (CnH2n-2, e.g., dodecyne, 166 Da, 
Scheme 2.2). 
In addition, several small fragment ions obtained after the complete loss of both alkyl tail 
groups or head group-tail regions showed more distinct differences among the R-7N(X-suc-β-
CD)-R and Ȓ(Py)-S-2-S-(Py)Ȓ compounds. For instance, the ammonium head group/tail-free 
fragment ions of the R-7N(X-suc-β-CD)-R compounds underwent further fragmentation, giving 
rise to smaller ions along with neutral loss of glycosyl residues, CO and H2O. In the case of the 
Ȓ(Py)-S-2-S-(Py)Ȓ compounds, further fragmentation of the pyridinium head group-free 
fragments ions showed cleavage (neutral losses) of segments of the alkyl tails as neutral 
hydrocarbon species such as CH2=CH2, CH2=CH-CH3. Thus, using a mixture of the R-7N(X-suc-
 135 
 
β-CD)-R and Ȓ(Py)-S-2-S-(Py)Ȓ compounds as a prototype multi-component sample, the 
respective individual compounds were screened and identified based on the distinct tandem CID-
MS/MS fragmentation patterns. 
2.5.4 Conclusion 
The analysis of novel R-7N(X-suc-β-CD)-R and Ȓ(Py)-S-2-S-(Py)Ȓ compounds using a 
combination of ESI-QqToF-MS and ESI-QqQ-LIT-MSn enabled a complete characterization of 
these doubly-charged gemini surfactants. Using the ESI-QqToF-MS system with two-point 
internal calibration, the tested compounds were detected with sub-1 ppm accuracy, an accuracy 
level that is sufficient for unambiguously confirming the compound’s molecular formula. 
The in-depth fragmentation patterns, which were established using ESI-QqQ-LIT-MSn (up 
to MS3), revealed diagnostic product ions which are characteristic of the individual R-7N(X-suc-
β-CD)-R and Ȓ(Py)-S-2-S-(Py)Ȓ compounds, thus providing further confirmation of the 
compound structure. Within the R-7N(X-suc-β-CD)-R series, eight common diagnostic product 
ions were observed, while six common diagnostic product ions were observed for the Ȓ(Py)-S-2-
S-(Py)Ȓ series. The fragmentation pathways established in this work (especially the [M]2+ → 
diagnostic ion transitions) can be used as a fingerprint pattern for rapid and accurate bioanalysis 
(identification and quantification) of these test compounds within complex biological samples. 
We are currently evaluating the intracellular localization and metabolic fate of the tested gemini 
surfactants which will be reported upon completion. 
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3.1 Abstract 
Diquaternary gemini surfactants have successfully been used to form lipid-based 
nanoparticles that are able to compact, protect and deliver genetic materials into cells. However, 
there is an absence of information about what happens to the gemini surfactants after they have 
released their therapeutic cargo. Such knowledge is critical in order to assess quality, safety and 
efficacy of gemini surfactant nanoparticles. Herein, we developed simple and rapid liquid 
chromatography tandem mass spectrometry (LC–MS/MS) method for the quantitative 
determination of various structures of gemini surfactants in cells. Hydrophilic interaction liquid 
chromatography (HILIC) was employed allowing for a short, simple isocratic run of only 4 
minutes, linearity range of 50 – 5000 ng/mL, and a 3 ng/mL lower limit of detection (LLOD). 
The method was applicable to 18 structures of gemini surfactants belonging to two different 
structural families with full validation for two lead compounds according to USFDA guidelines. 
The HILIC-MS/MS was ideally compatible with the physicochemical properties of gemini 
surfactants that bear permanent positive change with both hydrophilic and hydrophobic elements 
within their molecular structure. In addition, the chromatographic separation was combined with 
effective liquid-liquid extraction method (98% recovery) that surpasses previously used methods. 
Data from the analysis of nanoparticle-treated cells showed an initial rise in the analyte 
intracellular concentration followed by a maximum and a somewhat more gradual decrease of 
the intracellular concentration. Two events that may account for the seeming intracellular 
depletion of the gemini surfactants are bio-transformation into metabolites and exocytosis from 
the host cells. 
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3.2 Introduction 
Dicationic gemini surfactants are a promising class of lipids currently being investigated 
for nanoparticle-mediated gene delivery.[1,2,3] They can effectively be complexed with DNA 
into therapeutic nano-lipoplexes which in turn can transfect cells. Gemini surfactants are 
structurally defined a general molecular architecture in which two monomer surfactants with 
polar or ionic head-groups are connected via a spacer moiety (Figure 3.1A). In dicationic gemini 
surfactants (frequently used as the bromide salts), the head-groups are positively charged to 
allow DNA complexation. Structural modification in gemini surfactants aims at increasing 
transfection efficiency while at the same time reducing toxicity. In fact, an expanding variety of 
gemini surfactants demonstrates effectiveness as non-viral DNA delivery agents.[4,5,6,7] However, 
there is an absence of information about what happens to the gemini surfactants after they have 
released their therapeutic cargo. Such knowledge is critical in order to assess quality, safety and 
efficacy of gemini surfactant nanoparticles. Therefore, effective analytical methods are urgently 
needed.  
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) offers the 
combined capability of analyte separation alongside sensitive, high-throughput and selective 
analysis.[8,9,10] Gemini surfactants are not compatible with fluorescent/UV-detection due to the 
lack of fluorescent or UV-active moieties. Therefore, LC-MS/MS is an ideal platform for the 
quantitative determination of the nanoparticles' amphiphilic constituents within complex 
biological mixtures. In addition, LC-MS/MS analysis with the use of multiple reaction 
monitoring (MRM) allows gemini surfactants to be monitored using precursor ion → product ion 
diagnostic transitions which provides specificity to target gemini surfactant analytes.  
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Figure 0.1: A) Schematic representation of gemini surfactant general structure; B) The exact 
molecular structures of intact compounds and monitored product ions during HILIC-
MS/MS of 16-3-16: N,N-bis(dimethylhexadecyl)-1,3-propanediammonium; C) 16(Py)-
S-2-S-(Py)16: 1,1'-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-diyl)]dipyridinium. 
 
 
m/z 203.09 (C10H19S2+)
 146 
 
To allow for the assessment of the cellular fate of gemini surfactants, our laboratory 
initiated studies to first establish the collision-induced dissociation (CID)-MS/MS fragmentation 
patterns and fingerprint ions of several gemini surfactant structures.[11,12,13,14] These 
qualitative studies allowed for the subsequent development of an LC-MS/MS method employing 
a cyano chromatographic column for the quantification of gemini surfactants in epidermal 
keratinocytes.[15] However, this method suffered from drawbacks, such as ion suppression due 
to the addition of an ion pairing reagent, long run times, relatively low sensitivity and the use of 
gradient elution. Other MS-based quantification methods, such as fast chromatography (FC)-MS, 
desorption electrospray ionization (DESI-MS/MS) and matrix assisted laser desorption 
(MALDI)-MS were also developed in our lab and their analytical capabilities were 
compared;[16] however, all the developed methods were only applicable to one structural family 
of gemini surfactants with full validation possible for the N,N-bis(dimethylhexadecyl)-1,3-
propanediammonium compound, denoted as 16-3-16 (Figure 3.1B). In fact, the fastest MS 
quantification method,[16] MALDI-MS, was not applicable to gemini surfactant structures that 
have more than three carbons within their spacer region due to the incomplete dissociation of the 
gemini surfactants within the MALDI source, preventing the possibility of developing 
quantification methods. Hence, there is need for a universal method that can produce quantitative 
data for varying gemini surfactant structures through the adoption of suitable chromatography 
platform such as hydrophilic interaction liquid chromatography (HILIC).  HILIC is an ideal 
stationary phase that can combine the benefits of both the normal and reversed-phases of 
separation.[17]  It has been widely used for the analysis of polar compounds including those 
bearing quaternary amines.[18] 
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In addition to traditional, non-substituted alkanediyl-α,ω-bis(dimethyl alkyl-ammonium) 
gemini surfactants (designated as m-s-m), other classes of gemini surfactants especially bis(alkyl-
pyridinum) compounds have emerged.[19,20] The latter is reported to be less toxic when 
comparing m-s-m and bis(alkyl-pyridinum) representative bromide compounds.[19] The 
representative m-s-m compound is N,N-bis(dimethylhexadecyl)-1,3-propanediammonium 
(denoted 16-3-16; Figure 3.1B), while the bis(alkyl-pyridinum) counterpart is 1,1'-[ethane-1,2-
diylbis(sulfanediylhexadecane-1,2-diyl)]dipyridinium (denoted 16(Py)-S-2-S-(Py)16; Figure 
3.1C). The 16-3-16 compound imposed higher toxicity than 16(Py)-S-2-S-(Py)16 [19,21] without 
a logical explanations based on their molecular structures. It is reasonable to speculate that 
possible differences in gemini surfactant nanoparticle entry into cells, nano-bio interactions, bio-
distribution, bio-transformation or bio-persistence could explain differences in toxicity. 
Therefore, we aimed at developing simple and fast LC-MS/MS method that can effectively 
quantify varying structures of gemini surfactants within treated cells. 
Herein, we report the utilization of HILIC-LC-MS/MS to allow for the quantitative 
determination of variable structures of gemini surfactants within cells. We were able, for the first 
time, to quantify gemini surfactants that belong to two different structural families with full 
method validation for 16-3-16 and 16(Py)-S-2-S-(Py)16 (Figure 3.1). 
3.3 Materials and Methods 
3.3.1 Materials 
The diquaternary ammonium and dipyridinium gemini surfactants, as well as their 
deuterated internal standards, used in this study were synthesized based on established 
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methods.[19,22,23] For the 16-13-6 analyte, the internal standard (16-13-6-d66) incorporated 
deuterated alkyl tails resulting in mass difference of +66 Da; while in the case of 16(Py)-S-2-S-
(Py)16, deuteration was within the pyridinium heads accounting for +10 Da mass difference for 
the internal standard, 16(Py)-S-2-S-(Py)16-d10 (Figure S3.6 in the supplementary information). 
The neutral lipid 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was purchased 
from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Chloroform, methanol and 1-Octanol 
(99%) were purchased from Fisher Scientific (Ottawa, ON, Canada). Ammonium formate, 
formic acid, mass spectrometric-grade water and acetonitrile were purchased from Fisher 
Scientific (Ottawa, ON, Canada). PAM 212 cells were kindly provided by Dr. S. Yuspa, National 
Cancer Institute, Bethesda, MD, USA. The cell growth medium contained minimum essential 
media (MEM), fetal bovine serum albumin (FBS) and antibiotic-antimycotic which were 
obtained from Sigma-Aldrich (Oakville, ON, Canada). Tissue culture flasks (with capacities: 
150-cm3, 75-cm3, 25-cm3) as well as 6-well plates, were purchased from Fisher Scientific 
(Ottawa, ON, Canada). 
3.3.2 LC-MS/MS instrumentation 
The hybrid LC-MS/MS analytical system comprised of an Agilent 1200 Series HPLC 
having a quaternary pump, a degasser and auto sampler (Agilent Technologies, Mississauga, ON, 
Canada) coupled to an AB Sciex API 4000 QTRAP mass spectrometer (AB Sciex, Concord, ON, 
Canada). The chromatography step used a ZIC®-HILIC column (150 × 2.1 mm, 5 µm, 200 Å; 
Merck SeQuant AB) held at 50 ˚C and an isocratic mobile phase flowing at 500 µL/min to 
analyze 2 µL injected aliquots. The mobile phase was 80:20 (v/v) acetonitrile/buffer, with the 
buffer containing 2.5 mM ammonium formate and 25 mM formic acid. No sample carryover was 
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detected and to eliminate any chances of carryover, double blank injections were run after the 
injection of the highest calibration curve concentration. 
The AB Sciex QTRAP 4000 mass spectrometer is equipped with an electrospray (ESI) 
source set at 5500 V ionspray voltage and 600 ◦C at the ion source interface, with 30 psi being 
set as the curtain gas pressure and 40 psi as the pressures for both GS1 (nebulizer gas) and GS2 
(heater gas). The mass spectrometer was operated in the multiple reaction monitoring (MRM) 
mode to monitor the analytes and the deuterated internal standards as [M]2+ species, including 
the following transitions: 16-3-16 [M]2+ m/z 290.33 → 355.40, 86.11; 16-3-16-d66 [M]2+ m/z 
323.54 → 388.61; and, 16(Py)-S-2-S-(Py)16 [M]2+ m/z 349.28 → 396.28, 203.09; 16(Py)-S-2-S-
(Py)16-d10 [M]2+ m/z 354.31 → 401.31. The MRM conditions and fingerprint structures for the 
monitored transitions are presented below (Table 3.1, Figure 3.1, and Figure S3.6 in the 
supplementary information). 
 
Table 1.1. Conditions for MRM transitions of the analytes on AB Sciex 4000 QTRAP® System. 
 
*Abbreviation: 
  DP: declustering potential, CE: collision energy, CXE: collision cell exit potential; X: neutral loss 
 Analyte   MRM Transition   DP* CE* CXE* 
Gemini surfactant Molecular Formula  [M]
2+ → [M − X]+ m/z  → m/z  (eV) (eV) (eV) 
16(Py)-S-2-S-(Py)16 C44H78N2S22+  [M]2+ → [M − C21H36N]+ m/z 349 → 396  30 22 10 
16(Py)-S-2-S-(Py)16 C44H78N2S22+  [M]2+ → [M − C34H59N2]+ m/z 349 → 203  30 22 10 
16(Py)-S-2-S-(Py)16-d10 C44H68D10N2S22+  [M]2+ → [M − C21H31D5N]+ m/z 354 → 401  30 25 10 
         
16-3-16 C39H84N22+  [M]2+ → [M − C16H33]+ m/z 290 → 355  40 21 10 
16-3-16 C39H84N22+  [M]2+ → [M − C33H70N2]+ m/z 290 → 86  40 35 6 
16-3-16-d66 C39H18D66N22+  [M]2+ → [M − C16D33]+ m/z 323 → 388  35 25 10 
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3.3.3 Preparation of standard solutions 
Aqueous stock solutions of all gemini surfactants at molarity of 3 mM were prepared, used 
with or without dilutions and routinely stored at −20 ˚C under darkness. The mass concentrations 
(equivalent to the 3 mM molarity) for purpose of analytical quantitation are detailed on Table 
S3.1. DOPE vesicles, a 1 mM solution, was prepared fresh in 9.25% w/v isotonic sucrose 
solution which had pH 9. Plasmid DNA (pGT·IFN-GFP) solution, 40 µg/mL, was prepared in 
ultrapure, organic-free water and was stored at −20 ˚C. The DOPE and plasmid DNA solutions 
were used without further dilutions. 
3.3.4 Preparation of nanoparticle formulations 
Plasmid DNA/gemini surfactant/lipid DOPE (P/G/L) nano-lipoplex formulations were 
prepared to a 1:10:100 molar ratio of the ingredients (combined in the order given) as previously 
described.[22] The mole of DNA is calculated per DNA base-pair with an average molecular 
weight of 660 Da.[24] Briefly, the required transfection dose of plasmid DNA was measured, to 
which the appropriate amount of gemini surfactant was added with an allowed 30-minute 
incubation at room temperature. DOPE was then added to the binary mixture, followed by 
further 15-minute incubation at room temperature to obtain a ternary (final) P/G/L system. The 
transfection dose of plasmid DNA was 0.3 µg for 1 × 106 cells/treatment. 
3.3.5 PAM 212 cell treatment and sample collection 
PAM 212 cells were routinely cultured inside humidified 95% air/5% CO2 incubators at 37 
˚C. The culture medium was MEM that was supplemented with 10% FBS and 1 unit/mL 
antibiotic-antimycotic. Cells cultured to 80% confluence were harvested by trypsinization and 
 151 
 
either subcultured or prepared for treatment. At 24 h before treatment, cells were seeded at 1 × 
106 cells/mL/well within 6-well plate format. At 1 h to transfection, the cell supernatant media 
was replaced with FBS-free media. Nanoparticle formulations, freshly prepared (Section 2.3), 
were added and allowed to interact with cells by placing the cells in the CO2 incubator (37 ˚C). 
This marked the reference point for recording any post-treatment incubation time-points where 
further steps are taken. 
After 5 h, the nanoparticle-dosed cell media was replaced with supplemented media (MEM 
with 10% FBS, 1 unit/mL), followed by a continued incubation of cells. All treatments were 
carried out in replicates (n ≥ 3) along with appropriate controls on at least three separate days. 
The controls included cells that underwent no treatment as well as cells that received formulation 
prepared without the inclusion of the gemini surfactant component. During the incubation period, 
replicates of treated cell samples were, at different time-points, trypsinized and collected into 1.5 
mL volumes. The collected cells were pelleted (14,000 rpm, 5 min, 4 ˚C), rinsed with phosphate-
buffered saline (PBS) and reconstituted into smaller sample volumes of 200 µL in (PBS), and 
then stored at −80 ˚C prior to analyte extraction and LC-MS/MS analysis. 
To better conduct sample collection and reduce tediousness in the process, an alternative 
approach was also used. During the post-treatment incubation period, replicates of treated cells 
were, at different time-points, retrieved from the CO2 incubator, rinsed (3×) with PBS and placed 
at −80 ˚C. All cells kept at −80 ˚C were then thawed, trypsinized and collected into 1.5-mL 
volumes. The 1.5-mL samples were reduced into smaller sample volumes of 200 µL using 
centrifugal evaporation (speed vacuum concentration). Results were identical using both 
approaches.  
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3.3.6 Sample Preparation for LC-MS/MS analysis 
The 200-µL treated cell samples kept at −80 ˚C were lysed by six freeze/thaw cycles along 
with 1-h sonication at 25 kHz. The samples were spiked with constant amounts of the internal 
standards by addition of 50-µL solutions obtained from a dilution of 1 250�  parts of the pure stock 
internal standard in water; the resultant concentration was 1,938 ng/mL for 16-3-16-d66 and 
2,086 ng/mL for 16(Py)-2-S-2-(Py)16-d10. For the construction of calibration curves, 200-µL cell 
lysates (equivalent to 1 × 106 cells each) which had not received any nanoparticle treatment were 
used. The untreated samples were spiked with 50-µL solutions containing the analyte and the 
corresponding internal standard. The resultant volume was 250 µL for all samples prior to 
subsequent steps. 
Liquid-liquid extraction (LLE) of the analytes and internal standards from the cellular 
matrix was achieved using the Bligh/Dyer method.[25] Briefly, the 250-µL samples were mixed 
with 950 µL (3.8 vols) of 2:1 (v/v) methanol/chloroform, followed by mixing with 310 µL (1.24 
vols) of both chloroform and water, in that order. Mixing was achieved by vortexing in all cases. 
The combined mixtures were centrifuged at 14,000 rpm for 1 min at room temperature to obtain 
separate aqueous and organic phases. The bottom organic phase (80% portion) was retrieved and 
dried using a gentle N2 gas stream, followed by reconstitution of the extracted analytes in 200 µL 
of n-octanol prior to LC-MS/MS analysis. 
For comparison, a recently reported alternative method, octanol extraction, was also 
used.[15] For the octanol extraction, which involves extracting samples with equal volumes of n-
octanol, the 250-µL samples were mixed with 250 µL of n-octanol. Separation of the aqueous 
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and organic phases was achieved by centrifugation as above. The organic phase (200-µL, i.e., 
80% portion) was retrieved for LC-MS/MS analysis. 
3.3.7 LC-MS/MS method validation  
The LC-MS/MS method was fully validated for the 16-3-16 and 16(Py)-2-S-2-(Py) gemini 
surfactants in accordance with USFDA guidelines.[26,27] To establish specificity and rule out 
interference due to co-eluting endogenous species, six different batches of PAM 212 cell samples 
were analyzed. Linearity was probed over a wide range of analyte concentrations, including 50 – 
5,000 ng/mL. Using least-square analysis along with 1/χ as the weighting factor, data was 
processed by plotting the ratio of summed peak areas for 16-3-16 and 16(Py)-2-S-2-(Py)16 over 
the peak areas for their respective internal standards, 16-3-16-d66 and 16(Py)-2-S-2-(Py)16-d10. 
Linearity was established with the slope, intercept and coefficient of determination (r2). The limit 
of detection (LLOD) was set as the lowest detectable concentration with a signal-to-noise (S/N) 
ratio of 3, while the lowest limit of quantification (LLOQ) was set at the lowest concentration 
having S/N ≥ 5, with precision and accuracy within ±20% of the nominal value as per the 
USFDA guidelines.[27] 
The intra- and inter-day precision and accuracy of the method was established through the 
analysis of six replicates of samples at four different concentrations (lower limit of 
quantification, LLOQ; lower quality control, LQC; middle quality control, MQC; and high 
quality control, HQC) on three different days. Single assay runs were accepted only when the 
relative standard deviation (RSD) was found to be less than ±15% at concentrations other than 
the LLOQ, which is allowed at ±20%. The criterion for accuracy was set at ±15% of the nominal 
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concentration of the QC samples and ±20% for LLOQ. In no case did more than one third of the 
QC samples violate these criteria.  
Studies involving freeze/thaw stability, bench-top stability and long-term stability were 
undertaken at LQC, MQC, and HQC. Freeze/thaw stability was tested after three freeze/thaw 
cycles spaced at least 24 h apart with sample storage at −20 ± 5 ˚C between sample thawing. 
Twenty-four hour stability of 16-3-16 and 16(Py)-2-S-2-(Py)16 in PAM212 cell lysate under 
bench-top conditions was evaluated. Predicted concentrations were calculated using newly 
prepared calibration curves. Samples were stored at −20 ± 5 ˚C for 105 days prior to analysis of 
long-term stability. Samples were considered stable when the USFDA criteria for precision and 
accuracy were met.[27] 
3.4 Results 
3.4.1 HILIC-LC-MS/MS specificity for gemini surfactant bio-analysis 
HILIC-LC-MS/MS method provided selectivity through the observed analyte-specific 
retention times and specificity through the MRM mode which monitors the analytes using 
precursor → product ion transitions. The specific retention times established for each analyte and 
the elimination of carryover effects made the HILIC chromatographic separation an ideal choice 
for the analysis of gemini surfactants.  In addition, the HILIC-LC-MS/MS method was 
applicable to various gemini surfactant structures as shown in Table 3.2. 
A characteristic chemical structure-dependent elution order was observed, establishing 
predictable HILIC retention time trends important for distinguishing the gemini surfactants. For 
instance, the alkyl tail length of three gemini surfactants with the same spacer moiety increase in 
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the order 12(Py)-S-2-S-(Py)12 (tail: dodecyl), 14(Py)-S-2-S-(Py)14 (tail: tetradecyl) and 16(Py)-
S-2-S-(Py)16 (tail: hexadecyl); the corresponding retention times (Rt) decreased in the reverse 
order, 2.88 min, 2.80 min, and 2.62 min, respectively (Table 3.2). Such trend was also notable in 
the case of the alkyl spacer portions. The increase in the alkyl spacer chains led to shorter 
retention times as observed for gemini surfactants: 12-3-12 (spacer: propyl) Rt = 2.96, 12-8-12 
(spacer: octyl) Rt = 2.56, 12-12-12 (spacer: dodecyl) Rt = 2.43 min (Table 3.2). Thus, gemini 
surfactants with longer hydrophobic alkyl tails or longer alkyl spacer chains showed shorter 
retention times on the HILIC column.  
 
 
 
Table 1.2. HILIC-LC-MS/MS bio-analysis of 17 gemini surfactants with varying molecular 
structures. 
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All tested compounds eluted before 4 minutes making the analysis a very fast approach for 
varying gemini surfactant structures.  The only exception is 12-7NH-12 eluting at 7.12 min 
(Table 3.2); this compound contains a secondary amine within the spacer region.  Therefore, it 
bears increased polarity within its structure leading to an overall stronger interaction and 
retention on the zwitterionic sulfoalkylbetaine stationary phase (ZIC®-HILIC column).  
In addition, the HILIC-LC-MS/MS platform demonstrated a capability in allowing for the 
analysis and differentiation of isobaric gemini surfactants, namely 16-7-16 and 18-3-18 (identical 
composition C43H92N22+, [M]2+ m/z 318). The differentiation of the isobaric gemini surfactants 
         Gemini surfactant Spacer region   Tail region   MRM Retention 
Symbol 
 Name 
Molecular 
formula  Name 
Molecular 
formula  
transitions 
m/z  → m/z 
time 
(min) 
12-3-12 Propyl C3H6  Dodecyl C12H25  234 → 299 2.96 
12-4-12 Butyl C4H8  Dodecyl C12H25  241 → 313 2.91 
12-8-12 Octyl C8H16  Dodecyl C12H25  269 → 369 2.57 
12-12-12 Dodecyl C12H24  Dodecyl C12H25  297 → 425 2.43 
12-16-12 Hexadecyl C16H32  Dodecyl C12H25  325 → 481 2.42 
16-3-16 Propyl C3H6  Hexadecyl C16H33  290 → 355 2.86 
16-7-16 Heptyl C7H14  Hexadecyl C16H33  318 → 411 2.52 
18-3-18 Propyl C3H6  Octadecyl C18H37  318 → 383 2.44 
18-7-18 Heptyl C7H14  Octadecyl C18H37  346 → 439 2.37 
18:1-3-18:1 Propyl C3H6  Octadec-9-ene C18H35  316 → 381 2.57 
18:1-6-18:1 Hexyl C6H12  Octadec-9-ene C18H35  337 → 423 2.50 
12(Py)-S-2-S-(Py)12 1,2-ethanedithiol C2H4S2  Dodecyl C12H25  293 → 340 2.86 
14(Py)-S-2-S-(Py)14 1,2-ethanedithiol C2H4S2  Tetradecyl C14H29  321 → 368 2.79 
16(Py)-S-2-S-(Py)16 1,2-ethanedithiol C2H4S2  Hexadecyl C16H33  349 → 396 2.78 
18(Py)-S-2-S-(Py)18 1,2-ethanedithiol C2H4S2  Octadecyl C18H37  377 → 424 2.63 
12-7NH-12 Dipropylamine C6H13N  Dodecyl C12H25  263 → 356 7.12 
Py-3-12 Propyl C3H6  Dodecyl, Hexapyrenyl, 
C12H25, 
C22H23 
 293 → 417 2.96 
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relied on the established characteristic chromatographic retention behaviour in combination with 
the analyte's unique mass spectrometric fingerprints (Table 3.2). Finally, it is worth noting that 
the developed method was not only applicable to the two classes of gemini surfactants, but it was 
also capable of separating the gemini surfactant Py-3-12, which contains two asymmetric tails, 
dodecyl chain and fluorescent pyrenyl-hexyl tail. The gemini surfactant Py-3-12 is generally 
used as a fluorescence probe for studying DNA complexation with gemini surfactants in addition 
to its gene transfection potential.[28,29] 
3.4.2 Method validation for bio-analysis of 16(Py)-S-2-S-(Py)16 and 16-3-16 
The method validation established the robustness of the HILIC-LC-MS/MS method for the 
bio-analysis of two specific gemini surfactants, 16(Py)-S-2-S-(Py)16 and 16-3-16, in accordance 
with USFDA guidelines.[27] Full method validation was established for these two promising 
molecules as they are currently being evaluated at the pre-clinical stage, assessing their toxicity 
alongside gene transfer capabilities. All method validation parameters are summarized in Table 
S3.2 (supplementary materials). 
3.4.3 Selectivity and matrix effects 
Selectivity was achieved as illustrated for both 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini 
surfactants as shown in Figure 3.2 and Figure S3.7 (supplementary materials), respectively. 
Figure 3.2A shows that no analyte peaks were detected in "double blank" samples, which 
represent the matrix background and contain neither the analyte nor the internal standard. This 
indicates the absence of interference from endogenous cellular components against the selective 
bio-determination of the 16(Py)-S-2-S-(Py)16. Also, no cross-interference occurred between the 
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analytes and the internal standards as show by Figure 3.2B and Figure 3.2C, representing 
separate LC-MS/MS runs for 16(Py)-S-2-S-(Py)16-d10 and 16(Py)-S-2-S-(Py)16, respectively. 
Similar data for 16-3-16 is shown in the supplementary materials (Figure S3.2). 
The cellular matrix did not have an effect on the ionization efficiency, that is, neither 
ionization enhancement nor suppression was observed.  The matrix effect was calculated to be 
approximately 101% for both 16(Py)-S-2-S-(Py)16 and 16-3-16 (criteria: >100% indicates 
enhancement, <100% indicates suppression). Determination of the matrix effect followed the 
method of Matuszewski et al,[30] as given below: 
Matrix effect(%) = Response post˗extraction spiked sampleResponse non˗extracted neat sample  × 100                                   (1); 
where the post-extraction spiked sample refers to standards spiked after extraction and contains 
the standard analyte added to extracted blank cell lysate. The non-extracted neat sample contains 
the analyte added to octanol (pure, cellular matrix-free). The determined value is the average for 
a set of 6 replicates. 
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Figure 1.2: Chromatograms of the 16(Py)-S-2-S-(Py)16 and 16(Py)-S-2-S-(Py)16-d10 gemini 
surfactants, i.e., the analyte and IS, respectively. Panel A indicates the absence of any 
interference against the selective determination of both 16(Py)-S-2-S-(Py)16 and 16(Py)-
S-2-S-(Py)16-d10 by showing the detection of no signals around the established HILIC-
LC-MS/MS elution times of these compounds within "double blank" cell samples. B) 
chromatogram from an injection of only 16(Py)-S-2-S-(Py)16-d10 and C) Chromatogram 
from an injection of only 16(Py)-S-2-S-(Py)16 at lower limit of quantitation, LLOQ. No 
cross-interference occurred between 16(Py)-S-2-S-(Py)16 and 16(Py)-S-2-S-(Py)16-d10. 
 
3.4.4 Calibration curve linearity and sensitivity 
The calibration curves for the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactant analytes 
were linear at a concentration range of 50 – 5000 ng/mL, with an r2 value ≥ 0.997 as shown in 
Figure S3.8 (supplementary materials). Figure 3.3 shows a representative chromatograms for 
16(Py)-S-2-S-(Py)16 at 6, 50 and 5,000 ng/mL. The lower limit of quantitation (LLOQ), 50 
ng/mL, was accepted as it met the USFDA guideline for the 20% reproducibility for accuracy 
and precision. The concentration determined as the lower limit of detection (LLOD) was based 
on a set limit of S/N ≥ 3; this led to an LLOD of 6 ng/mL for 16(Py)-S-2-S-(Py)16, (Figure 
3.3C). The LLOD for 16-3-16 was 3 ng/mL, with corresponding chromatograms given in the 
supplementary information (Figure S3.9). 
HILIC-LC-MS/MS showed a substantially higher sensitivity in comparison with a recent 
cyano-based stationary phase LC-MS/MS method for the cellular analysis of 16-316 gemini 
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surfactant, with reported LLOD of 180 ng/mL and LLOQ of 300 ng/mL.[15] With the reported 
cyano-LC-MS/MS method, triethylamine (TEA) along with gradient elution were needed and 
the analyte extraction from aqueous medium utilized n-octanol which had a 71% recovery.[15] 
In the current work, the increased limit of detection up to 60-fold over previous work can be 
attributed to the change to the utilization of HILIC chromatography, coupled with the exclusion 
of the ion-pairing reagent, TEA, and better analyte recovery using the Bligh/Dyer lipid 
extraction method.[25] 
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Figure 1.3: Chromatograms of the 16(Py)-S-2-S-(Py)16 gemini surfactant at LLOQ, ULOQ and 
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zoomed in spectrum of the analyte and B) ULOQ in relation to the internal standard, 
16(Py)-S-2-S-(Py)16-d10, which was present at a constant concentration. C) Extracted ion 
chromatogram for 16(Py)-S-2-S-(Py)16 at LLOD. 
 
3.4.5 Recovery 
Liquid-liquid extraction of the 16(Py)-S-2-S-(Py)16 gemini surfactant analytes gave more 
than 96% recovery using the Bligh/Dyer lipid extraction method while the recovery was 67.5-
73.9% for octanol extraction (Table 3.3). The corresponding data for 16-3-16 is available in the 
supplementary materials (Table S3.3) showing similar trends. The recovery values were 
computed as proposed by Matuszewski et al,[30]: Recovery(%) = Response from extracted cells 
Response from spiked extracted cells  × 100                                           (2);  
where the response from extracted cells refers to standards spiked before extraction where 
samples were processed as per the extraction procedure.  Response from spiked extracted cells 
refers to known standards spiked after the extraction procedure was employed on cells. 
 
Table 1.3. Recovery of 16(Py)-S-2-S-(Py)16 from the aqueous cellular matrix. 
 
   Bligh/Dyer extraction    Octanol extraction  
Theoretical 
concentration 
 Extracted cells 
(mean ± SD, ng/mL) 
Spiked extracted 
cells  
 (mean ± SD, ng/mL) 
Recovery 
(%) 
 Extracted cells  
(mean ± SD, ng/mL) 
Spiked extracted 
cells  
(mean ± SD, ng/mL) 
Recovery 
(%) 
16(Py)-S-2-S-(Py)16         
50 ng/mL (LLOQ)  47.44 ± 4.73 48.31 ± 3.74 96.2  32.88 ± 4.42 48.73 ± 4.74 67.5 
150 ng/mL (LQC)  151.16 ± 10.61 155.36 ± 9.31 97.3  104.51 ± 11.02 145.36 ± 8.98 71.9 
375 ng/mL (MQC)  369.75 ± 41.33 377.68 ± 37.93 97.9  270.87 ± 19.16 375.68 ± 47.92 72.1 
4375 ng/mL (HQC)  4309.51 ± 359.41 4344.25 ± 222.53  99.2   3209.64 ± 179.11 4343.22 ± 182.33  73.9  
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For the separate extraction methods, the average recoveries were consistent for replicate 
determinations and were equal for the analyte (at three concentrations: lower, middle and upper 
limit of quantitation). With such improved recovery (Figure 3.4 and Figure S3.10 in 
supplementary materials), our routine analyte extractions adopted the Bligh/Dyer extraction for 
its better efficiency, increasing the sensitivity of the LC-MS/MS method.  
 
  
 
Figure 1.4: Analyte recovery efficiencies for Bligh/Dyer lipid extraction vs octanol extraction. 
Bligh/Dyer lipid extraction gave a better recovery (typically 98%) of the analyte and was 
the chosen liquid-liquid extraction method, departing from a recent report in which 
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octanol extraction (70% efficiency) was used. Unsurprisingly, the new HILIC-LC-
MS/MS methods reported herein show better sensitivity (60-fold increase). 
 
3.4.6 Accuracy and precision 
In general, the validated method satisfied the USFDA-recommended accuracy and 
precision limits for all standard curve and quality control samples. Table 3.4 shows the accuracy 
and precision obtained for 16(Py)-S-2-S-(Py)16 gemini surfactant at four concentrations chosen 
per USFDA guidelines: LLOQ, LQC, MQC and HQC (corresponding data for 16-3-16 are 
available in the supplementary information, Table S3.4). For both the intra- and inter-day 
experiments, the accuracy (computed by expressing the observed concentrations as percentage of 
the theoretical values) varied between ~92 – ~110%. For precision, the values were within ~3 – 
~11% relative standard deviation for both intra- and inter-day cases. 
 
Table 1.4. Intra- and inter-day accuracy and precision in the analysis of 16(Py)-S-2-S-(Py)16. 
Quality Control  Observed concentration 
(mean ± SD, ng/mL) 
Accuracy 
(%) 
Precision 
(%RSD) 
INTRA-DAY:    
 Analysis Day (#)    
LLOQ: 50 ng/mL Day 1 46.44 ± 4.73 92.9 10.2 
 Day 2 51.26 ± 5.08 102.5 9.9 
 Day 3 55.06 ± 3.33 110.1 6.0 
LQC: 150 ng/mL Day 1 145.96 ± 8.61 97.3 9.0 
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 Day 2 154.64 ± 13.9 103.1 8.4 
 Day 3 161.14 ± 9.99 107.4 6.2 
MQC: 375 ng/mL Day 1 363.75 ± 11.33 97.0 3.1 
 Day 2 393.36 ± 21.73 104.9 5.5 
 Day 3 369.03 ± 19.77 98.4 5.4 
HQC: 4375 ng/mL Day 1 4032.50 ± 359.41 92.2 8.9 
 Day 2 4411.38 ± 272.55 100.8 6.2 
 Day 3 4321.99 ± 323.09 98.8 7.5 
INTER-DAY:    
 Concentration    
LLQC 50  ng/mL 51.15 ± 4.84 102.3 9.7 
LQC 150 ng/mL 157.25 ± 10.84 104.8 7.7 
MQC 375 ng/mL 375.38 ± 17.61 100.1 4.7 
HQC 4375 ng/mL 4255.29 ± 318.53 97.3 7.5 
 
3.4.7 Stability 
Both the 16(Py)-S-2-S-(Py)16 and 16-3-16 analytes were stable beyond 24 h when stored 
at room temperature (bench top stability) and long-term stability when stored at –20 ˚C (Table 
3.5, Table S3.5). The analytes also showed very good freeze/thaw stability after three 
freeze/thaw cycles. The autosampler stability was within USFDA guidelines for 
accuracy/precision and was determined for samples re-injected for analysis for up to two 
consecutive days. Overall, the stabilities were within ~96 – ~105% accuracy and ~2 – ~9% 
precision for all the determinations (Table 3.5, Table S3.5). 
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Table 1.5. Stability of 16(Py)-S-2-S-(Py)16 analyte within the sample matrix. 
Quality Control 
Storage condition/ 
period 
Observed concentrations 
(mean ± SD, ng/mL) 
Accuracy 
(%) 
Precision 
(%RSD) 
     LQC: 150 ng/mL 0 h 150.33 ± 11.14 102.3 9.7 
 24 h on bench top 148.83 ± 10.04 99.3 7.7 
 Three freeze/thaw cycles 145.87 ± 13.13 94.3 8.5 
 ‒20 ˚C for 105 days (LT) 146.16 ± 9.91 96.7 10.1 
 48 h extract in autosampler  150.15 ± 8.43 96.6 9.2 
     MQC: 375 ng/mL 0 h 365.03 ± 18.18 102.3 9.7 
 24 h on bench top 381.73 ± 17.98 99.3 7.7 
 Three freeze/thaw cycles 355.05 ± 18.17 94.3 8.5 
 ‒20 ˚C for 105 days (LT) 355.22 ± 18.68 96.7 10.1 
 48 h extract in autosampler  375.88 ± 15.76 96.6 9.2 
     HQC: 4375 ng/mL 0 h 4358.23 ± 198.08 102.3 9.7 
 24 h on bench top 4398.23 ± 201.27 99.3 7.7 
 Three freeze/thaw cycles 4151.53 ± 229.38 94.3 8.5 
 ‒20 ˚C for 105 days (LT) 4324.56 ± 186.83 96.7 10.1 
 48 h extract in autosampler  4308.93 ± 191.77 96.6 9.2 
LT (long term): ‒20 ˚C for 105 days 
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3.4.8 Bio-analysis of P/G/L-nanoparticle-treated cells 
Using the validated HILIC-LC-MS/MS methods, the uptake and intracellular deposition 
profile of the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants was studied within PAM 212 
cells which had been treated with the gemini surfactant-containing P/G/L-nanoparticles. Figure 
3.5 shows the intracellular concentration vs. time profile for 16(Py)-S-2-S-(Py)16 and 16-3-16. 
The intracellular concentration of the analyte increased rapidly throughout the 5-h duration when 
the administered nanoparticles remain in contact with cells, followed by a noticeable decrease 
within the next 5 h after removal of the nanoparticle-dosed supernatant culture media. The 
intracellular amount rose to 900 ng (maximum) with the initial increase followed by subsequent 
decreased by ~60%. A similar trend was observed in the case of 16-3-16; however, its 
intracellular amount  rose to 400 ng (maximum) while its subsequent decrease of ~40% occured 
less rapidly than that observed for 16(Py)-S-2-S-(Py)16.  
The above observations are consistent with a progressive nanoparticle uptake, which 
reached a maximum before a seeming depletion of the intracellular analyte. For both analytes, an 
observed intracellular remnant proportion did not undergo further depletion within the 
intracellular investigation lasting 54-h. For the 16-3-16 gemini surfactant, its partial depletion 
from the host cells is in disagreement with our recent reports[15,16] showing no depletion of this 
compound. The apparent discrepancy is attributed to differences in the extraction method and the 
extensive washing of treated cell cultures in the present work. Adequate washing steps were not 
conduced in the past work. Gemini surfactants tend to be adherent to bio-membranes and to 
plastics including walls of plastic cell culture containers. The washing was thus critical for 
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eliminating potential gemini surfactant that is adherent to plastic walls or loosely adsorbed to 
exterior cell surfaces. 
 
 
 
 
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
In
tr
ac
el
lu
la
r 
co
nc
. o
f 
 1
6(
Py
)-
S-
2-
S-
(P
y)
16
 [
ng
 /
 1
 ×
10
6
ce
lls
]
Time (hours)
16(Py)-S-2-S-(Py)16 gemini surfactant
 170 
 
 
 
Figure 1.5: Representative experiments showing the intracellular concentration vs. time profile 
of the gemini surfactants, 16(Py)-S-2-S-(Py)16 (top panel) and 16-3-16 (bottom panel). 
The intracellular concentration increased progressively throughout the duration of 
nanoparticle administration to cells, followed by a gradual decrease after removal of the 
nanoparticle-dosed supernatant culture media. The dashed horizontal line “y-axis = 200 
ng/mL” shows that the results is reported only for data with concentration above 200 
ng/mL as noted under Section 3.8. Each plotted data point represents mean ± SD, n = 3. 
 
To verify the methodology and results, the cell transfection experiments and the 
subsequent LC-MS/MS quantification procedures were repeated. The results reported attests to 
the reproducibility of the methods and consistency of the quantitative results on the uptake and 
subsequent intracellular profile of the investigated gemini surfactants. 
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3.5 Discussion 
The present study describes the development of novel fast and simple HILIC-MRM-
MS/MS methods that were applicable to 18 gemini surfactants with varying molecular structures 
(Table 3.2). To-date, only one LC-MS/MS method has been reported for the quantification of 
gemini surfactants[15] but was only applicable to one class of gemini surfactants, the m-s-m 
family. This gives importance to the demonstrated applicability of the HILIC-LC-MS/MS 
platform to different structures of gemini surfactants. 
The choice of HILIC chromatography (with sulfoalkyl betaine-based zwitterionic 
stationary phase, ZIC-HILIC column[31,32]) contributed to a high sensitivity, which is 60-fold 
higher in terms of LLOD relative to the sensitivity of the method reported for the analysis of 16-
3-16.[15] Our choice of the ZIC-HILIC column, based on its compatibility with the diquaternary 
ammonium gemini surfactant analytes through +N/–SO3 HILIC mode interaction, led to more 
efficient chromatographic separation. Unlike the previous method,[15] no ion pairing reagent 
(i.e. TEA) was needed resulting in better ionization efficiency within the ESI source. TEA can 
compete for ionization within the ESI source resulting in undesirable ion suppression. Another 
major advantage of the HILIC-MS/MS is the use of isocratic elution rather than gradient system. 
In fact, the isocratic option was not possible when the cyano column was utilized.[15] 
The mobile phase was optimized to ensure that retention times are established to correlate 
with the gemini surfactant structural properties; a low buffer concentration (2.5 mM formate) 
was used. This buffer concentration (lower than concentrations of up to 50 mM in some cases) 
allows the chance for dominant interaction between the stationary phase and the analyte so that 
the gemini surfactants can display specific retention times as a result of their different structural 
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features. Here, an added potential benefit is that low buffer concentrations are associated with 
better sensitivity as opposed to high buffer concentrations. In addition, the buffered mobile phase 
was optimized to pH 6.2; deviation from this pH resulted in weak and inconsistent response as 
well as unstable retention times. The HILIC system is very sensitive to variations in analytical 
conditions including pH and temperature. In fact, deviation from the optimized column 
temperature resulted in increased pressure within the column thus preventing chromatographic 
separation. 
In addition to adopting HILIC chromatography, a high efficiency analyte recovery was 
achieved through the use of Bligh/Dyer lipid extraction. Bligh/Dyer method uses 2:1 (v/v) 
methanol/chloroform binary extractant-solvent allowing for high compatibility with the gemini 
surfactants' amphiphilic nature[25] (as defined by having both hydrophobic and hydrophilic 
moieties, Figure 3.1). In fact, we have previously employed liquid-liquid extraction using either 
methanol or octanol with 63% and 70% recoveries[16], respectively.  While methanol may favor 
the solubilisation of the hydrophilic component within gemini surfactants, octanol is more 
compatible with the hydrophobic elements. The methanol/chloroform system of the Bligh/Dyer 
method can, therefore, solubilize both components within gemini surfactants resulting in 
approximately 98% extraction efficiency.  The high recovery is clearly illustrated in Figures 3.6 
and S3.11 in which a direct comparison with octanol extraction is shown. Overall, the superior 
sensitivity achieved for the reported HILIC-LC-MS/MS method underscores a strategic use of 
HILIC chromatography in conjunction with high analyte extraction efficiency and a suitable 
mobile phase. 
 173 
 
Data from the analysis of nanoparticle-treated cells showed an initial rise in the analyte 
intracellular concentration followed by a maximum and a somewhat more gradual decrease of 
the intracellular analyte. Herein, the findings are consistent with a progressive nanoparticle 
uptake, which reached a steady state before a seeming depletion of the intracellular analyte. Two 
events that may account for the intracellular depletion of the gemini surfactant are its bio-
transformation into metabolites and its exocytosis from the host cells. An advantage with LC-
MS/MS includes its versatility that allows adapting the described method, with major or minor 
modifications, for the investigation of both bio-transformation and exocytosis. Accumulated data 
from such superior HILIC-LC-MS/MS bio-analyses of lipid-based nanoparticles should uncover 
structure-property-activity relationship. The knowledge can impact decision regarding the safe 
use of biomedical nanoparticles as well as provide insights into engineering new nanoparticles. 
3.6 Conclusion 
Sensitive, robust and simple HILIC-LC-MS/MS methods for the determination of the 
16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants in cells have been developed and fully 
validated according to USFDA. A high-efficiency liquid-liquid extraction was adopted along 
with a ZIC-HILIC column to attain high sensitivity and a run time of merely 4 minutes. The 
validated method is suitable for monitoring the fate of therapeutic nano-lipoplex within cells. In 
addition to cellular uptake shown in this study, we are currently investigation the intracellular 
deposition of gemini surfactants as well as metabolite formation. Such knowledge can shed light 
into the varying toxicities reported for gemini surfactants.[19,33] Finally, it should be noted that 
gemini surfactants have many other industrial applications[34] such as detergents, cosmetics and 
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solubilisation agents. The newly developed versatile HILIC-LC-MS/MS can serve as a 
starting point for the analysis of gemini surfactants regardless of the application. 
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3.9 Supplementary Information 
Supplementary Figure S3.9.1 
 
 
Figure S1.6: Product ions monitored for the internal standards 16(Py)-S-2-S-(Py)16-d10 and 
16-3-16-d66 during HILIC-LC-MS/MS analysis. 
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Figure S1.7: Chromatograms of the gemini surfactants, 16(Py)-S-2-S-(Py)16, 16-3-16, 16(Py)-
S-2-S-(Py)16-d10, 16-3-16-d66. [Panel A indicates the absence of any interference against 
the selective determination of all four compounds by showing the detection of no signals 
around the established HILIC-LC-MS/MS elution times of these compounds within 
"double blank" cell samples. B) chromatogram from an injection of only 16(Py)-S-2-S-
(Py)16-d10 and C) Chromatogram from an injection of only 16(Py)-S-2-S-(Py)16 at lower 
limit of quantitation, LLOQ. No cross-interference occurred between 16(Py)-S-2-S-
(Py)16 and 16(Py)-S-2-S-(Py)16-d10]. D) Chromatogram from an injection of only 16-3-
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16; and, E) Chromatogram from an injection of only 16-3-16-d66. No cross-interference 
occurred between 16-3-16 and 16-3-16-d66 since the injections produced signal for only 
the respective but not both compounds. In general, the chromatograms showed symmetry 
and smoothness for quantitative analysis as shown. 
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Supplementary Figure S3.9.3 
 
   
 
Figure S1.8: Calibration curves for the 16-3-16 and 16(Py)-S-2-S-(Py)16 gemini surfactants. In 
both cases, the linear range was 50 – 5000 ng/[1 × 106 cells], r2 ≥ 0.99. 
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Supplementary Figure S3.9.4 
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Figure S1.9: Chromatograms of the 16-3-16 gemini surfactant at LLOQ, ULOQ and LLOD. The 
relative response signal is shown for the analyte at: A) LLOQ and B) ULOQ in relation to 
the internal standard, 16-3-16-d66, which was present at a constant concentration. C) 
Extracted chromatogram for 16-3-16 at LLOD. 
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Supplementary Figure S3.9.5 
 
 
 
 
 
Figure S1.10: Contrasting analyte recovery efficiencies for Bligh/Dyer lipid extraction vs 
octanol extraction. Bligh/Dyer lipid extraction gave a better recovery (typically 98%) of 
the analyte and was the chosen liquid-liquid extraction method, departing from a recent 
report in which octanol extraction (70% efficiency) was used. 
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Table S1.6. Gemini surfactant mass concentrations equivalent to 3 mM molarity. 
Gemini 
surfactant 
Mass concentration 
(≈ 3 mM) 
12(Py)-S-2-S-(Py)12 2.24 mg/mL 
14(Py)-S-2-S-(Py)14 2.40 mg/mL 
16(Py)-S-2-S-(Py)16 2.57 mg/mL 
18(Py)-S-2-S-(Py)18 2.74 mg/mL 
16-3-16 2.22 mg/mL 
16-7-16 2.39 mg/mL 
12-3-12 1.88 mg/ml 
12-4-12 1.92 mg/mL 
12-8-12 2.09 mg/mL 
12-10-12 2.18 mg/mL 
12-12-12 2.26 mg/mL 
12-16-12 2.43 mg/mL 
18-3-18 2.39 mg/ml 
18-7-18 2.55 mg/mL 
18:1-3-18:1 2.37 mg/mL 
18:1-6-18:1 2.50 mg/mL 
12-7NH-12 2.05 mg/mL 
Py-3-12 2.24 mg/mL 
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Table S1.7. Overview of the HILIC-LC-MS/MS method validation parameters. 
Analyte  16(Py)-S-2-S-(Py)16 16-3-16 
Internal standard (IS)  16(Py)-S-2-S-(Py)16-d10 16-3-16-d66 
Method description  LLE, HILIC-LC-MS/MS LLE, HILIC-LC-MS/MS 
QC range  150 – 4375 ng/mL 150 – 4375 ng/mL 
Calibration curve range  50 – 5000 ng/mL 50 – 5000 ng/mL 
Lower limit of detection 
(LLOD) 
 6 ng/mL 3 ng/mL 
Average analyte recovery  97.7%  (Bligh/Dyer method) 98.2%  (Bligh/Dyer method) 
Intra-day accuracy range  92 – 110% 92 – 110% 
Intra-day precision range  3 – 11% 3 – 11% 
Inter-day accuracy range  92 – 110% 92 – 110% 
Inter-day precision range  3 – 11% 3 – 11% 
Bench-top stability (hrs)  24 24 
Autosampler stability (hrs)  48 48 
Freeze-thaw stability (cycles)  3 3 
Long-term stability (days)  105 105 
Specificity (i.e., matrix effects)  No net matrix effects No net matrix effects 
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Table S1.8. Recovery of 16-3-16 (analyte) from the aqueous cellular matrix. 
   Bligh/Dyer extraction    Octanol extraction  
Theoretical 
concentration 
 Extracted cells  
(mean ± SD, ng/mL) 
Spiked extracted cells  
 (mean ± SD, ng/mL) 
Recovery 
(%) 
 Extracted cells  
(mean ± SD, ng/mL) 
Spiked extracted cells  
 (mean ± SD, ng/mL) 
Recovery 
(%) 
16-3-16         
50 ng/mL (LLOQ)  48.24 ± 5.73 49.38 ± 3.74 97.7  36.38 ± 5.02 52.21 ± 4.74 69.7 
150 ng/mL (LQC)  147.19 ± 13.61 150.53 ± 15.31 97.8  114.51 ± 8.72 159.26 ± 11.38 71.9 
375 ng/mL (MQC)  371.57 ± 51.33 383.46 ± 47.32 96.9  277.87 ± 33.16 385.06 ± 37.92 72.2 
4375 ng/mL (HQC)  4359.45 ± 359.41 4368.17 ± 212.57 100.2  3210.64 ± 179.11 4528.22 ± 182.33 70.9 
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Table S1.9. Intra- and inter-day accuracy and precision in the analysis of 16-3-16. 
Quality Control  Observed concentration 
(mean ± SD, ng/mL) 
Accuracy 
(%) 
Precision 
(%RSD) 
INTRA-DAY:    
 Analysis Day (#)    
LLOQ: 50 ng/mL Day 1 47.45 ± 4.22 94.9 8.9 
 Day 2 49.61 ± 3.77 99.2 7.6 
 Day 3 50.19 ± 3.31 100.4 6.6 
LQC: 150 ng/mL Day 1 160.95 ± 14.65 107.3 9.1 
 Day 2 159.45 ± 13.39 106. 3 8.4 
 Day 3 163.78 ± 14.58 109.2 8.9 
MQC: 375 ng/mL Day 1 343.88 ± 34.73 91.7 10.1 
 Day 2 392.62 ± 33.37 104.7 8.5 
 Day 3 336.75 ± 32.33 89.8 9.6 
HQC: 4375 ng/mL Day 1 4480.01 ± 456.96 102. 4 10.2 
 Day 2 4536.88 ± 426.47 103.7 9.4 
 Day 3 4738.13 ± 355.36 108.3 7.5 
INTER-DAY:    
 Concentration    
LLQC 50  ng/mL 55.05 ± 5.84 110.1 10.6 
LQC 150 ng/mL 145.955 ± 11.09 97.3 7.6 
MQC 375 ng/mL 393.03 ± 34.19 104.8 8.7 
HQC 4375 ng/mL 4475.63 ± 434.14 102.3 9.7 
 193 
 
Table S1.10. Stability of the 16-3-16 gemini surfactant within the sample matrix. 
Quality Control 
Storage condition/ 
period 
Observed concentrations 
(mean ± SD, ng/mL) 
Accuracy 
(%) 
Precision 
(%RSD) 
LQC: 150 ng/mL 0 h 150.31 ± 11.57 100.2 7.7 
 24 h on bench top 164.42 ± 10.69 109.6 6.5 
 Three freeze/thaw cycles 135.45 ± 14.22 90.3 10.5 
 ‒20 ˚C for 105 days (LT) 134.85 ± 8.23 89.9 6.1 
 48 h extract in autosampler  144.15 ± 13.84 96.1 9.6 
     MQC: 375 ng/mL 0 h 362.63 ± 34.45 96.7 9.5 
 24 h on bench top 353.62 ± 34.31 94.3 9.7 
 Three freeze/thaw cycles 338.63 ± 32.17 90.3 9.5 
 ‒20 ˚C for 105 days (LT) 345.38 ± 36.26 92.1 10.5 
 48 h extract in autosampler  399.75 ± 37.58 106.6 9.4 
     HQC: 4375 ng/mL 0 h 4147.51 ± 443.78 94.8 10.7 
 24 h on bench top 4379.38 ± 381.01 100.1 8.7 
 Three freeze/thaw cycles 4038.13 ± 415.93 92.3 10.3 
 ‒20 ˚C for 105 days (LT) 4239.38 ± 390.02 96.9 9.2 
 48 h extract in autosampler  4392.51 ± 347.01 100.4 7.9 
LT (long term): ‒20 ˚C for 105 days 
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4.1 Abstract 
Introduction: The lipid molecules termed dicationic gemini surfactants have been explored 
successfully for the delivery of genetic materials into cells. However, the fate of the gemini 
surfactants after the delivery of their DNA cargo into cells remains poorly studied. Thus, the safe 
and efficient use of gemini surfactants requires a better understanding of their cellular and 
subcellular fate namely, cellular uptake, bio-distribution, metabolism and excretion. 
Methods: The subcellular profiles of two lead gemini surfactants, denoted as 16(Py)-S-2-S-
(Py)16 and of 16-3-16, was investigated using hydrophilic interaction liquid chromatography 
electrospray–ionization-tandem mass spectrometry (HILIC–ESI–MS/MS) employing the 
standard addition method. Keratinocytes were treated with gemini surfactant-based nanoparticles 
and subsequently fractionated using differential centrifugation, resulting in five subcellular 
fractions. The gemini surfactants were then extracted using the Bligh/Dyer method. 
Results: The standard addition–HILIC–ESI–MS/MS platform was suitable for the quantification 
within multiple subcellular fractions as well as the whole-cell homogenates. The accuracy of the 
measurements was within ±15% as established by evaluation of quality control samples spiked 
within the various samples. Subcellular analysis showed a gemini surfactant distribution to all 
the cellular compartments, with an uneven distribution for 16(Py)-S-2-S-(Py)16 and a somewhat 
even distribution for its counterpart, 16-3-16. 
Discussion/conclusions: The distinct subcellular distribution, observed for the first time, provides 
possible explanations for the different toxicities of the studied compounds, 16(Py)-S-2-S-(Py)16 
and of 16-3-16. It also demonstrates a new approach for screening and toxicity elucidation for a 
vast array of bio-active gemini surfactants. 
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4.2 Introduction 
In gene therapy, dicationic gemini surfactants are promising molecules used as non-viral 
vectors for nanoparticle-mediated gene delivery.[1] Gemini surfactants represent a versatile 
family of lipids, with a general structure of two monomer surfactants interconnected through a 
spacer, where both monomers contain a polar or ionic head-group and a hydrophobic alkyl tail 
(Figure 4.1A)[2]. Gemini surfactants are synthetically tailored for effective gene delivery through 
the rational design and selection of molecular building blocks (i.e. head-groups, hydrocarbon 
tails and spacers).[3-5] The aim is to increase gene transfection abilities and reduce undesired 
cytotoxic effects. The positively charged head-groups can be modified, for example, to di-
pyridinium or di-quaternary amines for effective complexation of nucleic acids into 
nanoparticles to achieve efficient cell transfection.[6-8] More recently, amino acids were added 
within the spacer region to enhance biocompatibility.[3]  
Despite their promising potency, the fate of the building blocks of gemini surfactant-based 
nanoparticles (herein, gemini nanoparticles) after entry into cells and release of their therapeutic 
cargo is poorly studied. It is possible to study their fate by adding a fluorescence tag to the 
gemini surfactant structure, such as pyrene.[9, 10] However, it was shown that the addition of such 
structure-modified moieties within the formulation alters the pharmacokinetics behaviour of the 
nanoparticles.[11, 12] In addition, gemini surfactants may degrade within biological systems and 
the fluorescence tag may detach from the parent molecule. Such limitations prompted us to 
develop multiple mass spectrometry (MS)-based methods to monitor the fate of gemini 
surfactants within cells.[13-15] Most recently, we reported a new hydrophilic interaction liquid 
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chromatography-tandem mass spectrometry (HILIC-MS/MS) method which, for the first time, 
allowed for monitoring the cellular uptake of structurally diverse gemini surfactants, such as 
16(Py)-S-2-S-(Py)16 and 16-3-16 (Fig 1B, 1C).[15]  
 
 
Figure 4.1: Gemini surfactant structures. 
 
m/z 203.09 (C10H19S2+)
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A) Schematic representation of gemini surfactant general structure; B) The exact 
molecular structures of intact compounds and monitored product ions during HILIC-
MS/MS of 16-3-16: N,N-bis(dimethylhexadecyl)-1,3-propanediammonium; C) 16(Py)-
S-2-S-(Py)16: 1,1'-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-diyl)]dipyridinium. 
 
The gemini surfactant compounds 16(Py)-S-2-S-(Py)16 and 16-3-16, are: 1,1'-[ethane-1,2-
diylbis(sulfanediylhexadecane-1,2-diyl)]dipyridinium and N,N-bis(dimethylhexadecyl)-1,3-
propanediammonium, respectively (Figure 4.1B, 1C). Both surfactants contain saturated C-16 
hydrocarbon tails; however, the former contains dipyridium head-groups and an ethane-1,2-
dithiol spacer, whereas the latter has diquaternary ammonium head-groups along with a propyl 
spacer.[16] Despite both being promising gene delivery agents,  the cytotoxicity associated with 
di-quaternary bearing gemini surfactants is relatively higher than that of their di-pyridinium 
counterparts.[8] 
The determination of the intracellular-fate of 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini 
surfactants using  HILIC-MS/MS method revealed that both compounds rapidly accumulated in 
PAM 212 epidermal keratinocytes when their nanoparticles were administered to cultured 
cells.[15] Subsequently, both compounds depleted in a similar fashion when monitored up to 55 
hours post transfection.[15] The identical trend in cellular uptake and degradation/elimination 
offers no explanation of the differential cytotoxicity between the two compounds as building 
blocks for the nanoparticles.  
Theoretically, lipid-based nanoparticles can migrate freely within different compartments 
in cells[17-21] or can be targeted to specific subcellular organelles.[22-26] In general, the overall 
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process of nanoparticle–cell interaction is a complex, multi-step mechanism. It involves the 
initial binding of nanoparticles to the cells' outer plasma membrane and an uptake of the 
nanoparticles into cells through multiple pathways that predominantly includes endocytosis and 
occasionally includes non-endocytotic routes.[17-21] Within cells, the nanoparticles can transition 
through multiple steps that involve various organelles, resulting either in successful drug release 
or degradation of the nanoparticles with or without exocytosis into the extracellular 
surrounding.[17-21] Therefore, the nanoparticles or their encapsulated materials may deposit at 
several subcellular sites including plasma membrane,[18, 21, 27] endosomes/lysosomes,[28-31] 
cytoplasm,[18, 32-37] mitochondria[23, 38] and the nucleus.[39-41] The deposition into subcellular sites can 
be reasonably expected to change with time and to vary among different subcellular 
compartments and is dependent on the molecular structure of the gemini surfactants.  
Therefore, investigation of the subcellular distribution profiles could explain the various 
cytotoxicity trends observed among various structures of gemini surfactants. In this reported 
work, a qualitative and quantitative HILIC-LC-MS/MS assessment of the subcellular 
distribution of gemini surfactants within PAM 212 cells is provided for the first time. 
4.3 Materials and Methods 
4.3.1 Materials 
A dipyridinium gemini surfactant 16(Py)-S-2-S-(Py)16, its diquaternary ammonium 
counterpart 16-3-16, and their deuterated internal standards 16(Py)-S-2-S-(Py)16-d10 and 16-3-
16-d66, respectively, were synthesized as described previously.[15] The deuterium atoms were 
located on the pyridinium ring in the case of the dipyridinium gemini surfactant and on the tail 
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regions in the case of 16-3-16. The zwitterionic phospholipid 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) was supplied by Avanti Polar Lipids Inc. (Alabaster, AL, USA). 
Chloroform, methanol and 1-octanol (99%), ammonium formate, formic acid, mass 
spectrometric-grade water and acetonitrile were purchased from ThermoFisher Scientific 
(Ottawa, ON, Canada). PAM 212 cells were from an original cell passage kindly provided by Dr. 
S. Yuspa (NIH, Bethesda, MD, USA). Ingredients for cell culture medium, namely minimum 
essential media (MEM), fetal bovine serum albumin (FBS) and antibiotic-antimycotic were 
obtained from Sigma-Aldrich (Oakville, ON, Canada). Plasmid DNA (pGT·IFN-GFP) was 
constructed in-house, as described previously.[42] Western blotting kit containing primary and 
secondary antibody cocktail was obtained from Abcam (Cambridge, MA, USA), while protease 
inhibitor cocktail came from Invitrogen (Carlsbad, CA, USA). Tissue culture flasks and Petri 
dishes (with 150-cm3 and 75-cm3 capacities) were purchased from ThermoFisher Scientific 
(Ottawa, ON, Canada). 
4.3.2 LC-MS/MS instrumentation 
The hybrid LC-MS/MS analytical system is as described in previous work.[15] It comprised 
of an Agilent 1200 Series HPLC with a quaternary pump, a degasser and auto sampler (Agilent 
Technologies, Mississauga, ON, Canada) coupled to an AB Sciex API 4000 QTRAP mass 
spectrometer (AB Sciex, Concord, ON, Canada). A typical chromatographic 4-min separation 
run to analyze 2 µL injected aliquots involved a ZIC®-HILIC column (150 × 2.1 mm, 5 µm, 200 
Å; Merck SeQuant AB, Umea, Sweden) held at 50 ˚C and an isocratic mobile phase flowing at 
500 µL/min. The mobile phase consisted of 80:20 (v/v) acetonitrile:buffer, with the buffer 
containing 2.5 mM ammonium formate and 25 mM formic acid. Sample carryover was absent; 
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however, to eliminate matrix build-up in the column, a 2-min double blank injection was run 
between every two samples using the same mobile phase but with the ammonium formate 
modified to 12.5 mM. Increasing the ammonium formate concentration was to help eliminate 
potential in-column buildup of sucrose, which was used as a differential centrifugation medium 
in the subcellular fractionation process (described below). 
The AB Sciex QTRAP 4000 mass spectrometer is equipped with an electrospray ionization 
(ESI) source set at 5500 V ionspray voltage and 600 ˚C at the ion source interface, with 55 psi 
being the pressure for the curtain gas pressure and 65 psi as the pressures for both GS1 and GS2. 
The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode for the 
analytes and the deuterated internal standards as [M]2+ species through the following transitions: 
16-3-16 [M]2+ m/z 290.33 → 355.40, 86.11; 16-3-16-d66 [M]2+ m/z 323.54 → 388.61; and, 
16(Py)-S-2-S-(Py)16 [M]2+ m/z 349.28 → 396.28, 203.09; 16(Py)-S-2-S-(Py)16-d10 [M]2+ m/z 
354.31 → 401.31 (Figure 4.1, Figure 4.2S). The MRM conditions for the monitored precursor → 
product ion transitions are presented in Table S4.1 (supplementary information).[15] 
4.3.3 Preparation of standard solutions 
Aqueous 3 mM stock solutions of the gemini surfactants including the deuterated internal 
standards were used and routinely stored at −20 ˚C under darkness. The 3 mM molarity give the 
equivalence of 2.2227 mg/mL for 16-3-16, 2.4219 mg/mL for 16-3-16-d66, 2.5771 mg/mL for 
16(Py)-2-S-2-(Py)16 and 2.6073 mg/mL for 16(Py)-2-S-2-(Py)16-d10. Liposomal DOPE solution 
at 1 mM was routinely prepared fresh in 9.25% w/v isotonic sucrose solution with pH 9. Plasmid 
DNA (pGT·IFN-GFP) solution at 200 µg/mL was prepared in ultrapure, organic-free water and 
was routinely stored at −20 ˚C. 
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4.3.4 Preparation of nanoparticle formulations 
Nano-lipoplex formulations for cell transfection were prepared through a 1:10:100 molar 
ratio of plasmid DNA/gemini surfactant/lipid DOPE (P/G/L) as described.[7] A mole of DNA is 
calculated per DNA base-pair with an average molecular weight of 660 Da. Briefly, the required 
transfection dose of plasmid DNA, that is 4.5 µg for 10 × 106 cells/treatment, was mixed with 
the appropriate amount of gemini surfactant for a 30-minute incubation at room temperature. The 
appropriate amount of the liposomal DOPE was added to the binary mixture, followed by further 
15-minute incubation at room temperature to obtain a ternary (final) P/G/L system. 
4.3.5 PAM 212 cell treatment and sample collection 
PAM 212 cells used in this study were routinely cultured to ~85% confluence in S-MEM 
(i.e., MEM supplemented with 10% FBS and 1 unit/mL antibiotic-antimycotic) inside 37 ˚C-
humidified 95% air/5% CO2 incubator. At 24 h before treatment, cells were seeded at 10 × 106 
cells/150-cm3 Petri dish in S-MEM, which was changed to FBS-free MEM after a rinse with 
same media within 1 h to transfection. Freshly prepared nanoparticle formulations (Section 2.4) 
were added to the cell cultures and allowed to interact with cells by returning cells to the CO2 
incubator. All treatments were carried out in replicates (n = 3). The addition of the nanoparticle 
formulation to the cell marks the reference point for recording post-treatment events and time-
points.  
At 5 h post-treatment, the nanoparticle-dosed cell media was removed and cells were 
rinsed with phosphate-buffered saline (PBS). The cells were detached by trypsinization and 
collected into 40 mL volumes. The collected cells were pelleted (1,500 rpm, 5 min, 4 ˚C), rinsed 
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with PBS, resuspended in 500 µL of ice-cold 0.25 M sucrose-HEPES-EDTA (SHE) (0.25 M 
sucrose, 10 mM HEPES, pH 7.5, 1 mM EDTA, 1× Halt™ protease inhibitor) and cooled on ice 
prior to subsequent steps. 
4.3.6 Subcellular fractionation and subcellular sample collection 
The ice-cooled 500-µL treated cell samples were gently homogenized using a motorized 
tissue-grinder/pellet homogenization apparatus (Fisher Scientific, #12-141-361, 12-141-368; 
Toronto, ON, Canada). The cell homogenates were transferred into ice-cooled tubes and 
resuspended to a total of 1,200 µL using ice-cold homogenization buffer. A 200-µL aliquot was 
stored at –80 ˚C until further analysis. 
The remaining 1,000-µL homogenates were then fractionated using established differential 
centrifugation schemes, Figure 4.2.[43] Briefly, the 1,000-µL homogenates were centrifuged at 
1,000 × g for 10 min, 4 ˚C. The resulting supernatant S1 (~1,000-µL) was retrieved and 
maintained on ice. The pellet P1 was resuspended to a total of 1,000-µL with 1.8 M sucrose final 
concentration. This was through initial resuspension of pellet P1 into 310 µL of 0.3 M sucrose-
Tris-magnesium (STM) buffer (0.30 M sucrose, 50 mM Tris, 3 mM MgCl2, protease inhibitor), 
followed by addition of 690 µL of 2.5 M STM buffer (2.5 M sucrose, 50 mM Tris, 0.5 mM 
MgCl2, protease inhibitor). The P1 suspension was centrifuged at 71,000 × g for 90 min, 4 ˚C.[43] 
The obtained plasma membrane supernatant S2 and the nuclear pellet P2, which was 
resuspended in 100 μL of PBS, and were subsequently stored at –80 ˚C until further analysis. 
Next, the supernatant S1 from the first centrifugation round was centrifuged at 8,000 × g 
for 15 min, 4 ˚C.[43] A mitochondrial pellet P3 was obtained, and was resuspend in 100 μL PBS 
and stored at –80 ˚C until further analysis. The supernatant S3 was subjected to further 
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centrifugation at 125,000 × g, 30 min, 4 ˚C. The resulting products were cytosolic supernatant S4 
and pellet P4,[43] which represents remnant fractionation residue and which was resuspended in 
100 μL of PBS. Both were stored at –80 ˚C until further analysis. 
 
 
 
Figure 4.2: Subcellular fractionation scheme based on differential centrifugation. 
Multiple subcellular fractions were isolated including nuclear, plasma membrane, 
mitochondrial and cytosolic fractions along with the leftover cellular residue. Adopted with 
Cultured cells
(treated, controls)
• Suspension in isotonic medium, 5 min
• Cell disruption (using motorized tissue-grinder/pestle)
• Contrast microscopy to verify effective cell lysis
Step 1: 1,000 × g,  10 min
Pellet 1
(Nuclei, plasma membrane)
Supernatant 1
(Organelles, cytosol, intracellular particles, vesicles)
Step 2: Into 1.8 M Sucrose;
71,000 × g,  90 min
Step 3: 8,000 × g,  15 min
Supernatant 3
(Cytoplasmic contents – remnants)
Homogenate
Into 0.25 M SHE buffer
Supernatant 2
(Plasma membrane)
Pellet 2
(Nuclei)
Pellet 3
(Mitochondria)
Step 4: 125,000 × g,  30 min
Supernatant 4
(Cytosol)
Pellet 4
(remnants: microsomes, vesicles, etc)
Whole cell lysate
(aliquot)
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some modifications from refs.[43] 
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4.3.7 Protein recovery, 1-Dimensional SDS-PAGE and western blotting 
Isolated subcellular fractions were analyzed to verify their composition and purity using 
immunoblot assays. The experimental procedure and the results are shown in supplementary 
materials (Section 4.3 Supplementary Information, ahead in this chapter). 
4.3.8 Sample preparation for LC-MS/MS analysis  
The whole-cell homogenates as well as the five subcellular fractions as shown in Section 2.6 
were processed for LC-MS/MS analysis according to the scheme shown in Figure 4.3. Briefly, 
the samples were retrieved from –80 ˚C, allowed to thaw and the volumes were brought to 1,000-
µL for samples that were below this volume. All samples were then lysed by six freeze/thaw 
cycles along with 1-h sonication at 25 kHz. Each lysed sample was then divided in half to give 
two identical samples equal to 500-µL (Figure 4.3). 
Standard addition method for quantification was carried out by adding known analyte 
concentration or appropriate blanks separately to the 500-µL samples. Briefly, either  16(Py)-2-
S-2-(Py)16 or 16-3-16 was spiked at 5000 ng/mL within the corresponding treated cells into only 
one of each two identical samples while an equal volume of blank was added to the other. 
Internal standards were then added at 2086 ng/mL for 16(Py)-2-S-2-(Py)16-d10 and 938 ng/mL 
for 16-3-16 through equal-volume additions. All additions were within a 25-µL allocated 
volume, giving a resultant volume of 525 µL per sample prior to extraction. 
For the construction of standard addition calibration curves, three levels of standard 
additions were prepared by spiking the standards into whole-cell lysate samples already 
containing a base concentration of the target analytes. Briefly, the concentrations 2500, 3750 and 
5000 ng/mL were spiked into 500-µL whole-cell lysate samples with a base concentration (1250 
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ng/mL) of the target analytes. In addition, a zero addition (0 ng/mL) sample was prepared by 
adding equal volumes blank solutions in place of a standard solution. Then, equal volumes 
containing equimolar amounts of the appropriate internal standard as stated above, 16(Py)-S-2-S-
(Py)16-d10 or 16-3-16-d66, were added to all samples. As above, all additions were within a 25-
µL allocated volume, giving a resultant volume of 525 µL per sample prior to extraction. 
 
 
 
Supernatant 2
(Plasma membrane)
1,000 µL
Pellet 2
(Nuclei)
Pellet 3
(Mitochondria)
Supernatant 4
(Cytosol)
1,000 µL
Pellet 4
(Cellular residue)
Whole cell lysate
200 µL (⅙ aliquot)
1,000 µL1,000 µL 1,000 µL 1,000 µL1,000 µL1,000 µL Reconstituted 
Volumes
500 µL500 µL 500 µL 500 µL500 µL500 µL Volume-
Splitting
500 µL500 µL 500 µL 500 µL500 µL500 µL
500 µL + std*500 µL + std* 500 µL + std* 500 µL + std*500 µL + std*500 µL + std* Standard
Addition
500 µL + blank500 µL + blank 500 µL + blank 500 µL + blank500 µL + blank500 µL + blank
into 200 µL into 200 µL into 200 µL
PROCESSING
STEPS
 Extraction of 
Analytes
Bligh/Dyer
method
Bligh/Dyer
method
Bligh/Dyer
method
Bligh/Dyer
method
Bligh/Dyer
method
Bligh/Dyer
method
Figure 4.3: Subcellular and whole-cell sample processing steps prior to LC-MS/MS analysis. 
Topmost panel shows all samples as collected from differential centrifugation. 'Std*' 
indicates a standard addition where both the analyte and internal standard were added and 
'blank' indicates a blank addition which involved only the internal standard. 
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All samples were then extracted using Bligh/Dyer method as described.[44] To the 525-µL 
samples, 1,900 µL (3.8 vols) of 2:1 (v/v) methanol/chloroform was added, followed by 625 µL 
(1.24 vols) of both chloroform and water, with vortexing in each case. The combined mixtures 
were centrifuged at 14,000 rpm for 10 min at room temperature to achieve aqueous/organic 
phase separation. A 1,000 µL of the bottom organic phase (i.e., 80% portion) was retrieved, dried 
using a gentle N2 gas stream and the analytes deposited in microvials were reconstituted into in 
200 µL of n-octanol. The reconstituted analytes were diluted 10 – 50× in the running mobile 
phase prior to LC-MS/MS analysis. 
4.3.9 Assessment of the suitability of the Standard addition–LC-MS/MS method  
The standard addition–HILIC-ESI-MS/MS method was validated for quantifying the target 
analytes within different subcellular fractions. It was suitable to apply the standard addition 
method since the HILIC-ESI-MS/MS, with linearity 50 – 5000 ng/mL, was fully validated in our 
previous report in accordance with USFDA guidelines.[15] Concentrations measured using the 
standard addition method should fall within the established linear range for reliable 
measurements. 
Linearity within the standard addition method was established through a 4-point calibration 
line consisting of three standard additions and a zero point spiked into a base concentration of the 
analytes. The data was processed by least-squares method along with a 1/χ weighting factor to 
obtain ratios of summed peak areas of the analytes, 16(Py)-S-2-S-(Py)16 and 16-3-16, to peak 
areas of the respective internal standards, 16(Py)-S-2-S-(Py)16-d10 and 16-3-16-d66.[15] The ratios 
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were then plotted against the standard addition concentrations (0, 2500, 3750, 5000 ng/mL) and 
the slope and coefficient of determination (R2) were determined for the lines of best fit. Here, the 
y-intercept is the signal response due to a given (or unknown) original analyte concentration, 
which is determined by extrapolating the plotted line to zero signal response. After establishing 
linearity, routine analysis was performed timely with only one standard addition, utilizing 
validated mathematical equation.[45, 46] 
For precision and accuracy determination, quality control (QC) samples of 4575 ng/mL of 
16(Py)-S-2-S-(Py)16 were prepared and analyzed across all subcellular fractions as well as the 
whole-cell homogenates. In the case of the analyte 16-3-16, the QC concentration was 1250 
ng/mL. All QC samples were analyzed in triplicates. Acceptance criterion for accuracy was 
±15% of the nominal QC concentration, while the criterion for precision, computed as relative 
standard deviation (RSD), was ±15%. The minimum acceptable signal response was set at a 
signal-to-noise (S/N) ratio of 5. 
4.3.10 Statistical analysis 
Statistical analyses and comparisons were performed by unpaired t-test. Significant 
difference between compared cases was established at the p < 0.05 level of significance. 
4.4 Results 
4.4.1 Purity and Western blot characterization of subcellular fractions 
Western blot results assessing the protein composition and purity of the subcellular 
fractions are presented in supplementary materials, Appendix B, Figure S4.1. It confirms the 
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separation of target organelles and indicates that the fractionation scheme employed allowed the 
isolation of intact organelles and cellular components. However, some cross contamination is 
observed and is actually expected in accordance with the manufacturer’s specifications. 
4.4.2 Standard addition–HILIC-LC-MS/MS for subcellular bio-analysis of gemini 
surfactants 
A standard addition calibration plot obtained for typical validation samples containing the 
16(Py)-S-2-S-(Py)16 and 16-3-16 compounds are shown in Figure 4.4. Four replicate injections 
were ran for each QC sample. On the other hand, triplicate injections of the samples were done 
after spiking with known concentrations of the analyte. The concentration of the analyte was 
obtained by extrapolating the calibration line to zero signal response. All calibration curves were 
linear with an R2 of 0.99 (Figure 4.4). 
 
 
◊ 16(Py)-S-2-S-(Py)16: y = 0.0063x + 8.5, R² = 0.9828
Δ 16-3-16: y = 0.0015x + 1.65, R² = 0.9816
-10
0
10
20
30
40
50
-2000 -1000 0 1000 2000 3000 4000 5000 6000
An
al
yt
e-
to
-in
te
rn
al
 s
ta
nd
ar
d 
ar
ea
 ra
tio
Analyte concentration │ ng/mL
 213 
 
 
The standard addition–LC-MS/MS method adopted our in-house developed HILIC-ESI-
MS/MS method (linearity 50 – 5000 ng/mL), which was validated as per the USFDA 
guidelines.[15] Analytical selectivity was gained from analyte-specific retention times and from 
monitoring of target analytes through the analyte's unique precursor → product ion transitions. 
No effect on the selectivity was observed in the use of the standard addition–LC-MS/MS method 
for different subcellular samples. This is evident from the absence of any interference or 
contaminant peaks from the LC-MS/MS chromatograms. The analytes co-eluted with their 
deuterated internal standards: 16(Py)-S-2-S-(Py)16 and 16(Py)-S-2-S-(Py)16-d10 co-eluted at 
2.62 mins,  while 16-3-16 and 16-3-16-d66 co-eluted at 2.42 mins. 
Once linearity is established, it is deemed suitable to perform routine analysis with only a 
single standard addition point (5000 ng/mL) which should ideally be greater than the expected 
unknown concentration by at least one order of magnitude. Such "one-level" standard addition 
approach is valid as long as the analyte concentrations in both the original and the standard 
addition sample falls within an established linear calibration range.[46] In our previous work, we 
demonstrated that the calibration curves for the two analytes, 16(Py)-S-2-S-(Py)16 and 16-3-16, 
were linear within the concentration range of 50 – 5000 ng/mL.[15] The original analyte 
concentration (unknown) in samples was calculated using the established equation:[45] 
Figure 4.4: Four-point ꞌstandard additionꞌ calibration curve. 
The original concentration of the analyte in the sample is found by extrapolating the calibration line 
to the zero signal response. 
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            …                        …                        …                        (1) 
 
where [X]i denotes the initial (original) concentration of analyte in the sample before spiking, [S] 
is the known concentration spiked into the sample, IX is the signal response from the initial 
sample before spiking, and I(S+X) is the signal response from the sample after it had been spiked 
with known analyte concentration. The one-level standard addition approach generated the 
needed results while at the same time significantly reducing the overall analysis time. 
4.4.3 Matrix effects, accuracy and precision in standard addition–LC-MS/MS 
Precision and accuracy results of QC samples analyzed across all subcellular fractions are 
given on Table 4.1. The results show that for samples containing the 16(Py)-S-2-S-(Py)16 and 
16-3-16 gemini surfactants, accuracy for the QC samples were all within ~88 – ~ 110% of the 
nominal values. The precision for both analytes, 16(Py)-S-2-S-(Py)16 and 16-3-16, were within 
3 – 13% (RSD) in all cases. These values serve as indicators for assessing possible matrix effects 
across the subcellular and whole-cell samples. The values indicate that the analytical accuracy 
and precision of the standard addition–LC-MS/MS method was not affected by the subcellular 
and whole-cell matrices. A recent LC-MS/MS method for subcellular lipids also showed 
quantitative accuracy and precision with no matrix effects across mitochondria fractions and a 
cell-mimetic fraction based on bovine serum albumin.[47] 
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Table 4.1. Accuracy and precision of quality control samples in the standard addition–HILIC-
ESI-MS/MS analysis gemini surfactants. 
 
 
4.4.4 Standard addition–HILIC-LC-MS/MS analysis of cellular and subcellular samples 
The standard addition–HILIC-LC-MS/MS was applied to the analysis of five subcellular 
fractions along with the whole-cell homogenates from cell-treatments using DNA-encapsulated 
nanoparticles of the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants. The results in Figure 
4.5 represent the gemini surfactant subcellular distribution after a 5-h duration in which cells 
remained in contact with a dose of nanoparticles containing the studied gemini surfactants. For 
both gemini surfactants, a large uptake into cells occurred: 70% uptake for 16(Py)-S-2-S-(Py)16 
and 90% uptake for 16-3-16, determined by analysing the whole-cell homogenates.  The 5-hour 
time point was chosen based on our published work on cellular uptake;[15] this point marks the 
Gemini surfactant 
identity  
 
Quality Control 
(concentration) 
Subcellular/cellular 
matrix types 
Observed 
concentrations 
(mean ± SD, ng/mL) 
Accuracy 
(%) 
Precision 
(%RSD) 
      
16(Py)-S-2-S-(Py)16  4575 ng/mL Plasma membrane fraction 4292.44 ± 236.81 93.82 5.18 
  Cytosolic fraction 4382.85 ± 401.03 95.80 9.15 
  Nuclear fraction 4198.02 ± 491.59 91.76 11.71 
  Mitochondrial fraction 4651.35 ± 439.26 101.67 9.60 
  ER/Cellular remnants 5014.16 ± 472.49 109.60 10.33 
  Whole cell lysate 4780.88 ± 617.53 104.50 12.92 
      
      
16-3-16 1250 ng/mL Plasma membrane fraction 1106.21 ± 133.12 88.50 10.65 
  Cytosolic fraction 1242.93 ± 105.43 99.43 8.48 
  Nuclear fraction 1128.47 ± 030.72 90.28 2.46 
  Mitochondrial fraction 1353.25 ± 161.18 108.26 11.91 
  ER/Cellular remnants 1201.15 ± 159.36 96.09 13.27 
  Whole cell lysate 1258.42 ± 153.23 100.67 12.26 
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maximum uptake point which is followed by gradual elimination and/or degradation.  It is also 
represents the ideal nanoparticle–cell contact time for transfection and gene expression in PAM 
212 cells.[7] 
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Figure 4.5: Subcellular distribution of the gemini surfactants, 16(Py)-S-2-S-(Py)16 and 16-3-16. 
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As shown in Figure 4.5, the 16(Py)-S-2-S-(Py)16 compound showed its highest 
distribution to the plasma membrane (22%), followed by its distribution to cytosol (15%), 
mitochondria (10%) and the nucleus (5%) (Figure 4.5). The distribution to the remnant 
subcellular residue which was not further 'fractionatable' was 9%. In the case of the 16-3-16 
compound, it was distributed across the subcellular compartments within a rather narrow 
variation margin of 18 – 24% among various compartments. It had a slightly higher distribution 
to the remnant subcellular residue (24%), followed by plasma membrane (22%), cytosol (20%), 
nucleus (19%), and mitochondria (18%) (Figure 4.5). 
Evidently, both compounds showed unequal distribution across the subcellular 
compartments. However, the 16-3-16 compound versus its counterpart 16(Py)-S-2-S-(Py)16 
showed particularly high distribution to the mitochondria (19% vs. 5%; p < 0.05), nucleus (18% 
vs. 10%; p < 0.05) and the remnant subcellular residue (24% vs. 9%; p < 0.05) (Figure 4.5). The 
distribution among other compartments including the membrane showed insignificant variation 
among the two structures. We initially hypothesized that the reported increased cytotoxicity 
associated with diquaternary gemini surfactants in comparison to the dipyrdinium surfactants 
was due to their disruptive effects on cell membranes. However, the membrane-distribution of 
the two gemini surfactants was not significantly different. 
The subcellular concentrations were determined after 5-hour treatment duration in which 
cultured PAM 212 epidermal keratinocytes had an administered dose of gemini 
surfactant/DNA nanoparticles. Each plotted data point represents mean ± SD, n = 3. 
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The obtained data may suggest that association with the mitochondria or the nucleus could 
be the reason for the varying toxicities. Distribution to mitochondria or nucleus may either be 
due to the entry of the gemini surfactants into these subcellular compartments or their association 
with the membranes of these organelles. Our findings provide the only qualitative and 
quantitative distinction in subcellular profile between the two compounds, without the need for 
fluorescence tag. It may provide the first experimental explanation on the cytotoxicity difference 
among these two promising gene delivery agents. 
In Figure 4.5, the data obtained for the different subcellular fractions was compared with 
that for the whole-cell homogenate. Theoretically, the combined content of the analyte from the 
five subcellular fractions can be equated to the content of the analyte within the whole-
cell homogenate. For the 16(Py)-S-2-S-(Py)16 gemini surfactant, its combined content from the 
five fractions was 61% while its content within the whole-cell homogenate was found to be 70% 
of the initial dose. The resultant percentage difference is 13.7%. In the case of the 16-3-
16 gemini surfactant, its combined content from the five subcellular fractions was 103% while its 
content within the whole-cell homogenate was 90%. This gives a difference of 13.5%. In both 
cases, values for the percentage difference fall below the widely accepted ± 15% accuracy 
standard, as per USFDA regulatory guidelines in bioanalytical methods. 
4.5 Discussion 
This study evaluated the subcellular distribution and fate of gemini surfactants within PAM 
212 epidermal keratinocytes with the aim of understanding the reasons behind the varying 
toxicities of two distinct gemini surfactant structures, namely 16(Py)-S-2-S-(Py)16 and of 16-3-
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16 (Figure 4.1). We previously assessed the cellular uptake of these gemini surfactants, reporting 
an almost identical intracellular accumulation and subsequent, more gradual depletion trend for 
the two structures.[15] As such, the similar intracellular accumulation and depletion did not 
explain the different toxicities, therefore, we focused in the present study on investigating the 
gemini surfactant subcellular distribution. 
Theoretically, to determine the subcellular distribution of gemini surfactants, different LC-
MS/MS methods with internal calibration must be developed/validated for application to the 
different subcellular fractions. This is because the subcellular organelles are different in their 
bio-complexity and therefore can possibly pose different matrix effects. This can be time 
consuming and challenging to achieve. 
Therefore, we implemented a simple standard addition method in using HILIC-LC-
MS/MS method as reported[15] in terms of mobile phase and experimental conditions. The use of 
standard addition with LC-MS/MS was only recently demonstrated in few reports;[45, 48, 49] 
however, the standard addition approach has been commonly combined with techniques such as 
atomic spectroscopy,[50-52] UV-Visible spectroscopy[53, 54] and fluorescent spectroscopy.[55] The 
standard addition approach requires no blank matrix; herein it eliminates the need for blank 
subcellular matrix and the time-consuming subcellular fractionation. It compensates for effects 
of varying matrix is as each sample is analyzed against its own matrix and the measured signal is 
calibrated against an added standard of the analyte. The method simultaneously allowed the 
analysis of different subcellular fractions as well as whole-cell samples. A key advantage of such 
method is the compensation of matrix effect since identical matrix is present in both the spiked 
samples (serving as calibration standards) and unspiked samples (i.e., actual samples).[45, 46]  
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Though no guidelines are yet available for bio-analytical method validation involving 
standard addition methods, we opted for establishing precision and accuracy to demonstrate the 
robustness of the analytical approach including matrix effects compensation across the 
subcellular and whole-cell lysates. Precision and accuracy were acceptable as shown in Table 4.1 
and were established by analyzing QC concentration of 4575 ng/mL for 16(Py)-S-2-S-(Py)16 
and 1250 ng/mL for 16-3-16 across the different subcellular and whole-cell samples (Table 4.1). 
The QC concentrations were chosen such that they fall in the range of analyte concentrations 
found within the studied subcellular samples for the respective analytes. Overall, the analytical 
accuracy and precision (Table 4.1) across the different subcellular and whole-cell samples 
suggest that the matrix effects did not affect signal response within the standard addition method. 
Subcellular data from the standard addition–HILIC-ESI-MS/MS analyses of nanoparticle-
treated cell samples showed a high cellular uptake of the test compounds, 16(Py)-S-2-S-(Py)16 
and 16-3-16 (70% and 90% uptake, respectively; Figure 4.5). The total uptake amount was found 
to be distributed across the studied subcellular organelles (or compartments), namely plasma 
membrane, cytosol, mitochondria, nucleus and the remnant subcellular residue. The amount of 
test compound per subcellular compartment ranged from 5 – 24%, and the combined content 
from the subcellular compartments was equal to the total uptake amount (within ± 15% margin 
of error).  
The subcellular distribution profiles (Figure 4.5) showed a significantly higher distribution 
to the mitochondria, nucleus and the remnant subcellular residue for 16-3-16 as compared to its 
counterpart 16(Py)-S-2-S-(Py)16 (Figure 4.5). Though 16-3-16 is reportedly more toxic than 
16(Py)-S-2-S-(Py)16,[8] studies to account for toxicity difference have been lacking. Herein, the 
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distinct subcellular distribution observed between these compounds may explain the reported 
difference in toxicity. 
The higher cellular uptake observed for the 16-3-16 compound is a plausible explanation of 
its reported higher toxicity relative to the 16(Py)-S-2-S-(Py)16 compound. Studies show that the 
cytotoxicity of gemini surfactants is concentration-dependent, where higher concentration leads 
to higher cytotoxicity.[6, 8] Herein, the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants were 
used for cellular gene transfection at equimolar concentrations, thus, the higher cellular uptake 
for 16-3-16 implies higher concentration in host cells and is consistent with its reported higher 
toxicity. The observed difference in cellular uptake was accompanied by different subcellular 
distribution that further accounts for different gemini surfactant toxicities. 
The subcellular distribution of 16-3-16 compound with higher overall uptake into cells 
showed higher accumulation within the mitochondria, nucleus and the remnant subcellular 
residue. The mitochondria and nucleus have crucial functions within cells, including cellular 
metabolism and energy generation; and, control of a cell's machinery by storage/regulation of 
genes, respectively.[56] The remnant subcellular residue encompasses such subcellular structures 
as ribosomes (sites of protein synthesis) and vesicular systems (for transport and defense against 
foreign particles).[56] Therefore, an accumulation of gemini surfactants (whether as nanoparticles 
or free-separate molecules) into these compartments could impact their outer membrane integrity 
and their normal function. Herein, it is reasonable to argue that the increased accumulation of 16-
3-16 particularly within the mitochondria and nucleus provides a basis for its higher toxicity 
relative to 16(Py)-S-2-S-(Py)16.  
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4.6 Conclusion 
Standard addition–HILIC-ESI-MS/MS was successfully implemented for the 
determination of the subcellular distribution of the 16(Py)-S-2-S-(Py)16 and 16-3-16 
gemini surfactants within cells, possibly shedding light for their varying toxicities. 
Obtained subcellular data showed that the 16-3-16 gemini surfactant showed increased 
distribution to the nucleus, mitochondria and the remnant subcellular residue. This 
distinction may thus account for the higher toxicity exhibited by this compound in relation 
to its counterpart 16(Py)-S-2-S-(Py)16. 
The analytical strategy applied in this study is applicable for the analysis of gemini 
surfactants not only for cell cultures but also for the case of tissues, organs and organisms; 
here, the analyte accumulation into and depletion from biological sub-compartments and 
sub-structures can both be evaluated. It is also applicable to environmental samples where 
the exposure and biodistribution pathways can be studied. We are currently evaluating 
additional gemini surfactant structures, assessing their cellular biodistribution to possibly 
provide new insights to both toxicity and transfection efficiency. 
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4.9 Supplementary Information 
4.9.1 Supplementary Methods 
4.9.1.1 Protein recovery, 1-Dimensional SDS-PAGE and western blotting 
Isolated subcellular fractions were analyzed to verify their composition and purity using 
immunoblot assays.[1-3] First, to recover proteins from whole-cell cell pellet, nuclear pellet P2, 
mitochondrial pellet P3 and remnant subcellular pellet P4, the freshly collected pellets were 
resuspended in ice-cold 200 μL RIPA buffer for 30 mins. The protein-containing supernatants 
were collected after centrifugation at 15,000 rpm for 20 min, 4 ˚C. NOTE: The RIPA buffer 
contained 50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% triton X 100, 0.5% sodium deoxycholate, 
0.1% SDS and protease inhibitor. For proteins from plasma membrane fraction (isolated as 
supernatants, Figure 4.3), the supernatant S2 having 1.8 M sucrose was resuspended into 
sucrose-free 0.25 M SHE buffer to have 0.25 M sucrose.[1, 4] The pellet obtained upon 
centrifugation (5,000 × g, 10 min, 4 ˚C) was resuspended in ice-cold 200 μL RIPA buffer for 30 
mins, followed further centrifugation at 15,000 rpm for 20 min, 4 ˚C to give the protein-
containing supernatant. To obtain higher protein concentrations, the individual supernatants were 
combined with equal volume of –80 ˚C-cold acetone and the precipitated protein was 
reconstituted in a smaller volume of RIPA buffer. For the cytosolic fraction (also isolated as 
supernatant, Figure 4.3) no protein recovery steps were necessary. 
For protein separation, protein from each fraction were mixed with equal volumes of 2× 
Leammli buffer and electrophoresed, 50 μg protein per lane, through 4-20% SDS-PAGE gels in 
tris-glycine running buffer. The resolved proteins were electrophoretically transferred to PVDF 
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membranes (GE Healthcare) at 400 mA for 1.75 h. The PVDF-bound proteins were blocked for 
2 h in TTBS/milk buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 0.1% Tween-20, and 
5% nonfat dry milk.[1, 2] The membranes were then incubated in the same buffer with primary 
antibody cocktail (AB140365; Abcam, Canada) overnight at 4 ˚C, washed in TTBS and 
subsequently incubated for 2-h at room temperature in secondary antibody cocktail from same 
Abcam kit as instructed.[5] Finally, the blots were washed in TTBS, developed with enhanced 
chemiluminescence assay (Bio-Rad, Canada) and the protein bands were visualized with 
AlphaImager system (Bio-Rad, Canada) after up to 5-min exposure at ambient temperature. 
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4.9.2 Supplementary Results 
4.9.2.1 Purity and Western blot characterization of subcellular fractions 
Western blot results assessing the protein composition and purity of the subcellular 
fractions are presented in Figure S4.1. Organelle-specific protein antibodies were detected for the 
confirmation of the fractions, namely plasma membrane, mitochondria, cytosol, nucleus and the 
remnant subcellular residue. The lanes in Figure S4.1 show protein patterns as expected for the 
subcellular fractions and the whole-cell homogenate. 
 
 
… 
Figure S0.1: Immunoblot verification and assessment of the subcellular fractions from differential 
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In the western blot experiments, the organelle-marker antibodies were applied in one-
single cocktail to probe the subcellular fractions. So antibodies for one-organelle marker gives 
positive indication for that organelle while at the same time giving negative indication for the 
other organelles. There were few cross-contaminations in the subcellular fractions, especially the 
mitochondrial fraction, cytosolic fraction and nuclear fractions. However, the contamination did 
not in any way overwrite the distinct, relatively pure nature of the fractions. It should be noted 
that the subcellular fractions were isolated in parallel from the same cell-homogenate samples. 
The qualitative purity of organelles as shown by Figure S4.1 is consistent with the best purity 
limits observed when several, parallel subcellular fractions are isolated from single cell-
homogenates.[6] Overall, the results show that the subcellular fractions were reasonably isolated, 
containing the right, intact organelles or cellular components. 
centrifugation. 
Lane M: protein molecular weight marker; lane 1: plasma membrane fraction; lane 2: 
endoplasmic reticulum (ER) fraction; lane 3: mitochondrial fraction; lane 4: cytosolic 
fraction; lane 5: nuclear fraction; lane 6: whole-cell homogenate. Samples in all lanes were 
probed with a single antibody cocktail containing all organelle-specific markers. The protein 
band sizes are:  Na+/K+ ATPase ≈ 100 kDa, plasma membrane;  GRP78 ≈ 78 kDa, ER;  
ATP5a ≈ 60 kDa, mitochondria; GAPDH ≈ 38 kDa, cytosol; histone H3 ≈ (di-methyl K9) ≈ 
17 kDa, nucleus. 
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4.9.3 Supplementary Figure S1 
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Figure S0.2: Product ions monitored for the internal standards 16(Py)-S-2-S-(Py)16-d10 and 
16-3-16-d66 during HILIC-LC-MS/MS analysis. 
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4.9.4 Supplementary Table S4.1 
Table S4.1. Conditions for MRM transitions of the analytes on AB Sciex 4000 QTRAP® System 
 
*Abbreviations: 
  DP: declustering potential, CE: collision energy, CXE: collision cell exit potential; X: neutral loss 
 
 
 
 Analyte   MRM Transition   DP* CE* CXE* 
Gemini surfactant Molecular Formula  [M]
2+ → [M − X]+ m/z  → m/z  (eV) (eV) (eV) 
16(Py)-S-2-S-(Py)16 C44H78N2S22+  [M]2+ → [M − C21H36N]+ m/z 349 → 396  30 22 10 
16(Py)-S-2-S-(Py)16 C44H78N2S22+  [M]2+ → [M − C34H59N2]+ m/z 349 → 203  30 22 10 
16(Py)-S-2-S-(Py)16-d10 C44H68D10N2S22+  [M]2+ → [M − C21H31D5N]+ m/z 354 → 401  30 25 10 
         
16-3-16 C39H84N22+  [M]2+ → [M − C16H33]+ m/z 290 → 355  40 21 10 
16-3-16 C39H84N22+  [M]2+ → [M − C33H70N2]+ m/z 290 → 86  40 35 6 
16-3-16-d66 C39H18D66N22+  [M]2+ → [M − C16D33]+ m/z 323 → 388  35 25 10 
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:  
DISCUSSIONS, CONCLUSION AND FUTURE WORK 
5.1 General Discussion 
Dicationic gemini surfactants have witnessed an intensive development and extensive 
exploration as non-viral vectors for nanoparticle-mediated delivery of therapeutic nucleic 
acids.[1] They have demonstrated promising gene transfection potencies through the ability to 
complex nucleic acids and compact them into nanoparticles, preserving the nucleic acid 
bioactivity and mediate the transport of the genetic cargo into target cells. This allows the 
expressing of therapeutic transgenes in host cells whereas such possibility is unachievable using 
control treatments involving naked nucleic acids.[2, 3] Along with this, gemini surfactants facilitate 
cellular internalization of other tested biomedical applications including anti-cancer drug 
delivery,[4] antimicrobial treatments[5-7] and bacterial transformations.[8] 
While current gemini surfactant gene transfection efforts are advancing towards clinical 
trials, there is still little insights regarding the fate of gemini surfactant-based nanoparticles after 
entry into cells and release of their therapeutic cargo. In fact, gemini surfactants show varying 
degrees of cytotoxicity,[9, 10] which may, theoretically, be linked to their fate within cells. 
Cellular and subcellular fate of gemini surfactants encompasses the concept of quantitatively 
analyzing and understanding their cellular uptake, intracellular deposition, subcellular 
distribution, and possible metabolism and/or exocytosis. A better understanding of how 
intracellular/subcellular fate of the gemini surfactant relates to toxicity will aid in the 
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development of less toxic and more efficient compounds. To investigate the cellular and 
subcellular fate of gemini surfactants, effective bioanalytical methods are needed. 
Therefore, my Ph.D. research investigated gemini surfactants using mass spectrometry, 
capitalizing on the specificity and selectivity of the technique for efficient detection and 
measurement of the target compound.  Gemini surfactants bear permanent positive charges (i.e. 
quaternary amines) making them excellent candidates for MS analysis. Initially, compound-
specific mass spectrometric fingerprints were established and adapted into bioanalytical methods 
for targeted analysis. 
The gemini surfactant bioanalysis within nanoparticle-treated cells can benefit from 
analytical methods that offer a range of suitable capabilities. The developed and validated liquid 
chromatography-tandem mass spectrometric (LC-MS/MS) methods for gemini surfactant 
quantification were fast, sensitive and provided target analyte selectivity andspecificity. The 
mass spectrometric detection is suitable for the studied gemini surfactants which are not 
compatible with fluorescent/UV-detection due to the lack of fluorescent or UV-active structural 
features. On the other hand, the chromatographic step was necessary for target analyte separation 
from potential endogenous species co-extracted from cellular matrix and was a means for 
reducing matrix effects for better sensitivity. 
5.1.1 Mass spectrometric characterization of dipyridinium and β-cyclodextrin-based 
diammonium gemini surfactants 
The mass spectrometric characterization of gemini surfactants allowed for the confirmation 
of their molecular composition and structures, and for the identification of unique diagnostic 
product ions for each compound. To date, CID-MS/MS characteristics have been studied for a 
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number of traditional m-s-m quaternary ammonium gemini surfactants[11, 12] and their 
amino/dipeptide derivatives[13]; however, the vast majority of bioactive gemini surfactants are 
yet to studied. The gemini surfactants evaluated in my Ph.D. comprise novel β-cyclodextrin-
based diquaternary ammonium and dipyridinium molecules, herein denoted as R-7N(X-suc-β-
CD)-R and Ȓ(Py)-S-2-S-(Py)Ȓ, respectively (Figure 1.5). A combination of high-resolution 
single-stage (MS), tandem (MS/MS) and multi-stage (MSn) analysis allowed for in-depth MS 
characterization. The high-resolution single-stage MS analysis showed abundant doubly-charged 
[M]2+ species for the evlauted compounds at sub-1ppm mass accuracies and strongly 
confirmed/established the compound molecular formula and identity. This was achieved using a 
two-point internal calibration on an ESI-QqToF-MS system (Table 2.1). 
The use of MS/MS and MS3 analyses revealed comprehensive CID fragmentation 
beheviour of the gemini surfactants, including both universal and distinctive fragmentation 
patterns. The β-cyclodextrin-based diquaternary ammonium gemini surfactants showed a 
universal MS/MS fragmentation pattern as was the case for compounds from the dipyridinium 
gemini surfactant family. For example within one gemini surfactant family, the observed 
fragmentation included similar neutral loss of full alkyl tail moieties and alkyl-ammonium or 
alkyl-pyridinium neutral fragments by the individual compounds. The loss of alkyl tail moieties 
was also universal in the CID fragmentation of other gemini surfactants investigated in previous 
reports.[11, 12, 13] 
However, there was a distinctive MS/MS pattern between compounds of these two 
families. The β-cyclodextrin-substituted compound fragmentation began with the loss of either 
one head-tail region or both head-tail regions; the resultant product ions, in both cases, further 
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dissociated through sequential cleavage of sugar moieties. For the bis-pyridinium gemini 
compounds, they either lost neutral pyridine(s) to give doubly-charged ions or formed 
complementary pyridinium alongside other singly-charged ions. For both gemini surfactant 
families, the MS/MS fragmentation generated compound-specific product ions marked by the 
presence of at least an intact alkyl tail portion. 
The compound-specific product ions served as diagnostic ions and thus authenticated the 
molecular structures of the studied compounds and differentiated between isobaric compounds 
(with identical molecular mass). They confirmed the presence of unique structural features 
including pyridinium head-groups for the dipyridinium compounds and quaternary ammonium 
head-groups for the β-cyclodextrin-based diquaternary ammonium compounds. 
Overall, at least eight diagnostic CID-MS/MS product ions were established for the β-
cyclodextrin-based diquaternary ammonium and dipyridinium gemini surfactants. With this 
number, more diagnostic product ions were established for each investigated compound herein 
than for other gemini surfactants investigated in previous reports.[11, 12, 13] Based on the 
diagnostic CID-MS/MS fragment ions and distinctive fragmentation patterns, the dipyridinium 
and β-cyclodextrin-based based diquaternary ammonium gemini surfactants can be theoretically 
detected and unambiguously identified within any biological or environmental matrices. 
5.1.2 Quantitative, hydrophilic interaction liquid chromatography tandem mass 
spectrometric method for of gemini surfactants 
Cellular/subcellular fate investigation of gemini surfactants requires the development of 
effective validated analytical techniques. Liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS) provides higher selectivity and sensitivity over other analytical 
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approaches for bioanalysis of gemini surfactants, their metabolites and endogenous molecules. 
Herein, zwitterionic hydrophilic interaction liquid chromatography-based (HILIC)-MS/MS 
methods were developed and validated for the separation of two lead gemini surfactants. The 
methods were also applicable to 18 compounds belonging to dipyridinium and diquaternary 
ammonium (m-s-m) gemini surfactant families (Table 3.2). 
The HILIC-MS/MS analysis detected each gemini surfactant within PAM212 keratinocyte 
lysate with a distinctive retention time combined with selective MRMs based on abundant yet 
diagnostic product ions. The specific retention times coupled with analyte selectivity allowed for 
the differentiation of gemini surfactants with varying molecular structures. It was shown that 
gemini surfactants having an overall longer hydrophobic alkyl tails or longer alkyl spacer chains 
have shorter retention times on the HILIC column with a zwitterionic sulfoalkylbetaine 
stationary phase (Table 3.2). 
The HILIC-MS/MS methods were fully validated as per the USFDA guidelines[14] for the 
quantitation of two lead dipyridinium and diquaternary ammonium gemini surfactants, 
designated as 16(Py)-S-2-S-(Py)16 and 16-3-16 respectively (Figure 2.1). The HILIC-MS/MS 
methods showed 60-fold higher sensitivity, 2-fold faster run times and are simplified with 
isocratic elution compared with other methods, most notably including a cyano-based LC-
MS/MS method[15] which was only applicable to diquaternary ammonium gemini surfactants. 
The HILIC-MS/MS superiority is attributable to multiple factors that are related to sample 
preparation and the chromatographic separation. A 98%-efficient liquid-liquid extraction was 
achieved via the use of Bligh/Dyer lipid extraction method[16]. In addition, the sulfoalkylbetaine 
HILIC stationary phase is more compatible with the physicochemical properties of the studied 
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gemini surfactants. This compares with the cyano-based LC-MS/MS method[15] with 70% 
extraction efficiency using octanol and the unfavorable use of an ion-pairing reagent known for 
its ion suppressive effects. 
Though the HILIC-MS/MS methods were effective for gemini surfactant determination at 
the whole-cell lysate, the ability to allow subcellular level analysis involving different 
subcellular fractions was also required. Therefore, a standard addition scheme in combination 
with HILIC-LC-MS/MS (i.e., standard addition–HILIC-MS/MS) was developed to allow 
simultaneous analysis of different subcellular fractions and to compensate for matrix effects. The 
standard addition–HILIC-MS/MS method exhibited accuracy and precision (within accepted ± 
15% margin), indicating that signal response was not affected by matrix effects across the 
different subcellular fractions. Overall, the HILIC-MS/MS and standard addition–HILIC-
MS/MS methods were effective for the determination of gemini surfactants at both the whole-
cell lysate and the subcellular level. 
5.1.3 Bio-quantfication of 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants: 
intracellular and subcellular fate in PAM 212 cells 
To demonstrate their bioanalytical application, the developed/validated methods achieved 
effective quantification of the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants in PAM212 
keratinocytes – through HILIC-MS/MS analysis of whole-cell lysates and standard addition–
HILIC-MS/MS analysis of subcellular fractions. This allowed accurate determination of the 
cellular uptake of gemini surfactant-based nanoparticles, the gemini surfactant intracellular 
concentration-vs-time profiles and their subcellular distribution. 
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The whole-cell data revealed that both the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini 
surfactants were rapidly internalized by PAM212 keratinocytes during a 5-hour treatment period 
when gemini surfactant-based DNA nanoparticles were applied to the cells. Upon removal of the 
added nanoparticles, the intracellular gemini surfactant content underwent a depletion, with a 40-
50% content remaining in cells after 54 hours. The depletion may indicate either gemini 
surfactant biodegradation or exocytosis from host cells, however, the overall similar trend 
presents no apparent explanation of a suggested toxicity difference between the 16(Py)-S-2-S-
(Py)16 and 16-3-16 gemini surfactants. 
Despite similar cellular uptake and intracellular depletion trends of the two compounds, 
their subcellular data showed different subcellular distribution profiles. The 16-3-16 gemini 
surfactant had a statistically significant increase in distribution to the mitochondria and nucleus 
relative to its 16(Py)-S-2-S-(Py)16 counterpart (p < 0.05), with the two having similar 
distribution to the cell membrane, cytosol and the remnant subcellular residue. This differential 
subcellular distribution, determined for the first time, may explain why 16-3-16 is apparently the 
more toxic compound. Its increased distribution to the mitochondria and nucleus may pose 
harmful effects to the biological integrity and function of the cells. 
5.2 Summary and conclusions 
The work accomplished in this research includes the mass spectrometric analysis of β-
cyclodextrin-based diquaternary ammonium and dipyridinium gemini surfactants, including the 
establishment of universal CID-MS/MS fingerprints. The fingerprints defined diagnostic MRM 
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transitions for subsequently developing effective MRM bioanalytical methods required for 
gemini surfactant identification and quantitation. 
The methods developed and validated were HILIC-MS/MS and the standard addition–
HILIC-MS/MS; they were new for the gemini surfactants, sensitive, fast and simple. The HILIC-
MS/MS and the standard addition–HILIC-MS/MS methods accomplished the quantification of 
target gemini surfactants, 16(Py)-S-2-S-(Py)16 and 16-3-16, within PAM212 whole-cell lysates 
and subcellular fractions after nanoparticle-based DNA transfection of cells. The generated data 
allowed a time-course monitoring of gemini surfactant internalization into cells along with their 
intracellular deposition and subcellular distribution. The rapid, initial cellular uptake of both 
gemini surfactants occurred as would be expected for successful entry of gemini surfactant-based 
DNA nanoparticles into cells. 
Herein, the first time-observed depletion of the intracellular gemini surfactant content 
maybe indicative of biodegradation, exocytosis or both. Based on subcellular distribution, the 
increased distribution of 16-3-16 than its counterpart, 16(Py)-S-2-S-(Py)16, to the mitochondria 
and nucleus may explain its suggested higher toxicity. Together, this work and findings offer a 
new paradigm for future gemini surfactant development and exploration, establishing molecular 
fragmentation fingerprints of novel compounds and comprehensive MRM bioanalytical 
strategies for studying biological fate, elucidating varying toxicity and assessing the possible 
metabolite formation. 
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5.3 Future directions 
The accomplished and described application of analytical mass spectrometric platforms for 
studying representative DNA transfection gemini surfactants highlight an effective investigative 
approach, at its pioneering stage, that can benefit future studies in two main directions. First, the 
CID-MS/MS analysis of fragmentation behaviour can be adapted and extended to other novel 
gemini surfactants, such as amino acid/peptide-based gemini surfactants. Second, fingerprint 
product ions established for the chosen and characterized compounds can then be adopted for 
developing/validating bioanalytical MS/MS methods for studying gemini surfactant biological 
fate. 
5.3.1 Evaluation of the tandem mass spectrometric fragmentation across structural 
varieties of gemini surfactants 
A wide variety of gemini surfactants developed for gene transfection represent worthy 
candidates for CID-MS/MS characterization to determine their fragmentation behaviour and 
establish unique product ions. For example, sub-categories of gemini surfactants with notable 
nucleic acid transfection abilities and low toxicity now include amine-/ammonium-containing 
compounds along with modified derivatives including sugar-based[17, 18], amino acid-/peptide-
based[9, 19] and heterocyclic (imidazole, pyridinium) compounds.[20-22] Herein, the data generated 
will serve as a platform for CID-MS/MS fragmentation studies of new compounds including the 
above-mentioned gemini surfactant sub-categories. 
Ultimately, the accumulation of fragmentation studies will build a library of diagnostic 
product ions for a vast range of gemini surfactants. This will offer unique MRM transitions for 
 248 
 
different analytical scenarios including confirmation of synthetic target compounds, metabolite 
identification and identification/quantitation of compounds within complex bio-samples. 
5.3.2 Quantitative assessment of in vivo and in vitro profiles of gemini surfactants 
The systematic investigation of gemini surfactant cellular/subcellular (in vitro) fate using 
HILIC-MS/MS analysis in this work can be broadened to incorporate multiple data points: this 
includes multiple/extended post-transfection time-points at the whole-cell investigation level and 
the exploration of additional subcellular level components such as endosome/lysosome and 
extracellular media. This will help obtain more information about the cellular internalization, 
bio-distribution and toxicity of the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants. In 
particular, the observed depletion of the gemini surfactants after uptake into cells could be 
further probed by exploring the extracellular fluid to examine possible gemini surfactant 
exocytosis. 
Beyond the PAM212 epidermal keratinocyte cellular model adopted for this work, the 
cellular/subcellular fate investigations can be extended to cover other cell lines so as to further 
explore the gemini surfactants studied herein. A noteworthy cell line is the breast cancer-derived 
cell, MCF-7, which has accounts for significant gemini surfactant-based anti-cancer gene 
delivery studies. Another cell line is the kidney fibroblast cell line, COS-7 cells[23], which has 
been widely used for evaluating the gene transfection and cytotoxic profiles of gemini 
surfactants, including 16-3-16. In addition, the investigations can be expanded into the in vivo 
biological fate, particularly for gemini surfactants tested in animal models for genetic and 
acquired diseases. Ultimately, the accumulation of data and insights into the in vitro and in vivo 
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fate of gemini surfactants will unearth and possibly help engineer desired relationships between 
compound structure, biological fate and toxicity. 
An important aspect of studying the fate of gemini surfactants as constitutive element of 
gene delivery nanoparticles in biological hosts is our improved ability to determine the influence 
of nanoparticle properties on their bioactivity, toxicity and the biological fate. Although the 
molecular structure of the gemini surfactant is a significant influential factor with regards to the 
efficiency of gene delivery systems, the physicochemical properties of nanoparticles as a whole 
can exert equally strong or greater influence. Therefore, future gemini surfactant biological fate 
studies can be integrated with detailed physicochemical analysis of nanoparticle size, surface 
charge (termed zeta potential), pH sensitivity, bio-stability and aggregation. This allows a 
comprehensive evaluation of gemini surfactant biological fate and the effects of both compound 
structure and nanoparticle properties. 
5.3.3 Investigation of gemini surfactant biodegradation and metabolite formation 
Based on the first evidence of depletion of the studied 16(Py)-S-2-S-(Py)16 and 16-3-16 
gemini surfactants within PAM212 epidermal keratinocytes as observed in this work, future 
research should evaluate the possible intracellular metabolism of gemini surfactants. Mass 
spectrometry offers an ideal tool for studying possible metabolites of the gemini surfactants due 
its ability to detect and identify structural modifications that accompany biotransformation of 
xenobiotics. That is, the capabilities of single-stage MS, CID-MS/MS and multi-stage MSn can 
analyze biotransformations which are marked by differences in m/z values between parent 
compounds and their metabolites. In addition, neutral losses and precursor ion scans can be 
employed to aid in the identification of metabolites. 
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In addition to probing metabolite formation, the possibility of gemini surfactant exocytosis 
from host cells should be studied to determine its contribution to the observed intracellular 
depletion. In this case, the HILIC-MS/MS quantitations described in this work could be adopted 
for the analysis of extracellular matrix components. Knowledge of gemini surfactant exocytosis 
(under the wider scope of subcellular distribution) and gemini surfactant metabolism and 
metabolic pathways/sites will ultimately benefit the platform of gemini surfactant development 
for more efficiency and minimal toxicity. 
 
 251 
 
5.4 References 
 
[1] M. Donkuru, I. Badea, S. Wettig, R. Verrall, M. Elsabahy, M. Foldvari, Advancing nonviral gene 
delivery: lipid- and surfactant-based nanoparticle design strategies, Nanomedicine (Future Medicine) 5(7) 
(2010) 1103−1127. 
[2] I. Badea, R. Verrall, M. Baca-Estrada, S. Tikoo, A. Rosenberg, P. Kumar, M. Foldvari, In vivo 
cutaneous interferon-γ gene delivery using novel dicationic (gemini) surfactant–plasmid complexes, 
Journal of Gene Medicine 7(9) (2005) 1200–1214. 
[3] Badea, Ildiko, Gemini cationic surfactant-based delivery systems for non-invasive cutaneous gene 
therapy   College of Pharmacy & Nutrition, University of Saskatchewan, Saskatoon, 2006, p. pp 237. 
[4] D. Michel, J.M. Chitanda, R. Balogh, P. Yang, J. Singh, U. Das, A. El-Aneed, J. Dimmock, R. 
Verrall, I. Badea, Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly 
soluble curcumin analogs for the treatment of melanoma, Eur J Pharm Biopharm, 2012 Elsevier B.V, 
Netherlands, 2012, pp. 548-56. 
[5] S. He, B. Wang, H. Chen, C. Tang, Y. Feng, Preparation and antimicrobial properties of gemini 
surfactant-supported triiodide complex system, ACS Appl Mater Interfaces 4(4) (2012) 2116–2123. 
[6] L. Caillier, E. Taffin de Givenchy, R. Levy, Y. Vandenberghe, S. Geribaldi, F. Guittard, 
Polymerizable semi-fluorinated gemini surfactants designed for antimicrobial materials, J. Colloid. 
Interface Sci. 332(1) (2009) 201-207. 
[7] J. Chlebicki, J. Węgrzyńska, I. Maliszewska, M. Oświęcimska, Preparation, surface-active properties, 
and antimicrobial activities of bis-quaternary ammonium salts from amines and epichlorohydrin, Journal 
of Surfactants and Detergents 8(3) (2005) 227–232. 
[8] L. Horniak, F. Devínsky, P. Balgavý, I. Lacko, L. Ebringer, Quaternary ammonium halides for 
increased efficiency of 
bacterial transformation, Commenius University in Bratislava, Czechoslovakia, 1990. 
[9] J. Singh, P. Yang, D. Michel, R.E. Verrall, M. Foldvari, I. Badea, Amino acid-substituted gemini 
surfactant-based nanoparticles as safe and versatile gene delivery agents, Curr Drug Deliv, United Arab 
Emirates, 2011, pp. 299-306. 
[10] M. Donkuru, S.D. Wettig, R.E. Verrall, I. Badea, M. Foldvari, Designing pH-sensitive gemini 
nanoparticles for non-viral gene delivery into keratinocytes, J. Mater. Chem. 22 (2012) 6232-6244. 
[11] J. Buse, I. Badea, E.R. Verrall, A. El-Aneed, Tandem Mass Spectrometric Analysis of the Novel 
Gemini Surfactant Nanoparticle Families G12-s and G18:1-s, Spectroscopy Letters 43 (2010) 447–457. 
[12] J. Buse, I. Badea, R.E. Verrall, A. El-Aneed, Tandem mass spectrometric analysis of novel 
diquaternary ammonium gemini surfactants and their bromide adducts in electrospray-positive ion mode 
ionization, J Mass Spectrom 46(10) (2011) 1060-70. 
[13] W. Mohammed-Saeid, J. Buse, I. Badea, R. Verrall, A. El-Aneed, Mass spectrometric analysis of 
amino acid/di-peptide modified gemini surfactants used as gene delivery agents: Establishment of a 
universal mass spectrometric fingerprint, Int. J. Mass Spectrom. 309 (2012) 182–191. 
[14] J. Kadavil, B. Booth, Bioanalytical Method Validation - Biopharmaceutics (guidance for Industry), 
Food and Drugs Administration, United States of America, 2013, pp. 1–28. 
[15] J. Buse, I. Badea, R.E. Verrall, A. El-Aneed, A general liquid chromatography tandem mass 
spectrometry method for the quantitative determination of diquaternary ammonium Gemini surfactant 
drug delivery agents in mouse keratinocytes’ cellular lysate, Journal of Chromatography A 1294 (2013) 
98–105. 
[16] E.G. Bligh, W.J. Dyer, A rapid method of total lipid extraction and purification, Can J Biochem 
Physiol 37(8) (1959) 911-7. 
 252 
 
[17] M.L. Fielden, C. Perrin, A. Kremer, M. Bergsma, M.C. Stuart, P. Camilleri, J.B. Engberts, Sugar-
based tertiary amino gemini surfactants with a vesicle-to-micelle transition in the endosomal pH range 
mediate efficient transfection in vitro, Eur J Biochem, Germany, 2001, pp. 1269-79. 
[18] L. Wasungu, M. Scarzello, G. van Dam, G. Molema, A. Wagenaar, J.B. Engberts, D. Hoekstra, 
Transfection mediated by pH-sensitive sugar-based gemini surfactants; potential for in vivo gene therapy 
applications, J Mol Med (Berl) 84(9) (2006) 774-84. 
[19] P. Yang, J. Singh, S. Wettig, M. Foldvari, R.E. Verrall, I. Badea, Enhanced gene expression in 
epithelial cells transfected with amino acid-substituted gemini nanoparticles., European Journal of 
Pharmacuetics & Biopharmacuetics 75(3) (2010) 311–320. 
[20] V.D. Sharma, M.A. Ilies, Heterocyclic cationic gemini surfactants: a comparative 
overview of their synthesis, self-assembling, physicochemical, and biological 
properties, Medicinal Research Reviews 34(1) (2014) 1–44. 
[21] A. Bhadani, S. Singh, R. Kamboj, V. Chauhan, Synthesis and self-aggregation properties of ester-
functionalized heterocyclic pyrrolidinium surfactants, Colloid and Polymer Science 291(10) (2013) 2289–
2297. 
[22] A. Bhadani, S. Singh, H. Sakai, M. Abe, Synthesis and Properties of Heterocyclic Cationic Gemini 
Surfactants, in: H. Ohshima (Ed.), Encyclopedia of Biocolloid and Biointerface Science, John Wiley & 
Sons, Inc., Hoboken, NJ, USA, 2016. 
[23] L. Li, Y. Nie, D. Ye, G. Cai, An easy protocol for on-chip transfection of COS-7 cells with a cationic 
lipid-based reagent, Lab Chip 9 (2009) 2230–2233. 
 
 
…
  
 
